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GENERAL INTRODUCTION 
 
The subject of this thesis is the Smith-Lemli-Opitz syndrome (SLOS; MIM 270400). This autosomal 
recessive multiple malformation syndrome was first described in 1964 by David Smith, Luc Lemli and 
John Opitz. First we will review several clinical, biochemical, pathophysiological, molecular and 
therapeutical aspects of SLO syndrome whereafter the outline of the thesis is given. 
 
Cholesterol (Figure 1), is an important constituent of the cell membrane of most eukaryotic cells, and 
secondly, acts as the precursor for steroid hormones, bile acids and myelin formation in the brain, 
spinal cord and peripheral nervous system. Finally, cholesterol has important interaction with proteins, 
which control embryonic development. 
   
 
Figure 1. Structure of cholesterol. 
 
SLOS, a severe developmental disorder associated with multiple congenital anomalies, is caused by a 
defect in cholesterol biosynthesis, i.e. a deficiency of the enzyme 7-dehydrocholesterol reductase, the 
final enzyme of the cholesterol biosynthetic pathway. Low cholesterol and high concentrations of its 
direct precursor 7-dehydrocholesterol (7DHC) and its isomer 8-dehydrocholesterol (8DHC) in blood 
and tissues are the biochemical hallmarks of the syndrome. The plasma sterol concentration generally 
correlates with severity and outcome. It remains uncertain however whether the clinical symptoms are 
primarily due to the shortage of cholesterol or to the abundance of the precursors 7DHC and 8DHC, or 
both.
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History 
In 1964 David Smith, Luc Lemli and John Opitz described three boys with a similar phenotype. 
Historically, the syndrome is often also named “RSH”syndrome, formed by the first letter of the 
original patients’ last names (Smith et al. 1964). This initial report was soon followed by descriptions 
of many new clinical cases. Since this original publication, the SLOS has remained a clinical diagnosis 
for 30 years. The SLOS phenotype described in male and female patients in many case reports 
disclosed a clinical spectrum with great variability. The estimated incidence of the autosomal recessive 
SLOS is 1/20,000 – 1/80,000 live births in individuals of European ancestry, but it has a lower 
incidence in most other ethnic groups (Ryan et al. 1998; Kelley & Hennekam 2000; Bzduch et al. 
2000; Nowaczyk et al. 2001; Witsch-Baumgartner et al. 2001).  
 In the past forty years case reports focused on the description of the various organ and 
dysmorfic anomalies in SLOS. Several experienced reviewers have discussed various clinical and 
biochemical aspects of SLOS (Cunniff et al. 1997; Neklason et al. 1999; Opitz 1999a; Fitzky et al. 
1999; Kelley & Hennekam 2000; Moebius et al. 2000; Waterham & Wanders 2000; Kelley & Herman 
2001). It is important to note that only the cases described from the mid-90s were biochemically 
proven after the discovery of the biochemical hallmark underlying the SLOS. Although experienced 
clinicians claimed to recognise patients with SLOS easily, it became clear that the broad spectrum of 
anomalies and very variable severity of this syndrome does not make the diagnosis always obvious. 
Even experienced dysmorphologists admit that making the clinical diagnosis SLOS, especially in mild 
cases, is not always straightforward and that individuals fulfilling the SLOS criteria in some cases 
could not be confirmed when biochemical proof became available (Guzetta et al. 1996; Nowaczyk et 
al. 2004; own observations).  
 
Clinical features 
The past years a delineation of SLOS has been made by many case reports and small series. Although 
structural defects in many organs may be involved and are described, in the majority of SLOS patients, 
heart, lungs, liver and kidneys usually are not affected. Conversely, in more severely affected patients, 
life span is often limited by lethal internal malformations. 
 
Craniofacial  
The distinctive craniofacial appearance of SLOS consists of a typical facies with a microcephaly, 
bilateral ptosis, broad and high forehead, broad nasal bridge, inner epicanthal folds, micrognatia, cleft 
palate, long philtrum and anteverted nares (as in the patient shown in Figure 2). 
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Figure 2. Typical facial appearance of a 6-year old boy with SLOS (Photo taken by the parents and printed with 
parental permission). 
 
 
Limbs 
The characteristic syndactyly of the second and third toe, although sometimes very subtle, is present in 
about 80-96% of patients with confirmed SLOS.  Polydactyly of feet and hands, oligodactyly of hands, 
short thumbs, hypoplastic thenar eminences and clubfeet are also common in combination with shorter 
limbs. 
 
Ophthalmologic 
Mild to moderate blepharoptosis is common in SLOS, while congenital bilateral cataract and bilateral 
optic nerve hypoplasia are described in more severe cases (Kretzer et al. 1981; Atchaneeyasakul et al. 
1998). Inherited defects in enzymes of cholesterol metabolism and use of drugs, which inhibit lens 
cholesterol biosynthesis, are associated with cataracts in animals and man. The basis of this 
relationship apparently lies in the need of the lens to satisfy its sustained requirements for cholesterol 
by on-site synthesis. Impairing this synthesis can lead to alteration of lens membrane structure. Lens 
membrane contains the highest cholesterol content of any known human membrane (Cenedella 1996). 
SLOS was diagnosed 1.2% of 250 paediatric patients with bilateral cataract and neurological features. 
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(Cruysberg 1996). Sterol analysis from ocular tissue in SLOS patients and fetuses showed markedly 
increased 7DHC and 8DHC, whereas the cholesterol concentration in the retinal pigment epithelium, 
lens, cornea, and sclera was lower (Atchaneeyasakul et al. 1998). 
 
Cardio-pulmonary 
Minor or major cardiac defects have been described up to 50% in large series of SLOS patients (Lin et 
al. 1997; Kelly & Hennekam 2000). A more specific association with atrioventricular canal defect and 
patients with an abnormal pulmonary venous return has been described. Striking is the documentation 
of non- or hypolobated lungs in autopsy studies of severe SLOS patients and animal models (Fitzky et 
al. 2001; Rakheja et al. 2003). 
 
Gastrointestinal 
Functional and anatomical gastro-intestinal abnormalities such as pyloric stenosis, aganglionosis coli 
(Hirschprungs’ disease), gastrointestinal reflux and failure to thrive, are common. 
 
Urogenital 
Genital malformations and its endocrine aspects are very interesting. Hypospadias, under-virilised 
male sex-differentiation ranging from cryptorchidism to complete sex reversal with a female 
appearance in 46 XY-individuals is described in SLOS. Further non-specific urogenital and renal 
abnormalities, as in other syndromes, are described to a lesser extent. 
 
Development and behaviour 
In SLOS psychomotor retardation and microcephaly are very common (80-95%). Mental development 
of SLOS patients ranges from profound mental retardation to borderline normal intelligence (Ryan et 
al. 1998; Langius et al. 2003; Mueller et al. 2003). The behavioural phenotype includes cognitive 
delay, sensory hyperreactivity, language impairment, sleep cycle disturbances, self-injury behaviour 
(up to 35%), syndrome specific motor movements, and autism spectrum behaviour (up to 50%). Some 
studies report aggression (52-63%), marked irritability from childhood throughout life. Sleeping 
disorders in the first and self-injurious behaviour in the second decade of live have a great impact on 
the family and parental acceptance of SLOS. Frequently SLOS patients demonstrate upper-body 
opisthokinesis; they arch their necks backwards frequently; and stereotypic stretching, accompanied 
by brief and rapid hand movements, can be observed (Tint et al. 1995; Kelley et al. 1996; Pauli et al. 
1997; Nwokoro et al. 1997; Ryan et al. 1998; Opitz et al. 1999b; Tierney et al. 2000; Tierney et al. 
2001). 
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Growth 
SLOS patients have short stature at diagnoses and growth-retardation as documented in several case 
reports and studies. Some initial attempts have been made with growth-hormone (GH) treatment in 
SLOS patients. They improved from –4.15 SD at the age of 5.5 years to –1.6 SD at 13 years (Ullrich et 
al. 2002). Larger trials are needed to evaluate the effect of GH on length and neuromotor 
development. Experience with GH-therapy in Prader-Willi syndrome, Noonan syndrome and Turner 
syndrome on growth and development may help to introduce this treatment strategy in SLOS.  
 
Dermatologic  
7DHC, also known as provitamin D3, is the precursor for Vitamin D (cholecalciferol) biosynthesis. In 
the presence of hundred to thousand-fold increased levels of 7DHC in serum and tissue one should 
expect high levels of Vitamin D in SLOS patients. No significant hypercalciaemia or nefrocalcinosis 
has been documented in SLOS, however.  
 Conversely, the majority of SLOS patients (60-70%) suffer from mild to severe skin 
photosensitivity (Charman et al. 1998; Anstey et al. 1999). Even after several minutes' exposure to 
bright sunlight, erythema occurs to exposed skin in some SLOS patients and is of permanent clinical 
concern to a circumscript group of patients. Monochromatic ultraviolet (UV) radiation and visible 
light testing revealed an immediate and persistent reaction to low-dose UVA at 350 nm and an 
abnormal erythemal response to visible light at 400 nm (Charman et al. 1998). UVA is known to cause 
peroxidation of membrane lipids with subsequent alterations in the structure and function of the 
membranes, leading to modifications in transmembrane transport and deregulation of receptors and 
messenger systems. Dietary cholesterol could improve photosensitivity in SLOS in some patients 
(Elias et al. 1997; Irons et al. 1997; Starck et al. 2002). 
 
Adrenal insufficiency 
Cholesterol is the precursor for corticosteroid production. Adrenal function and stress reaction have 
been tested in patients, showing conflicting data. Adrenal insufficiency has been suggested in some 
SLOS patients with low blood sodium, increased blood potassium, high levels of ACTH and renin but 
normal values of cortisol (Chemaitilly et al. 2002). Adrenal insufficiency with persistent hypertension 
has been documented in a newborn infant with SLOS (Nowaczyk et al. 2001). 
 
Endocrine 
Precocious puberty, under-virilisation and even complete sex reversal is frequently described in SLOS 
(Starck et al. 1999). Since cholesterol is the precursor of steroid hormones, reports speculated about 
endocrine abnormalities in SLOS patients. Abnormal steroid production and metabolites have been 
detected by some researchers but the cause for under-virilisation in SLOS remains speculative. Recent 
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studies on 40 SLOS patients (age 1 day – 25 years) studied urinary steroids using GC/MS and 
selected-ion-monitoring. Neonates with SLOS excreted conventional 3β-hydroxy-5-ene steroids, 
mostly 16α-hydroxylated and 7 and 8-dehydro homologues. Dominant novel steroids excreted by 
older children and SLOS adults are 7 and 8-dehydro variants of pregnanetriol (Shackleton et al. 2002). 
Recently 17 alpha-hydroxypregna-4,7-diene-3,20-dione and 17 alpha-hydroxy-5 beta-pregn-7-ene-
3,20-dione have been tentatively identified as steroid metabolites in SLOS (Guo et al. 2003). 
Abnormal neurosteroidogenesis can influence behaviour and development pre- and postnatally. Delta-
7 and/or delta-8-unsaturated neurosteroids may be produced in the brain. Analysis of urinary steroids 
in post-pubertal SLOS females confirmed the presence of neurosteroid-like compounds in SLOS 
(Marcos et al. 2004). 
 
Brain 
Brain imaging and post-mortem examination in SLOS case reports revealed abnormal cerebral gyri, 
cerebellar hypoplasia, delayed myelinisation, holoprosencephaly, lissencephaly, agenesis or 
hypoplasia of the corpus callosum, hippocampal malrotation and choroidal cyst. Aspecific migration 
disorders were documented in up to 37% in smaller series (Kelley et al. 1996; Ryan et al. 1998; 
Nowaczyk et al. 2001). These observations confirm that SLOS is a multiple malformation/retardation 
syndrome and patients are at risk for an impaired development from birth. Neuro-imaging in a series 
of 18 SLOS patients showed four callosal abnormalities, one Dandy Walker variant and one 
arachnoidal cyst (Caruso et al. 2003).   
 
Neurophysiology 
Abnormal nerve conduction velocities have been documented in SLOS patients (Starck et al. 1999). 
Some groups studied rod photo responses in children with SLOS and found slow kinetics of photo 
transduction in all but 3 of 13 patients. Their observation demonstrates altered kinetics of a membrane-
bound signaling system. This may be caused by altered sterol composition in the cell membranes of 
rod photoreceptors (Elias et al. 2003). In a rodent-model, the retina revealed anatomical, degenerative 
and conductive abnormalities when the ratio of 7DHC/Cholesterol was increased (Fliesler et al. 2004).  
Progressive polyneuropathy improved on cholesterol supplementation, whilst stationary forms did not 
(Starck et al. 2002).  
 
Cholesterol biosynthesis 
The great breakthrough for SLOS was the discovery of its biochemical characteristics in 1993 by the 
group of Mira Irons and Richard Kelly (Irons et al. 1993; Tint  et al. 1995). Patients typically show 
reduced levels of cholesterol and increased levels of 7DHC and its isomer, 8DHC, in plasma and all 
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tissues. This biochemical abnormality in SLOS is caused by an enzymatic defect in the last step in 
normal cholesterol biosynthesis (Figure 3).  
Cholesterol is a main end product derived from the isoprenoid biosynthetic pathway. This 
cascade supplies cells with a variety of compounds, collectively called isoprenoids, which function in 
diverse cellular processes. Among these are Ubiquinone-10 and Heme A, involved in electron 
transport, dolichol, mediator of protein glycosylation, isopentyl tRNAs, and farnesyl and geranyl 
groups for prenylation of proteins that are involved in cell signaling and differentiation (Goldstein & 
Brown 1990). A series of enzyme reactions is required to eventually produce cholesterol. Acetyl-CoA 
(C2) is converted into the isoprene unit, isopentenyl-PP (C5), by six different serial enzyme reactions. 
After adding C5 to geranyl-PP (C10) through farnesyl-PP (C15), squalene (C30) is transformed to 
lanosterol (4,4,14-trimethylcholesta-8(9), 24-dien-3-ol) by cyclization (Figure 3).  
Not only humans but the majority of organisms, including animals, plants, fungi and micro-
organisms, are equipped with the crucial de novo cholesterol biosynthetic pathway, supplying sterols 
and steroids to cells, membranes and tissues, illustrating the importance of cholesterol biosynthesis for 
intermediate and end-products.  
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Figure 3. The cholesterol biosynthetic pathway. HMG-CoA reductase is the rate-limiting step for the entire 
enzymatic pathway. The sterol Δ7-reductase (DHCR7) catalyses the last step in cholesterol formation. This 
enzyme is defective in SLOS. 
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DHCR7 (7-dehydrocholesterol-reductase) deficiency 
The SLOS is caused by a deficient enzyme: 7-dehydrocholesterol reductase (DHCR7; E.C. 1.3.1.21; = 
3 β-hydroxysterol Δ7- reductase),  localised intracellulary in the membrane of the endoplasmic 
reticulum (Witsch-Baumgartner et al. 2000). The only structural difference between cholesterol and 
7DHC is the unsaturated double bond in the B ring at the 7th position  in 7DHC (Figure 4.)  
 
Figure 4. Last steps in the post-squalene part of the cholesterol biosynthesis. Reduction of the Δ24 double bond 
by 3β-hydroxysterol-Δ24-reductase can occur at any point along the pathway. The 3β-hydroxysterol-Δ5-
desaturase (lathosterol-dehydrogenase), 7-dehydrocholesterol-reductase and 3β-hydroxysterol-Δ8-7-isomerase, 
respectively add, remove and translocate a double bond in the B ring. 
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Biochemical diagnosis in SLOS 
When a patient is clinically suspected of SLOS, the diagnosis can be confirmed by the detection of 
7DHC (and or 8DHC) in various tissues. The presence of increased concentrations of 7DHC in 
plasma, CSF, amniotic fluid, or tissues is diagnostic for SLOS (Irons et al. 1994, Tint et al. 1995, 
Shefer et al. 1995; Mills et al. 1996; van Rooij et al. 1997). Routine hospital laboratories use 
cholesterol-oxidase methods to measure serum cholesterol. This test however is not useful in 
diagnosing SLOS while it does not detect abnormal sterols. 7DHC-detection can be performed with 
different techniques such as Gas Chromatography (GC), Gas Chromatography-mass spectrometry 
(GC-MS), HPLC, electrospray ionization tandem mass spectrometry, time-of-flight secondary ion 
mass spectrometry and Tandem MS (Irons et al. 1993; Tint et al. 1995; Guzzetta et al. 1996, 
Zimmerman et al. 1997; Starck et al. 2000; Rizzo et al. 2000; Johnson et al. 2001; Scalco et al. 2003). 
Most European countries have one or more laboratories that can biochemically confirm the clinical 
diagnosis of SLOS.  
DHCR7-enzyme activity has been studied in fibroblasts, liver microsomes and chorionic villus 
samples (Salen et al. 1996; Bae et al. 1997; Shefer et al. 1997). Total body sterol balance studies using 
stable isotopes are time consuming and expensive (Shefer et al. 1995; Honda et al. 1996; Lund et al. 
1996; Steiner et al. 2000; Linck et al. 2000). Neither are primary diagnostic tools but can be important 
in research setting and may give important answers to experimental questions concerning cholesterol 
biosynthesis and metabolism in patients.  
 
Prenatal Diagnosis 
Prenatal diagnosis in the late 90’s was available through measurement of 7DHC levels in chorionic 
villi at 11-12 weeks and amniotic fluid at 15-16 weeks of gestation. Currently, more accurate 
diagnosis is possible by molecular genetic studies of mutations in the DHCR7 gene of the unborn 
child. Abnormal synthesis of cholesterol in the adrenal foetal glands with SLOS results in equine-type 
estrogens in the maternal plasma and urine detected by GC-MS and may serve as a potentially non-
invasive alternative screening (Shackleton et al. 1999). Prenatal screening for SLOS by measuring 
maternal plasma levels of non-conjugated estriol (uE3), as performed at 15-20 weeks of pregnancy to 
determine the risk of Down’s syndrome, trisomy 18 and open neural tube defects, is suggested, since 
uE3 synthesis is dependent on cholesterol produced by the fetal tissue (McKeever et al. 1990). 
 
Molecular Genetics 
Although initial evidence suggested that the human SLOS gene was located at 7q32.1, the human 
DHCR7 (Gen Bank accession number: AF034544) was identified in 1998 and assigned to 
chromosome region 11q13 (Fitzky et al. 1998; Wassif et al. 1998; Waterham et al. 1998). The cDNA 
has an open reading frame of 1,425 base-pair coding for a polypeptide of 475 amino acids. Mutations, 
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expression and genotype/phenotype studies have been performed on SLOS patients. Molecular genetic 
work elucidated many pathogenic mutation and enabled accurate prenatal diagnosis.  
 
Cholesterol and the brain 
Cholesterol in the human brain, developing sheep brain, and rat pup brain is made locally from 
glucose, acetate, or polyunsaturated fatty acids (Jurevics et al. 1995; Likhodii et al. 1995; Snipes et al. 
1997). Sterols formed in the brain by the mevalonate pathway have an active and independently 
regulated biosynthesis. Cholesterol is not imported from peripheral blood across the Blood Brain 
Barrier (BBB) by lipoprotein uptake (Andersson et al. 1990; Björkhem et al. 1997). Even during fetal 
brain development, including the time before closure of the BBB, lipoproteins circulating through the 
central nervous system are not used as a source of cholesterol, but are synthesized locally (Serougne et 
al. 1976; Andersson et al. 1990; Edmond et al. 1991; Saheki et al. 1994; Turley et al. 1996; Björkhem 
et al. 1997). 
Chronic treatment with cholesterol synthesis-blocking agents impaired brain sterols and 
associative learning in rats. Exogenous cholesterol, however, failed to correct for the learning 
impairment produced by the chemical DHCR7-inhibition (O’Brien et al. 2002). Neurons from both 
control and mutant pups exhibited similar reversible, tetrodotoxin-sensitive sodium currents in 
response to a voltage step to –30 mV from a holding potential of –90 mV. Mean peak amplitudes of 
the control and the mutant sodium currents were not significantly different and both were able to 
generate a single action potential upon injection of a depolarising current from a potential of –55 mV. 
However, an impaired glutamate response was detected in mutated pups. How the NMDA receptor 
function could be influenced is not known in SLOS. Neurosteroids are thought to be endogenous 
ligands for sigma 1(σ1) receptors and to modulate NMDA receptor function. Whether elevations of 
sterol biosynthetic intermediates might competitively inhibit neurosteroid synthesis or affect 
neurosteroid interaction with sigma 1(σ1) receptors should be studied in future (Wassif et al. 2001). 
Behavioural phenotypes and autistic behaviour is studied with mouse models and linked to abnormal 
and increased 5-HT (serotonin) neurons and fibres (Waage-Baudet et al. 2003). In the hindbrains of 
mutant (Dhcr7-/-) mice an impressive increase in 5-HT immunoreactivity could be observed. This 
increase in 5-HT immunoreactivity was suggested to represent an increase in total number of 5-HT 
neurons and fibres and may help to explain the behavioural phenotype seen in SLOS (Waage-Baudet 
et al. 2003). SLOS and other disorders in cholesterol biosynthesis can provide new insights in 
development, brain growth and brain function. 
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Other disorders of cholesterol biosynthesis 
Eight distinct inherited disorders have been linked to different defects in cholesterol biosynthesis 
(Table 1 and Figure 5). Two disorders are known to result from an enzyme defect in the pre-squalene 
segment of the pathway: the classical form of mevalonic aciduria and the hyperimmunoglobulinemia 
D/Periodic fever syndrome, also known as Dutch-type periodic fever.  
 All six enzyme defects in the post-squalene segment of the pathway, have been resolved on 
the basis of elevated levels of specific sterol intermediates in tissues of affected patients, followed by 
demonstrating disease-causing mutations in the encoding genes. These include the two X-linked 
dominant inherited and male-lethal disorders Conradi-Hünermann-Happle syndrome and Congenital 
Hemidysplasia with Ichthyosiform erythroderma and Limb Defects: CHILD syndrome, caused by 
deficiencies of sterol Δ8-7 isomerase and sterol C-4 demethylase, respectively. The three extremely rare 
autosomal recessive disorders, Greenberg skeletal dysplasia (=HEM, Hydrops Ectopic calcification 
Moth-eaten skeletal dysplasia), lathosterolosis and desmosterolosis, characterized by multiple 
congenital anomalies, have clinical overlap with the most common inborn error of cholesterol 
biosynthesis: SLOS. Table 1 gives a summary of disorders in cholesterol biosynthesis, genes, 
enzymes, most important features and their references. 
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Figure 5. Pre and post-squalene cholesterol biosynthesis. The eight human disorders are shown in grey boxes.  
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Cholesterol deficiency in teratology and embryogenesis 
Shortly after the discovery of cholesterol impairment in SLOS in the mid 90’s, researchers focused on 
its role in morphogenesis. Cholesterol has a pivotal role during embryogenesis where it functions as a 
transporter molecule for the Sonic hedgehog (Shh) signaling protein, which is essential for normal 
morphogenesis. Without cholesterol, Shh transport and/or function is impaired (Hall et al. 1995; Porter 
et al. 1996; Hall et al. 1997; Lanoue et al. 1997; Cooper et al. 1998). The Cholesterol modification of 
Shh activates signaling molecules such as Patched (Ptc), Smoothened (Smo) and Gli, which function 
in the development of numerous tissues by regulating cellular differentiation and proliferation (Theil 
et al. 1999; Wallis and Muenke 1999; Ogden et al. 2004). 
Teratology 
Some of the major malformations seen in SLOS can be mimicked in animal models utilising specific 
cholesterol-lowering drugs: BM 15.766, AY-9944 and YM 9429 inhibiting the Δ7-reductase enzyme in 
cholesterol biosynthesis (Honda et al. 1996; Kolf-Clauw et al. 1996; Dehart et al. 1997; Roux et al. 
2000). Treatment of pregnant rats with inhibitors of DHCR7, either AY9944 or BM15.766, has 
provided a valuable model to study the pathogenesis in SLOS (Gofflot et al. 1999). In brain tissue a  
7DHC/Cholesterol ratio as high as 3 easily can be detected after treating rats with AY9944 (Keller et 
al. 2004). The most characteristic malformations in this animal "holoprosencephalic syndrome" 
include cyclocephaly, cyclopia, monorhinia, palatoschizis and agenesis of the pituitary gland in up to 
80 % of subjects (Honda et al. 1996; Kolf-Clauw et al. 1996; Incardona et al. 2000). Teratogenic 
compounds/inhibitors used to study SLOS interfere with the morphogenetic Shh-Ptc-Smo-Gli 
signaling pathway. In animal studies, reduced or absent expression of Shh has been proven to 
influence expression of several other important morphogenetic genes in brain, heart, limb and mid-
face development (Gofflot et al. 2003; Digilio et al. 2003; Hill et al. 2003; Cox 2004). Indeed, in a 
large molecular genetic study of 200 holoprosencephaly patients, not only SHH mutations but also 
mutations in ZIC2, SIX3, and TGIF genes could be disclosed (Dubourg et al. 2004). This provides 
further evidence that malformations in several organs may originate directly from cholesterol 
disruption or impaired Shh signaling activity.  
 
SLOS knockout-mice model: Dhcr7-/- 
A targeted mutation of the Dhcr7 gene eliminates enzyme activity, making it virtually undetectable (1 
± 1 pmol/mg protein/min) in mice (Wassif et al. 2001). As in human patients, the SLOS/RSH mouse 
model showed marked reduction of circulating and tissue cholesterol and marked increase of 7DHC. 
Serum 7DHC levels were increased one hundred to one thousand fold and the percentage of 7DHC to 
total sterols of 50-80% in tissues of Dhcr7-/- mice (Wassif et al. 2001). 
Dhcr7-/- pups weighed significantly less: 1.11-1.14 g compared with 1.42-1.44 g for Dhcr7 
+/+ pups (Wassif et al. 2001 ; Fitzky et al. 2001). Homozygotes do not die prenatally but within 18 
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hours, presumably from respiratory failure or dehydration. Dhcr7-/- pups are easily identified shortly 
after birth by their laboured breathing, blue coloration, and lack of movement. Homozygous Dhcr7-/- 
mutant pups had craniofacial malformations, demonstrated decreased movement and none of the pups 
suckled and therefore failed to feed (Wassif et al. 2001). In 30 % of the Dhcr7-/- pups a nasal plug was 
noted and in 9% even the absence of an nasal opening. Mutant pups, rarely vocalised alarm, had a 
hypotonic appearance and had less vigorous movements, compared with control groups. In Dhcr7-/- 
mice isolated cleft palate was noted in 8-12 % (Wassif et al. 2001; Fitzky et al. 2001). 
Surprisingly, histological analysis showed no gross abnormalities of brain, heart, intestine, 
adrenal gland or kidney, as in severe human cases of SLOS. However, microscopic examination of 
fixed and stained sections of lung sections from Dhcr7-/- mice demonstrated compact lungs with 
sparse, unconnected air spaces that were similar in appearance to normal 15 to 16-gestational day 
mice. Diffuse alveolar atelectasis, however, was often detected but no limb or skeletal malformations 
(Wassif et al. 2001; Fitzky et al. 2001). Mutant pups lack a stereotypic rhythmic sucking/swallowing 
reflex leading to aspiration in trachea, bronchi and lung parenchyma. Gross and histological 
examination of the pharynx and trachea revealed no malformation (Wassif et al. 2001). 
Although smaller, mutant brain weights were proportional to body weight; there was no 
increased apoptosis in brains of Dhcr7-/- pups. Cholesterol deficits in homozygous mutant mice were 
most profound in the brain with dehydrocholesterols making up 80% of total sterols. In Dhcr7-/- mice 
sterol biosynthesis is suppressed as in the average child with SLOS, illustrated as a percentage of 
reductions in liver total sterols, HMG-CoA reductase protein levels, and HMG-CoA reductase 
activities (68%, 64%, and 83%, respectively) (Fitzky et al. 2001). In the central nervous system, 3β-
hydroxysterol Δ7-reductase (DHCR7) reduces 7DHC to form desmosterol and, as expected, 
desmosterol levels were markedly reduced in cortex and midbrain from Dhcr7-/- pups, compared with 
levels found in samples from either Dhcr7+/+ or Dhcr7+/- pups. Neuronal impairment might be the 
result of replacement of cholesterol and desmosterol by cholesterol-precursors: 7DHC and 8DHC in 
neuronal membranes. 
 
Pathophysiology 
Hedgehog-signaling proteins are involved in numerous developmental processes. They are modified 
by the addition and presence of cholesterol that appears to be required for the proper action and 
transport of hedgehog morphogens in the cell and tissues (Hall et al. 1997; Ingham 2001; Jeong et al. 
2002). The Sonic hedgehog must be covalently linked to cholesterol to be activated and is essential for 
the development of the brain, limbs and face (Roux et al. 2000). Cooper and co-workers could 
demonstrate a compromised Hedgehog signal in mutant cells from mouse models of SLOS and in 
normal cells pharmacologically depleted of sterols (Cooper et al. 2003). Molecular mechanisms 
underlying limb- (syn/polydactyly) and (non-lobulated) lung anomalies are studied to understand 
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imbalance of hedgehog expression or disruption of cascades as seen in SLOS (Gofflot et al. 2003; Yu 
et al. 2004). Different chemo- and phenotypes in SLOS patients with the same genotype suggest that 
there are more factors that have a pre- and postnatal effect on cholesterol biosynthesis and its 
important signaling cascades (Witsch-Baumgartner et al.  2004). Alternative pathways, maternal apo E 
genotype, LDL receptor gene variations, maternal diet during pregnancy and other factors must be 
studied in relation to modulation of embryonic development and SLOS malformations. 
 
Therapy 
Soon after the discovery of reduced cholesterol synthesis in SLOS, baseline cholesterol and precursor 
levels were associated with severity and developmental impairment. Several trials with dietary 
supplementation were initiated with the aim of increasing cholesterol and reducing the de novo 
synthesis and accumulation of 7DHC and 8DHC. Therapeutic trials in SLOS patients used dietary 
supplementation of cholesterol powder or egg yolk, with or without bile acids. (Xu  et al. 1995a; Xu et 
al. 1995b; Irons et al. 1995; Ulrich et al. 1996; Elias et al. 1997; Irons et al. 1997; Nwokoro et al. 
1997; Linck et al. 2000). The concentration of plasma cholesterol could be increased to subnormal 
levels in some SLOS patients. However, dietary cholesterol could not decrease levels of 7DHC and 
8DHC in plasma or tissues.  
Overall clinical improvement with cholesterol supplementation in SLOS is disappointing (Xu  
et al. 1995a; Xu et al. 1995b; Irons et al. 1995; Ulrich et al. 1996, Elias et al. 1997; Irons et al. 1997; 
Nwokoro et al. 1997; Linck et al. 2000). Cholesterol and bile acid supplementation could improve 
photosensitivity in SLOS in some patients (Elias et al. 1997; Azurdia et al. 2001; Starck et al. 2002) 
Progressive polyneuropathy improved on cholesterol supplementation, whilst stationary forms did not 
(Starck et al. 2002). In a study of 14 SLOS children receiving cholesterol supplementation, 
developmental quotients did not improve over time (Sikora et al. 2004).  
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AIM OF THE STUDY 
 
Following the first clinical description in 1964 and the elucidation of the biochemical defect in 1993, a 
number of questions related to Smith-Lemli-Opitz syndrome remained to be answered. Among these 
were:  
Is there a laboratory test to confirm the clinical diagnosis SLOS and are there any pitfalls ?  
Is substitution of cholesterol or reduction of precursors more effective in the treatment of SLOS ?  
Can we design new treatment stategies to improve neuro-motor development in SLOS patients ? 
What is the gene responsible for SLOS and can we detect mutations in our patients ? 
Could the broad clinical spectrum be explained by a genotype-phenotype correlation in SLOS and 
what is the real incidence of this disease and its carrier frequency in different parts of the world ? 
Is it the deficient cholesterol or the excess of precursors in plasma, membrane and tissue that 
contribute to the pathophysiology of SLOS ? 
Do we understand how an inborn error of metabolism can lead to a multiple malformation syndrome ? 
What is the mechanism of a disturbed cholesterol biosynthesis leading to a human malformation 
syndrome ? 
 
The aim of our study was to 
  
Introduce the reader in the Smith-Lemli-Opitz syndrome and 7-dehydrocholesterol reductase 
(DHCR7) deficiency and to share our current knowledge about diagnosis, clinical 
manifestations, molecular genetic aspects, therapy and pathophysiology in SLOS 
(Chapter 3). 
Investigate plasma of 8 patients, clinically diagnosed with SLOS and furthermore, describe 
pitfalls in measuring plasma cholesterol in SLOS with common oxidase methods used 
routinely in laboratories (Chapter 4). 
Explore new treatment strategies in SLOS. To describe and discuss sterol-exchange kinetics 
between plasma and erythrocyte-membranes, the effect of plasma exchange 
transfusions and longterm effect of HMG-CoA reductase inhibition with simvastatin 
in patients (Chapter 5 and 6). Explain the beneficial effect of simvastatin on plasma 
precursor / cholesterol ratio as observed during long-term therapy in SLOS. 
Understand this effect by studying the molecular effects of simvastatin on DHCR7 
enzyme activity and DHCR7 mRNA levels in SLOS fibroblasts and finally correlate 
biochemical, molecular and clinical effect in SLOS patients (Chapter 7). 
Search for new and known mutations in the DHCR7-gene in 13 patients with SLOS and study 
possible genotype-phenotype correlation (Chapter 8). 
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Describe a patient with a “Smith-Lemli-Opitz-like” phenotype caused by a distal chromosome 
7q36 deletion disrupting the human Sonic Hedgehog (SHH) gene and discuss 
remarkable finding in the perspective of SLOS pathogenesis (Chapter 9). 
Finally, summarize and discus all findings and highlight some specific future perspectives in 
SLOS and cholesterol biosynthesis in general (Chapter 10). 
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SUMMARY 
 
Smith-Lemli-Opitz syndrome, a severe developmental disorder associated with multiple congenital 
anomalies, is caused by a defect of cholesterol biosynthesis. Low cholesterol and high concentrations 
of its direct precursor 7-dehydrocholesterol in plasma and tissues are the diagnostic biochemical 
hallmarks of the syndrome. The plasma sterol concentrations correlate with severity and disease 
outcome. 
Mutations in the DHCR7 gene lead to a deficient activity of 7-dehydrocholesterol reductase (DHCR7), 
the final enzyme of the cholesterol biosynthetic pathway. The human DHCR7 gene is localised on 
chromosome 11q13 and its structure has been characterized. Ninety different mutations in the DHCR7 
gene to date have been published. This paper is a review on clinical, biochemical and molecular 
genetic aspects.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY WORDS: Smith-Lemli-Opitz Syndrome, 7-dehydrocholesterol reductase, mutations, 
cholesterol. 
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INTRODUCTION 
 
 Smith-Lemli-Opitz syndrome (SLOS MIM 270400), a severe developmental disorder associated with 
multiple congenital anomalies, is caused by a defect of cholesterol biosynthesis, i.e. a deficiency of the 
enzyme 7-dehydrocholesterol reductase (DHCR7; EC 1.3.1.21), the final enzyme of the cholesterol 
biosynthetic pathway. Low cholesterol and high concentrations of its direct precursor 7-
dehydrocholesterol (7DHC) and its isomer 8-dehydrocholesterol (8DHC) in blood and tissues are the 
biochemical hallmarks of the syndrome (Smith et al. 1964; Irons et al. 1993; Tint et al. 1995). The 
plasma sterol concentration generally correlates with severity and outcome (Tint et al. 1995; Witsch-
Baumgartner et al. 2000). That a single metabolic (enzymatic) defect in humans could lead to a 
multiple malformation syndrome was new and unexpected. Cholesterol, an important constituent of 
the cell membrane of most eukaryotic cells, has important interaction with proteins, which control 
embryonic development. In addition, cholesterol acts as the precursor for steroid hormones, bile acids 
and myelin formation in the brain, spinal cord and peripheral nervous system (Figure 1).  
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Figure 1. Cholesterol biosynthetic pathway. 
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Recently, several other reviewers have discussed various aspects of SLOS and other defects of 
cholesterol biosynthesis (Opitz 1999; Fitzky et al. 1999; Kelley & Hennekam 2000; Moebius et al. 
2000; Waterham & Wanders 2000; Battaile & Steiner, 2000; Haas et al. 2001; Nwokoro et al. 2001; 
Kelley & Herman 2001). Here we discuss the clinical, biochemical and molecular genetic aspects of 
SLOS. 
 
 
CLINICAL ASPECTS OF SLOS 
 
 Since the first description of SLOS as a clinical entity in 1964 (Smith et al. 1964) many papers have 
appeared describing a variety of common and less common clinical findings in patients with this 
multiple malformation/retardation syndrome (e.g. Opitz 1999; Kelley & Hennekam 2000; Cunnif et al. 
1997; Ryan et al. 1998). The clinical spectrum includes different morphogenic abnormalities such as 
craniofacial, internal organ, limb/skeletal and urogenital anomalies besides (intrauterine) growth and 
mental retardation, failure to thrive and behavioral problems. The frequently occurring clinical 
symptoms apparent in 164 biochemically confirmed SLOS cases (Kelley & Hennekam 2000) are 
summarized in Table 1. While many of the signs on itself are not disease-specific for SLOS, the 
combination of several may point to this disorder. Indeed the occurrence of second/third toe 
syndactyly, polydactyly, microcephaly, ptosis, long philtrum, (congenital) cataract, photosensitivity, 
Hirschprungs’ disease (colonic aganglionosis), pyloric stenosis, genital developmental anomalies 
(ranging from hypospadias to a complete sex reversal) in combination with neuro-developmental 
delay, should raise the clinical suspicion of SLOS (Figure 2). Through the years attempts have been 
made to distinguish a severe (lethal) type II form from the relatively mild type I form. The 
identification of the biochemical and molecular basis of SLOS however, has made clear that SLOS 
forms a clinical and biochemical continuum ranging from hardly recognizably mild to severe lethal 
forms (Kelley 1998; Kelley 2000; Waterham et al. 1998; Cunnif et al. 1997; Tint et al. 1995; Jira et al. 
2001). The clinical description in the literature on SLOS probably is biased towards more severely 
affected and thus readily recognizable patients. Reviewing published SLOS families, the incidence of 
fetal death and spontaneous abortions is twice as high as in the general population suggesting the 
occurrence of severe cases leading to early death. With the introduction of selective screening and the 
availability of biochemical and genetic testing following the recent elucidation of the underlying cause 
of SLOS, mildly affected cases or even patients without clinical suspicion of SLOS can be readily 
diagnosed. 
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Table 1. Clinical symptoms in SLOS. Findings in 164 biochemically confirmed cases (Kelly & 
Hennekam 2000) 
 
 
 
  Finding     (%)    
 
 
2/3 toe syndactyly   97 
Mental retardation   95     
Microcephaly    84 
Postnatal growth retardation  82 
Anteverted nares   78 
Ptosis     70 
Genital anomalies   65 
Congenital heart defects   54 
Polydactyly†    48 
Cleft palate*)    47 
Abnormal lung lobation   45 
Renal anomalies   43 
Structural brain anomalies  37 
Cataract    22 
Colonic aganglionosis   16 
Pyloric stenosis    14 
 
 
 
*)    Includes cleft soft palate, submucous cleft, and cleft uvula.  
†    Includes postaxial polydactyly of hand(s)/foot. 
  44
 
 
Figure 2. Clinical characteristics in SLOS. Facial dysmorphias including: mild ptosis, a long philtrum, 
anteverted nares in a 5 year old boy (A) and a 3 year old girl (B). Genital anomalies in boys (C) and 2/3 toe 
syndactyly (D) present in respectively 65 % and 97 % of SLOS cases. 
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Therapeutic trials using dietary supplementation of cholesterol with or without bile acids have shown 
that plasma cholesterol levels can be increased in some patients. Concentrations of the precursors 
7DHC and 8DHC, however, were only marginally altered and clinical effects of the treatment so far 
have been rather disappointing (Irons et al. 1995; Ullrich et al. 1996; Elias et al. 1997). An alternative 
therapeutic strategy has been developed, treating 5 SLOS patients with Simvastatin (an oral HMG-
CoA reductase inhibitor) for a median period of 2 years. The overall biochemical effect was 
impressive with a decrease of 7DHC+8DHC and increase of cholesterol in plasma to respectively 28 
% and 162 % of  the initial concentration with promissing clinical improvement (Jira et al. 1997; Jira 
et al. 2000; and unpublished data). This therapeutic statin approach is currently being tested in a 
multicenter European Trial. 
 
 
 BIOCHEMICAL ASPECTS 
 
 SLOS is caused by a deficiency of the enzyme 7-dehydrocholesterol reductase (DHCR7; EC 1.3.1.21), 
the final enzyme of the cholesterol biosynthetic pathway. Molecular cloning of the cDNA showed that 
the human enzyme is a protein with a calculated molecular weight of 54.5 kDa and nine 
putative/predicted transmembrane segments. It is microsomal membrane-bound and in humans the 
mRNA is expressed ubiquitously with the highest expression in adrenal gland, liver, testis, and brain 
(Moebius et al. 1998).  
   Cholesterol is a main endproduct derived from the isoprenoid biosynthetic pathway 
(Goldstein and Brown 1990). This pathway supplies cells with a variety of compounds, collectively 
called isoprenoids, which function in diverse cellular processes. Among these are ubiquinone-10 and 
heme A, involved in electron transport, dolichol, mediator of protein glycosylation, isopentyl tRNAs, 
and farnesyl and geranyl groups for prenylation of proteins that are involved in cell signalling and 
differentiation (Goldstein & Brown 1990). Acetyl-CoA (C2) is converted into the isoprene unit: 
isopentenyl-PP (C5) by six different serial enzyme reactions. After adding C5 to geranyl-PP (C10) 
through farnesyl-PP (C15), squalene (C30) is transformed to lanosterol (4,4,14-trimethylcholesta-8(9), 
24-dien-3-ol) by cyclization. A series of enzyme reactions is required to eventually produce 
cholesterol (Figure 1). Not only humans but the majority of organisms including animals, plants, fungi 
and micro-organisms are equipped with this important de novo (chole)sterol biosynthetic pathway, 
supplying sterols and steroids to cells, membranes and tissues. Cholesterol has a pivotal role during 
embryogenesis where it functions as a transporter-molecule for the Sonic hedgehog (Shh) signalling 
protein, which is essential for normal morphogenesis. Without cholesterol, Shh-transport and/or 
function is impaired (Hall et al. 1995; Porter et al. 1996; Hall et al. 1997; Lanoue et al. 1997; Cooper 
et al. 1998). The sterol derangement in SLOS (accumulation of 7DHC/8DHC and shortage of 
available cholesterol) undoubtedly influences the proper activation of the Shh-receptor. These findings 
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may explain the phenotypic consequences of the DHCR7 deficiency as observed in this syndrome: 
microcephaly, a distinctive facies, cataract, syn/polydactyly, and a variety of organ malformations 
including genital abnormalities ranging from intersex to complete sex reversal in boys. Although the 
mechanism of Shh-induced signaling pathway in vertebrates is not completely defined, it is known to 
regulate dorso-ventral patterning within the neural tube, limb, lung, genital, ocular, and retinal 
development as well as craniofacial morphogenesis (Krishnan et al. 1997; Hayes et al. 1998; Imokawa 
et al. 1997; Levine et al. 1997; Helms et al. 1997; Marigo et al. 1995; Hall et al. 1995; Kumar et al. 
1996). In a recent null mutation mouse model without DHCR7 activity, accumulated 7-
dehydrocholesterol was found to suppres sterol biosynthesis posttranslationally in line with earlier 
observations in skin fibroblasts from SLOS patients (Shefer et al. 1997). This effect might exacerbate 
abnormal development in SLOS by increasing the fetal cholesterol deficiency (Fitzky et al. 2001). 
The most predictive biochemical value in SLOS is the 7DHC/cholesterol ratio in plasma (Tint et al. 
1995; Witsch-Baumgartner et al. 2000). In general, patients with plasma 7DHC/cholesterol ratio 
between 0.5 – 1.0 have moderate SLOS. Patients with a plasma ratio <0.5 have a mild presentation 
and course while plasma 7DHC/cholesterol ratio >1.0 is associated with severe SLOS (Krakowiak.et 
al. 2000; Jira et al. 2001). This biochemical ratio could be a usefull tool for prognosis and treatment in 
SLOS but cannot predict severity accurately. 
 
To date, seven distinct inherited disorders have been linked to different defects in cholesterol 
biosynthesis. Two disorders are known to result from an enzyme defect in the pre-squalene segment of 
the pathway: the classical form of mevalonic aciduria (MIM 251170: Hoffmann et al. 1986; Houten et 
al. 2000; Haas et al. 2001) and the hyperimmunoglobulinemia D and periodic fever syndrome also 
known as Dutch-type periodic fever (MIM 260920: Houten et al. 1999; Drenth et al. 1999; Houten et 
al. 2000). Of the remaining five disorders, all due to different enzyme defects in the post-squalene 
segment of the pathway, four have been resolved at the molecular level recently by the demonstration 
of disease-causing mutations in the encoding genes. These include SLOS and the two X-linked 
dominant inherited and male-lethal disorders Conradi-Hünermann-Happle syndrome (CDPX2; MIM 
302960: Happle 1979 and CHILD syndrome; MIM 308050: Happle et al. 1980) caused by 
deficiencies of sterol Δ8-7-isomerase (EBP gene at Xp11.22-23) or a sterol C-4 demethylase (NSDHL 
gene at Xq28) respectively. In patients with Desmosterolosis, a rare autosomal recessive disorder, 
characterized by multiple congenital anomalies, elevated levels of the cholesterol precursor 
desmosterol, in plasma, tissue, and cultured cells suggested a deficiency of the enzyme 3beta-
hydroxysterol Δ24-reductase (MIM 602398: FitzPatrick et al. 1998). Four mutations in two patients, 
only recently, gave the molecular confirmation of this defect (DHCR24 gene at 1p31.1-p33: Waterham 
et al. 2001). The last, extremely rare and probably autosomal recessively inherited disorder of sterol 
synthesis, namely Greenberg skeletal dysplasia (MIM 215140: Greenberg et al. 1988), presumably 
due to a deficiency of sterol Δ14-reductase, is detected by elevated levels of specific sterol 
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intermediates in conjunction with decreased levels of cholesterol in tissues and cells of affected 
patients. Confirmation at the molecular level of this disorder awaits the identification of the 
corresponding gene and/or molecular analysis in affected patients.  
 
 
 MOLECULAR GENETICS OF THE DHCR7 GENE 
 
Organisation and conservation 
 In 1998, the human 7-dehydrocholesterol reductase gene (DHCR7 Gen Bank accession number: 
AF034544) was identified and assigned to chromosome region 11q13 (Fitzky et al. 1998: Wassif et al. 
1998: Waterham et al. 1998). Ninety different mutations in the DHCR7 gene of patients with Smith-
Lemli-Opitz syndrome have been described to date (Fitzky et al. 1998; Wassif et al. 1998; Waterham 
et al. 1998; Yu et al. 2000; De Brasi et al. 1999; Witsch-Baumgartner et al. 2000; Patrone et al. 2000; 
Waterham & Wanders 2000; Krakowiak et al. 2000; Jira et al. 2001; Witsch-Baumgertner et al. 2001; 
Evans et al. 2001; Prasad et al. 2002). The cDNA has an open reading frame of 1,425 base-pairs 
coding for a polypeptide of 475 amino acids (Figure 3). Alternative splicing has not been described. 
Structurally,  the protein is strongly related to plant and yeast sterol reductases (Rahier et al. 1996: 
Waterham et al. 1998). The percentage of identity of the human DHCR7 with the A. thaliana sterol 
Δ7-reductase and the S. cerevisiae sterol Δ14-reductase is 38 and 34 respectively (Waterham et al. 
1998). 
 
Frequency and ethnic aspects 
SLOS is the most frequently occurring defect of cholesterol biosynthesis known to date. Estimated 
incidences of SLOS have historically been based on clinical diagnosis and initially ranged from 
1:40,000-50,000 births (Opitz et al. 1994; Cunniff et al. 1997). Now that biochemical and genetic 
testing for this trait has become available the incidence turns out to be significantly lower due to 
formerly incorrect inclusions of cases with SLOS-like phenotypes. Based on biochemically confirmed 
cases an incidence of approximately 1:60,000 births has now been reported in the UK and the USA 
(Ryan et al. 1998; Kelley & Hennekam 2000). From the number of biochemically and genetically 
confirmed Dutch SLOS cases we have estimated an incidence of approximately 1:80,000 births in The 
Netherlands (Jira et al. 2001; Waterham & Wanders 2000). On the other hand, an incidence of 1: 
20,000-26,500 of biochemically confirmed SLOS cases has been reported for Slovakia and Canada, 
respectively (Bzduch et al. 2000; Nowaczyk et al. 2001). 
   The reason for the rather high incidence of SLOS is unclear but may be a consequence of 
both founder effects and heterozygote advantage. A founder effect has been suggested to explain the 
fact that SLOS is most common in Caucasian populations from east-European descent. As possible 
advantage for heterozygotes a relative protection from atherosclerosis due to lowered blood 
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cholesterol levels as well as a lower risk for children to acquire rickets due to increased vitamin D 
production from elevated 7-DHC levels has been suggested (Kelley 1998; Kelley & Hennekam 2000). 
 
Pathogenic mutations and polymorphisms 
We performed a survey of the literature on mutations described in patients diagnosed with SLOS. 
Molecular data are presented in Table 2. The position of the mutations related to the position of the 
transmembrane segments and loops of the DHCR7 protein is illustrated in Figure 3.  
 
N
C
Cytoplasm
ER-Lumen
20
40
60
80
120 200
140
220
260
460
440
400
380
360
330
300
290
Null mutations
Missense mutations
175
230
 
 
5’UTR 3’UTR1 4 5 6 7 8 9
Transmembrane segment 1 2 3 4 5 6 7 8 9
2 3
 
 
Figure 3. Predicted membrane topology (upper part) and intron-exon organisation (lower part) of the 7-
dehydrocholesterol reductase, based on the data of Fitzky et al.1998. Transmembrane segments 4 to 8 represent 
the, highly conserved, sterol-sensing domain. The coding sequences of the transmembrane segments are given as 
grey areas in the lower part of the figure. Position of null mutations (black) and missense mutations (grey) are 
indicated. 
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Table 2 summarizes mutations described in SLOS patients by: nucleotide change, effect on coding 
sequence (for numbering of nucleotides and amino acids see: Waterham et al. 1998), affected exon, 
localisation in DHCR7 protein, incidence in study cohorts, their references and overall incidence. 
DNA sequencing of almost 400 SLO-alleles identified 90 different mutations. The DHCR7 gene 
mutations identified in SLOS patients were shown to have deleterious effects on the function of the 
DHCR7 protein (Fitzky et al. 1998; Wassif et al. 1998; Waterham et al. 1998).  
   Apart from the majority of missense mutations, four nonsense mutations (W37X, Q149X, 
W151X, Y217X), eight frameshift mutations leading to a premature stop; four deletions: IVS3-1-195 
del, 384-IVS5+4del, and 720-735del, and 1057Gdel), two splice site mutations (IVS8-1G>C and 
IVS8-1G>T), and two insertions (682insC; and 762insT) have been reported. Recently a 3 bp deletion 
has been detected resulting in the in-frame removal of a single histidine residue from position 356 of 
the DHCR7 protein. This deletion of one codon does not lead to a premature truncation of the protein 
and some residual activity may be expected although expression has not been determined.  
The seven most frequent mutations described to date are: IVS8-1G>C, T93M, R404C, W151X, 
V326L, R352W and E448K with a frequency of: 31.5, 11.2, 10.7, 6.4, 6.3, 3.2 and 3.2 percent, 
respectively, representing two third of the mutations in analysed alleles. Eighty mutations detected in 
SLOS alleles are single amino acid substitutions. 
   Two splice site mutations have been described at the same position (The frequent IVS8-1 
G>C mutation and a rare variant, namely an IVS8-1 G>T ; Jira et al. 2001). The G>C mutation causes 
aberrant splicing producing a mRNA with 134 base-pairs of retained intron 8 sequence at nucleotide 
position 963, which upon translation will lead to a frame shift and a stopcodon at nucleotide 1235 
(TGA) predicted to produce an inactive, truncated protein lacking 154 amino acids of its original C-
terminal sequence (Waterham et al. 1998; Waterham et al. 2000). This was confirmed by enzyme 
activity measurements in patients homozygous for this mutation (Moebius et al.1998; Waterham et 
al.1998; Witsch-Baumgartner et al. 2000; Waterham & Wanders 2000; Yu et al. 2000; Bataille et al. 
1999) which revealed no activity. Severely affected patients with extremely short life span have been 
identified who were homozygous for this mutation (Waterham et al. 1998; Witsch-Baumgartner et al. 
2000) with plasma cholesterol levels as low as 20 μmol/l/ (Jira et al. 2001). The number of 
homozygotes for this mutation, however, is lower than expected on the basis of the Hardy Weinberg 
equation. Hence, homozygosity for this null allele have been predicted to lead to spontaneous 
termination of pregnancy in many cases and consequently to an underestimation of the true incidence 
of SLOS (Kelley & Hennekam 2000; Waterham & Wanders 2000). 
So far fifteen polymorphic silent mutations are found in the DHCR7 gene (Table 2). 
  
50
T
ab
le
 2
. 9
0 
M
ut
at
io
ns
 in
 th
e 
D
H
C
R7
 g
en
e 
ca
us
in
g 
SL
O
S 
(A
) a
nd
 1
5 
po
ly
m
or
ph
ic
 m
ut
at
io
ns
 fo
un
d 
in
 S
LO
S 
pa
tie
nt
s a
nd
 c
on
tr
ol
s (
B)
.  
 A
 
 N
uc
le
ot
id
e 
 
Ef
fe
ct
 o
n 
 
 
Ex
on
  
Lo
ca
lis
at
io
n 
in
  
Pe
rc
en
ta
ge
 o
f  
 
 
 
 
 
R
ef
er
en
ce
  
O
ve
ra
ll 
 
C
ha
ng
e 
 
 
co
di
ng
 se
qu
en
ce
  
 
 
 
D
H
C
R
7 
 
 
 
pu
bl
is
he
d 
m
ut
at
io
ns
  
 
 
 
 
 
In
ci
de
nc
e 
 3G
>A
 
 
M
1 
 
 
 
3 
 
 
N
- t
er
m
in
us
  
 
2/
64
  
 
 
 
 
 
 
 
2 
98
-1
94
de
l 
 
W
33
-S
65
de
l 
 
 
3 
 
 
- 
 
 
 
 
 
1/
6 
 
 
 
 
 
 
 
 
5 
99
G
>A
 
 
W
37
X
  
 
 
4 
 
 
- 
 
 
 
 
 
1/
60
  
 
 
 
 
 
 
 
3 
15
1C
>T
 
 
P5
1S
  
 
 
4 
 
 
M
A
H
1 
 
 
 
2/
16
8,
 2
/6
0 
 
 
 
 
 
 
1,
3 
17
6G
>T
 
 
M
59
R
  
 
 
4 
 
 
M
A
H
1 
(lo
op
1-
2)
 
1/
64
  
 
 
 
 
 
 
 
2 
18
5A
>T
 
 
D
62
V
  
 
 
4 
 
 
Lo
op
1-
2 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
27
8C
>T
 
 
T9
3M
  
 
 
4 
 
 
Lo
op
1-
2 
 
 
 
14
/1
68
, 6
/6
4,
 7
/6
0,
 7
/1
8,
 4
/3
0 
 
1,
2,
3,
4,
7 
 
11
.2
 %
 
29
6T
>C
 
 
L9
9P
  
 
 
4 
 
 
M
A
H
2 
(lo
op
1-
2)
 
2/
16
8,
 1
/6
0 
 
 
 
 
 
 
1,
3 
32
1G
>C
 
 
Q
10
7H
 
 
 
4 
 
 
M
A
H
2 
 
 
 
1/
68
, 1
/3
0 
 
 
 
 
 
 
1,
7 
32
6T
>C
 
 
L1
09
P  
 
 
5 
 
 
M
A
H
2 
 
 
 
1/
16
8,
 1
/6
4,
 1
/3
0 
 
 
 
 
1,
2,
7 
35
6A
>T
 
 
H
11
9L
 
 
 
5 
 
 
M
A
H
2 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
38
4-
IV
S5
+4
de
l 
Fr
am
es
hi
ft 
 
 
 
 
 
- 
 
 
 
 
 
1/
18
  
 
 
 
 
 
 
 
4 
38
5-
IV
S5
+5
de
l 
Fr
am
es
hi
ft 
 
 
 
 
 
- 
 
 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
44
0G
>A
 
 
G
14
7D
 
 
 
6 
 
 
Lo
op
2-
3 
 
 
 
1/
16
8,
 1
/3
0 
 
 
 
 
 
 
1,
7 
44
3T
>G
 
 
L1
48
R
 
 
 
6 
 
 
Lo
op
2-
3 
 
 
 
1/
60
  
 
 
 
 
 
 
 
3 
44
5C
>T
 
 
Q
14
9X
 
 
 
6 
 
 
- 
 
 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
45
2G
>A
 
 
W
15
1X
 
 
 
6 
 
 
- 
 
 
 
 
 
14
/1
68
, 2
/6
4,
 1
/1
8,
 1
/3
0 
 
 
1,
2,
4,
7 
 
 6
.4
 %
 
46
1C
>T
 
 
T1
54
M
 
 
 
6 
 
 
M
A
H
3 
 
 
 
3/
16
8,
 2
/6
4,
 1
/3
0 
 
 
 
 
1,
2,
7 
47
0T
>C
 
 
L1
57
P  
 
 
6 
 
 
M
A
H
3 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
50
2T
>A
 
 
F1
68
I 
 
 
 
6 
 
 
M
A
H
3 
 
 
 
1/
60
  
 
 
 
 
 
 
 
3 
50
6C
>T
 
 
S1
69
L 
 
 
 
6 
 
 
M
A
H
3 
 
 
 
4/
16
8,
 1
/6
4,
 1
/6
0 
 
 
 
 
1,
2,
3 
52
3G
>C
 
 
D
17
5H
 
 
 
6 
 
 
Lo
op
3-
4 
 
 
 
1/
60
  
 
 
 
 
 
 
 
3 
52
9T
>C
 
 
W
17
7R
 
 
 
6 
 
 
M
A
H
4 
 
 
 
1/
30
  
 
 
 
 
 
 
 
7 
53
3T
>A
 
 
I1
78
N
  
 
 
6 
 
 
M
A
H
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
 
 
 
 
53
6C
>T
 
 
P1
79
L 
 
 
 
6 
 
 
M
A
H
4 
 
 
 
1/
60
  
 
 
 
 
 
 
 
3 
54
5G
>T
 
 
W
18
2L
 
 
 
6 
 
 
M
A
H
4 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
54
6G
>C
 
 
W
18
2C
 
 
 
6 
 
 
M
A
H
4 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
54
8G
>A
 
 
C
18
3Y
 
 
 
6 
 
 
M
A
H
4 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
  
51
59
2A
>G
 
 
K
19
8E
 
 
 
6 
 
 
M
A
H
4 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
65
1C
>A
 
 
Y
21
7X
 
 
 
7 
 
 
- 
 
 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
68
2C
in
s 
 
Fr
am
es
hi
ft 
 
 
7 
 
 
- 
 
 
 
 
 
1/
6 
 
 
 
 
 
 
 
 
5 
72
0-
73
5d
el
 
 
Fr
am
es
hi
ft 
 
 
7 
 
 
- 
 
 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
72
4C
>T
 
 
R
24
2C
 
 
 
7 
 
 
M
A
H
5 
 
 
 
3/
16
8,
 1
/3
0 
 
 
 
 
 
 
1,
7 
72
5G
>A
 
 
R
24
2H
 
 
 
7 
 
 
M
A
H
5 
 
 
 
1/
64
, 1
/3
0 
 
 
 
 
 
 
2,
7 
72
8C
>G
 
 
P2
43
R
  
 
 
7 
 
 
M
A
H
5 
 
 
 
2/
60
  
 
 
 
 
 
 
 
3 
73
0G
>A
 
 
G
24
4R
 
 
 
7 
 
 
M
A
H
5 
 
 
 
2/
64
  
 
 
 
 
 
 
 
2 
74
0C
>T
 
 
A
24
7V
 
 
 
7 
 
 
M
A
H
5 
 
 
 
1/
16
8,
 1
/3
0 
 
 
 
 
 
 
1,
7 
74
4G
>T
 
 
W
24
8C
 
 
 
7 
 
 
M
A
H
5 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
75
3C
>G
 
 
I2
51
M
  
 
 
7 
 
 
M
A
H
5 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
75
5A
>G
 
 
N
25
2S
 
 
 
7 
 
 
M
A
H
5 
 
 
 
2/
64
  
 
 
 
 
 
 
 
2 
76
2T
in
s 
 
Fr
am
es
hi
ft 
 
 
7 
 
 
- 
 
 
 
 
 
1/
6 
 
 
 
 
 
 
 
 
5 
76
5C
>A
 
 
F2
55
L 
 
 
 
7 
 
 
M
A
H
5 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
80
8A
>G
 
 
M
27
0V
 
 
 
7 
 
 
M
A
H
6 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
83
9A
>G
 
 
Y
28
0C
 
 
 
8 
 
 
M
A
H
6 
 
 
 
1/
2 
 
 
 
 
 
 
 
 
 
10
 
84
1G
>A
 
 
V
28
1A
 
 
 
8 
 
 
M
A
H
6 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
85
2C
>A
 
 
F2
84
L 
 
 
 
8 
 
 
M
A
H
6 
 
 
 
2/
64
, 1
/6
0 
 
 
 
 
 
 
1,
3 
86
1C
>A
 
 
N
28
7K
 
 
 
8 
 
 
Lo
op
6-
7 
 
 
 
3/
60
  
 
 
 
 
 
 
 
3 
86
2G
>A
 
 
E2
88
K
 
 
 
8 
 
 
Lo
op
6-
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
86
6C
>T
 
 
T2
89
I  
 
 
8 
 
 
Lo
op
6-
7 
 
 
 
2/
16
8,
 2
/3
0 
 
 
 
 
 
 
1,
7 
90
6C
>G
 
 
F3
02
L 
 
 
 
8 
 
 
Lo
op
6-
7 
 
 
 
1/
64
, 1
/6
0 
 
 
 
 
 
 
1,
3 
92
0G
>A
 
 
G
30
7D
 
 
 
8 
 
 
M
A
H
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
92
5G
>A
 
 
G
30
9S
 
 
 
8 
 
 
M
A
H
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
93
1T
>G
 
 
C
31
1G
 
 
 
8 
 
 
M
A
H
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
93
2G
>A
 
 
C
31
1Y
 
 
 
8 
 
 
M
A
H
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
95
2T
>C
 
 
Y
31
8N
 
 
 
8 
 
 
M
A
H
7 
 
 
 
1/
30
  
 
 
 
 
 
 
 
7 
95
6C
>T
 
 
T3
19
M
 
 
 
8 
 
 
M
A
H
7 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
95
7G
>A
 
 
T3
19
A
 
 
 
8 
 
 
M
A
H
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
IV
S8
-1
G
>C
 
 
Fr
am
es
hi
ft 
 
 
 
 
 
- 
 
 
 
 
 
49
/1
68
,1
9/
64
,2
0/
60
, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1/
6,
1/
2,
11
/3
0,
5/
8,
1/
2 
 
 
 
1,
2,
3,
5,
6,
7 ,
9,
10
 
31
.5
%
 
IV
S8
-1
G
>T
 
 
Fr
am
es
hi
ft 
 
 
 
 
 
- 
 
 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
97
0T
>C
 
 
Y
32
4H
 
 
 
9 
 
 
M
A
H
7 
 
 
 
3/
16
8,
 1
/6
0 
 
 
 
 
 
 
1,
3 
97
6G
>T
 
 
V
32
6L
 
 
 
9 
 
 
M
A
H
7 
 
 
 
12
/1
68
, 1
/6
4,
 5
/6
0,
 1
/8
 
 
 
1,
2,
3,
9 
 
 6
.3
%
 
98
6C
>T
 
 
P3
29
L 
 
 
 
9 
 
 
Lo
op
7-
8 
 
 
 
1/
 2
 
 
 
 
 
 
 
 
 
6 
  
52
10
22
T>
C
 
 
L3
41
P  
 
 
9 
 
 
M
A
H
8 
 
 
 
1/
30
  
 
 
 
 
 
 
 
7 
10
54
C
>T
 
 
R
35
2W
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
5/
16
8,
 1
/6
4,
 2
/6
0,
 2
/1
8 
 
 
1,
2,
3,
4 
 
 3
.2
 %
 
10
55
G
>A
 
 
R
35
2Q
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
3/
16
8  
 
 
 
 
 
 
 
3 
10
57
G
de
l 
 
Fr
am
es
hi
ft 
 
 
9 
 
 
- 
 
 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
10
58
T>
C
 
 
V
35
3A
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
10
63
A
>G
 
 
N
35
5D
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
64
  
 
 
 
 
 
 
 
2 
10
68
-1
07
0d
el
  
35
6d
el
H
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
8 
 
 
 
 
 
 
 
 
9 
10
84
C
>T
 
 
R
36
2C
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
11
38
T>
A
 
 
C
38
0S
  
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
11
38
T>
C
 
 
C
38
0R
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
11
39
G
>A
 
 
C
38
0Y
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
2/
16
8,
 1
/6
4 
 
 
 
 
 
 
1,
2 
11
90
C
>T
 
 
S3
97
L 
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
12
10
C
>T
 
 
R
40
4C
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
18
/1
68
 
 
 
 
 
 
 
 
1 
 
 
10
.7
 %
 
12
10
C
>A
 
 
R
40
4S
  
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
2/
16
8,
 1
/6
0 
 
 
 
 
 
 
1,
2 
12
19
A
>T
 
 
N
40
7Y
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
18
  
 
 
 
 
 
 
 
4 
12
22
T>
C
 
 
Y
40
8H
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
16
8,
 1
/3
0 
 
 
 
 
 
 
1,
7 
12
28
G
>A
 
 
G
41
0S
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
2/
16
8,
 1
/6
0 
 
 
 
 
 
 
1,
3 
12
28
G
>C
 
 
G
41
0R
 
 
 
9 
 
 
Lo
op
8-
9 
 
 
 
1/
16
8  
 
 
 
 
 
 
 
1 
13
27
C
>T
 
 
R
44
3C
 
 
 
9 
 
 
C
-te
rm
in
us
  
 
1/
16
8,
 1
/6
4 
 
 
 
 
 
 
1,
2 
13
28
G
>A
 
 
R
44
3H
 
 
 
9 
 
 
C
-te
rm
in
us
  
 
 
 
 
 
 
 
 
 
 
 
8 
13
31
G
>A
 
 
C
44
4Y
 
 
 
9 
 
 
C
-te
rm
in
us
  
 
1/
30
  
 
 
 
 
 
 
 
7 
13
37
G
>A
 
 
R
44
6Q
 
 
 
9 
 
 
C
-te
rm
in
us
  
   
   
 2
/1
68
  
 
 
 
 
 
 
 
1 
13
42
G
>C
 
 
E4
48
Q
 
 
 
9 
 
 
C
-te
rm
in
us
  
 
1/
16
8  
 
 
 
 
 
 
 
1 
13
42
G
>A
 
 
E4
48
K
 
 
 
9 
 
 
C
-te
rm
in
us
  
 
3/
16
8,
2/
64
,2
/6
0,
 2
/1
8,
 1
/3
0,
1/
8 
 
1,
2,
3,
4,
7 
 
 2
.9
 %
 
13
49
G
>T
 
 
R
45
0L
 
 
 
9 
 
 
C
-te
rm
in
us
  
 
1/
16
8  
 
 
 
 
 
 
 
1 
13
84
T>
C
 
 
Y
46
2H
 
 
 
9 
 
 
C
-te
rm
in
us
  
 
1/
60
  
 
 
 
 
 
 
 
3 
14
00
C
>T
 
 
P4
67
L 
 
 
 
9 
 
 
C
-te
rm
in
us
  
 
 
 
 
 
 
 
 
 
 
 
8 
14
06
G
>C
 
 
R
46
9P
  
 
 
9 
 
 
C
-te
rm
in
us
  
 
2/
60
  
 
 
 
 
 
 
 
3 
 *)
 M
A
H
=M
em
br
an
e 
as
so
ci
at
ed
 h
el
ix
 (s
ee
 fi
gu
re
 3
). 
  
 
 
 
 
To
ta
l o
f 3
58
 S
LO
S-
al
le
le
s. 
 1 
) F
itz
ky
 e
t a
l. 
19
98
 ; 
W
its
ch
-B
au
m
ga
rtn
er
 e
t a
l. 
20
00
. 2
 ) 
W
at
er
ha
m
 e
t a
l. 
19
98
; d
e 
D
ie
-S
m
ul
de
rs
 e
t a
l. 
19
99
; W
at
er
ha
m
 &
 W
an
de
rs
 2
00
0;
 Ji
ra
 e
t a
l. 
20
01
.   
3 
) Y
u 
et
 a
l. 
20
00
. 4
 ) 
D
e 
B
ra
si
 e
t a
l. 
19
99
. 5
 ) 
W
as
si
f e
t a
l. 
19
98
. 6
 ) 
Pa
tro
no
 e
t a
l. 
20
00
. 7
 ) 
K
ra
ko
w
ia
k 
et
 a
l. 
20
00
. 8
 ) 
W
its
ch
-B
au
m
ga
rtn
er
 e
t a
l. 
20
01
 (t
hi
s  
st
ud
y 
is
 n
ot
 in
cl
ud
ed
 in
 th
e 
ca
lc
ul
at
io
n 
of
 th
e 
ov
er
al
l i
nc
id
en
ce
 o
f m
ut
at
io
ns
). 
9)
 E
va
ns
 e
t a
l. 
20
01
. 1
0)
 P
ra
sa
d 
et
 a
l. 
20
02
.  
 
  
53
B
 
 15
 P
ol
ym
or
ph
is
m
s (
si
le
nt
 m
ut
at
io
ns
) 
 N
uc
le
ot
id
e 
 
Ef
fe
ct
 o
n 
 
 
Ex
on
  
Lo
ca
lis
at
io
n 
in
  
Pe
rc
en
ta
ge
 o
f  
 
 
 
 
 
R
ef
er
en
ce
  
O
ve
ra
ll 
 
C
ha
ng
e 
 
 
co
di
ng
 se
qu
en
ce
  
 
 
 
D
H
C
R
7 
 
 
 
pu
bl
is
he
d 
m
ut
at
io
ns
  
 
 
 
 
 
In
ci
de
nc
e 
 -2
23
T>
C
 
 
N
on
 c
od
in
g 
 
 
1 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
1 
-2
3T
>C
 
 
N
on
 c
od
in
g 
 
 
2 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
8 
13
9C
>T
 
 
L4
7 
 
 
 
4 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
8 
18
9A
>G
 
 
Q
63
Q
  
 
 
4 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
1,
2,
3,
4 
20
7C
>T
 
 
T6
9T
  
 
 
4 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
2,
3 
23
1C
>T
 
 
T7
7T
  
 
 
4 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
1,
2,
3,
4 
28
5A
>G
 
 
K
95
K
  
 
 
4 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
1 
IV
S4
-6
0T
>G
  
N
on
 c
od
in
g 
 
 
- 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
8 
43
8C
>T
 
 
N
14
6N
 
 
 
6 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
1,
2,
3 
96
9G
>T
 
 
L3
23
L  
 
 
9 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
1 
10
20
C
>T
 
 
V
34
0V
 
 
 
9 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
9 
11
58
C
>T
 
 
D
38
6D
 
 
 
9 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
1,
2,
3 
12
72
T>
C
 
 
G
42
4G
 
 
 
9 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
1,
2,
3,
4 
13
41
C
>T
 
 
D
44
7D
 
 
 
9 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
2 
13
50
C
>G
 
 
R
45
0R
 
 
 
9 
 
 
Po
ly
m
or
ph
is
m
  
 
 
 
 
 
 
 
 
 
 
1 
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  54
 
Localization of mutations in the protein 
Mutations occur further throughout the whole gene/protein without evident hotspots. A substantial 
number of mutations, however, are found in the so called "sterol-sensing domain" encompassing five 
transmembrane segments 4 – 8 as proposed by Fitzky et al. 1999 and Bae et al. 1999 (Figure 3). The 
specific DHCR7 membrane-spanning segments show strong homology to segments found in five other 
human proteins. These proteins in nature all have crucial interaction with sterols: 1] HMG-CoA 
reductase (Olender et al. 1992), 2] Niemann-Pick C1 gene product (Loftus et al. 1997), 3] Sterol 
regulatory element-binding protein-SCAP (Nohturfft et al. 1998), 4] the morphogene receptor 
PATCHED (Loftus et al. 1997) and 5] the DISPATCHED protein (Burke et al. 1999). According to 
the hydrophobicity in the DHCR7 protein, membrane-spanning segments 4 to 8 are closely spaced and 
connected by relatively short hydrophilic amino acid loops. In contrast to DHCR7, SCAP and HMG-
CoA reductase have a long COOH-terminal domain that projects into the cytosol (Nohturfft et al. 
1998).  
   The majority of SLOS patients are compound heterozygous for two different mutations in 
DHCR7. Sibs with the same DHCR7-mutations or genotypically identical patients, reported by 
different groups, may display similar or rather different plasma sterol values and/or different 
phenotypes (Krakowiak et al. 2000; Jira et al. 2001). The mutational site and effect on the coding 
sequence seemed to be only partially predictive for clinical and biochemical severity. 
 
Expression studies and Genotype-Phenotype 
Enzymatic activities of DHCR7 can be determined by assaying the conversion of either isotope-
labeled 7DHC or its precursors such acetate or lathosterol (cholesta-7-en-3β-ol) to cholesterol using 
thin layer chromatography or HPLC (Lund et al. 1996; Shefer et al. 1997; Necklason et al. 1999). An 
alternative is the use of non-radiolabeled ergosterol (ergo-5,7,22-trien-3β-ol) as substrate for DHCR7. 
Incubation of microsomal preparations or cell homogenates from rat and human with ergosterol results 
in the reduction of the Δ7 double bond which produces brassicasterol (ergo-sta-5,22-dien-3β-ol). The 
ergosterol conversion followed by GC-MS detection of produced sterols, although less sensitive than 
the isotope-based assays, avoids the problems caused by the instability and availability of the 
radiolabeled precursors (Honda et al. 1996; Shefer et al. 1998). Functional analysis, by expression of 
DHCR7 mutations in mammalian cells, demonstrated that all but one of the missense (R450L; C-
terminus) mutations result in unstable protein (Waterham et al. 1998; Witsch-Baumgartner et al. 2000; 
Jira et al. 2001). Residual enzyme activity may explain some of the phenotypic variability seen in 
SLOS. Enzyme kinetic studies support this theory (Neklason et al. 1999).  
   Mutations that alter, interfere with or truncate the sterol-sensing domain of the DHCR7 
protein are likely to cause a more severe clinical and biochemical SLOS-phenotype. Making 
predictions of the SLOS phenotype from genotype, however, continues to be difficult since there is 
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significant clinical and biochemical variability among genetically identical infants. A higher incidence 
of severe null mutations (IVS8-1C>G insertion and W151X) in a population could explain a lower 
incidence of SLOS occurring. The 50 % incidence of the IVS8-1G>C mutations observed in our 
European SLOS-study (Jira et al. 2001) exceeds the findings of others who identified the IVS8-1G>C 
mutation in 21 of 66 (32%) and 18 of 52 (35%) SLOS-alleles, respectively (Yu et al. 2000; Bataille et 
al. 2000). The development of a simple PCR-RFLP can be used as a screening-method for detecting 
this frequent SLO-mutation. Data on population screening for the IVS8-1G>C mutation indicated the 
high carrier frequency of about 1 in 100 and 1 in 30 for U.S. Caucasians and European Caucasians, 
respectively (Yu et al. 2000, Nowaczyk et al. 2001). A study of DHCR7 mutations from three 
European areas (Poland, Germany/Austria and Great Britain) revealed extreme frequency gradients for 
this mutation. The frequency gradient of the W151X mutation is in a direction opposite to the gradient 
of  the IVS8-1G>C mutation (Witsch-Baumgartner et al. 2001). 
 
In conclusion, SLOS is a multiple malformation/retardation syndrome with a clinical and biochemical 
spectrum ranging from a lethal to a difficult to diagnose very mild presentation. Among the 90 
different mutations observed and reviewed, the majority are missense mutations (80). There is a 
clustering in three domains of the DHCR7 protein; 1] in the transmembrane domain, 2] in the fourth 
cytoplasmatic loop, 3] and at the C–terminus.  
Twelve null mutations (4 nonsense, 4 deletions , 2 splice site mutation and 2 single nucleotide 
insertions) lead to absent enzyme activity. As far as studied, missense mutations, on the other hand, 
have demonstrated only decreased protein stability in expression studies.  
Severe clinical phenotype in SLOS patients is due to null allele and fourth loop mutations whereas C-
terminal and transmembrane mutations cause a mild to moderate clinical phenotype. Further molecular 
genetic studies will enable insight in carrier frequency of specific DHCR7 mutations in various 
populations. Additional clues for prenatal, maternal, environmental, other genetic and compensatory 
biochemical determinants that can modify the phenotypical consequences of the functional DHCR7 
deficiency in SLOS is needed. 
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ABSTRACT 
 
Correct quantitative results for plasma cholesterol, 7-dehydrocholesterol (7-DHC), and 8-
dehydrocholesterol (8-DHC) are invaluable for making the correct diagnosis in patients with the 
Smith–Lemli–Opitz syndrome (SLO) and for biochemical monitoring of these patients during therapy. 
The enzymatic method for cholesterol measurement based on cholesterol oxidase gives falsely high  
values for plasma cholesterol in samples from patients with SLO. Both 7-DHC and 8-DHC contribute 
substantially to the test result, given that they are accepted substrates of cholesterol oxidase. All 
cholesterol methods making use of this enzyme are expected to give unreliable results with plasma 
samples from SLO patients. Cholesterol values found with these methods may be low-normal in  
individual cases with SLO. Therefore, other techniques for measuring cholesterol, 7-DHC, and 8-
DHC, e.g., gas chromatography, should be used for diagnosing these patients and for follow-up during 
therapy. However, a normal value for plasma cholesterol, as obtained by gas chromatography, does 
not exclude SLO. The diagnosis should always be confirmed or excluded by testing for the presence of 
high concentrations of 7-DHC and 8-DHC in plasma. We found that one patient with a severe form of 
the disease had a plasma cholesterol concentration of 20 µmol/L, to our knowledge, the lowest value 
ever recorded in a human being.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY WORDS:  cholesterol oxidase, inborn errors of metabolism, gas chromatography,  
dehydrocholesterol, enzymatic assays, analytical error 
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INTRODUCTION 
 
In 1964, Smith et al. (Smith et al. 1964) described a syndrome, now generally referred to as the 
Smith–Lemli–Opitz syndrome (SLO), characterized by a number of birth defects affecting nearly 
every organ system.1 The patients are mentally retarded, have a growth disorder, and show failure to 
thrive. Both dysmorphic facial signs (microcephaly, palatoschizis, cataracts, ptosis, micrognathia) and 
limb abnormalities (syndactyly of the second and third toe, polydactyly) occur in the patients. Genital 
disorders, hypospadias, and cryptorchidism have been described.  
The syndrome is estimated to be among the most common autosomal recessive 
disorders among Caucasians, its prevalence being ~1:20 000 births (Opitz 1994). A possible 
abnormality of steroid secretion was first postulated by Chesalow et al. (Chesalow et al. 1985). Since 
then, Irons et al. have shown that SLO is caused by a defect in the cholesterol biosynthesis pathway 
(Irons et al. 1993; Tint et al. 1994). Patients have decreased concentrations of cholesterol in plasma 
and increased concentrations of the precursor 7-dehydrocholesterol (cholesta-5,7-dien-3ß-ol; 7-DHC) 
and its isomer 8-dehydrocholesterol (cholesta-5,8-dien-3ß-ol; 8-DHC) in plasma, erythrocytes, 
cultured skin fibroblasts, amniotic fluid, and various tissues (Irons et al. 1993; Tint et al. 1994; 
McGaugran et al 1994; Johnson et al. 1994; Batta et al. 1995), findings that suggest a block in 
reduction of the C-7 double bond (Irons et al. 1993; Tint et al. 1994). Recently, those researchers 
confirmed that the enzyme defect involved the 7-dehydrocholesterol-7-reductase in liver microsomes 
(Shefer et al. 1995).  
The aim of our study was to evaluate the reliability of the standard enzymatic assay (based on 
cholesterol oxidase) for measuring plasma cholesterol in samples from SLO patients. Because the 
technique for measuring 7-DHC in plasma is not widely available, clinicians may wish to use the 
presence of low concentrations of plasma cholesterol in patients with SLO as a first step towards 
confirming the diagnosis. Furthermore, measurement of plasma cholesterol will play a role in the 
follow-up of therapy strategies with high-cholesterol diets. We also compared the plasma cholesterol 
results obtained with the cholesterol oxidase method with those of a gas-chromatographic (GC) 
technique. 
 
 
MATERIALS AND METHODS 
 
Patients 
We analyzed plasma from eight patients (ages 2 weeks to 33 years) who had the characteristic clinical 
signs and symptoms of SLO. Forty-eight plasma samples, included as a diseased control group, had 
been sent to our laboratory for metabolic screening; however, the patients in this control group did not 
show clinical signs and symptoms characteristic for SLO, and some were under special clinical 
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conditions (e.g., feeding problems, metabolic crises, special dietary formulas). This group provides the 
background against which metabolic screening laboratories have to diagnose patients with SLO. 
Because this study was not devised to obtain reference ranges for cholesterol in various age groups, 
the data presented later (in Table 1) should not be considered as such. 
 
Enzymatic assays  
Plasma cholesterol was measured at 30 °C with an enzymatic test on a Hitachi 747 analyzer 
(Boehringer Mannheim, Mannheim, Germany) according to the instructions of the manufacturer and 
with use of Boehringer reagents (CHOD-PAP test; SYS-3:1127578/1489704). In this test, cholesterol 
and cholesterol esters are converted by the sequential action of cholesterol esterase and cholesterol  
oxidase. The H2O2 formed in the latter reaction is determined quantitatively in the last step by using a 
peroxidase that converts phenol and 4-aminophenazone into 4-(p-benzoquinone-monoimino)-
phenazone. 
 
GC assays  
For GC determination of cholesterol and its precursors (7-DHC and 8-DHC), we combined 60 µL of 
plasma with 7.58 nmol of 5ß-cholestane-3-ol as internal standard (no. C5050; Steraloids, Wilton, NH) 
in 1 mL of a solution of 0.32 mol/L KOH in 95% ethanol. The CFAS-calibrator for cholesterol was 
used (no. 759350; Boehringer Mannheim) in combination with two control sera (Precinorm and  
Precipath; also from Boehringer Mannheim). After an incubation of 15 min at 55 °C, 1 mL of H2O 
and 4 mL of pentane were added and mixed for 5 min. The steroids, which were extracted into the 
pentane layer, were taken up by pipetting after centrifugation (5000g • min). The pentane was then 
evaporated with nitrogen at ~50 °C. To derivatize the steroids, we added 100 µL of an equivolume 
solution of N,O-bis(trimethylsilyl)trifluoroacetamide (no. 15238; Fluka, Buchs, Switzerland) and 
pyridine and incubated at 60 °C for 30 min. GC analysis was performed with a Hewlett-Packard 
(Amstelveen, The Netherlands) Model 5890 GC and a 25 m x 0.25 mm (i.d.) CP-Sil-19 CB column 
(film thickness 0.2 µm; Chrompack, Bergen op Zoom, The Netherlands). The temperature program 
was started at 240 °C, increased to 300 °C at 5 °C/min, and held for 3 min at 300 °C. Temperatures of 
the injector and detector were 280 and 300 °C, respectively. Pure 7-DHC for calibration purposes was 
purchased from Sigma Chemical Co., St. Louis, MO; no. D-3625); to quantify 8-DHC, we used the 
calibration curve for 7-DHC because 8-DHC for calibration was not available commercially. 
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Table 1. Sterol concentrations (μmol/La) in plasma from patients with Smith-Lemli-Opitz syndrome and from 
disease controls. 
 
SLO 
patient 
Sex, age Enzymatic 
cholesterol 
                                     Gas chromatography 
Cholesterol       7-DHC        8-DHC         Totalb                Ratioc 
1 F, 11 d  700 20 430 266 716 34.8 
2 M, 7 m 1000 260 300 385 945 2.6 
3 M, 7 y 1820 975 280 264 1519 0.6 
4 M, 26 y 1560 1118 182 127 1427 0.3 
5 M, 27 y 1300 884 143 107 1134 0.3 
6 M, 28 y 1700 1170 220 284 1674 0.4 
7 F, 29 y 2080 1261 442 308 2011 0.6 
8 F, 33 y 3800 2030 848 555 3433 0.7 
<1 y (12)d 2400-4900 2523-4805 <7 <5  <0.004 
1-5 y (12) 2100-5300 2139-5447 <5 <5  <0.003 
6-15 y (10) 3200-5700 3138-5775 <5 <5  <0.002 
Range, 
disease 
control 
group >15 y (14) 2900-8600 3174-8226 <8 <10  <0.003 
1-3 y 1150-4700 
4-6 y 2800-4800 
Reference 
intervals  
for healthy 
childrene 
7-9 y 2900-6400 
 
a To convert cholesterol from μmol/L to mg/dL: 1000 μmol/L = 38.67 mg/dL. 
b Cholesterol (GC) + 7-DHC (GC) + 8-DHC (GC). 
c [7-DHC (GC) + 8-DHC (GC)]/cholesterol (GC). 
d n for each group is listed in parentheses. 
e 0.025-0.975 fractiles, according to Lockitch et al. 1988 
 
GC-MS  
Mass spectra from peaks separated by GC were obtained by using a VG Trio 2 quadrupole mass 
spectrometer (Micromass, Altrincham, Cheshire, UK) coupled to the Hewlett-Packard 5890 GC. The 
cholesterol peak was characterized by fragments at m/z 329, 353, and 458. 7-DHC and 8-DHC gave 
identical spectra, with characteristic fragments at m/z 351 and 456. 
 
Recovery studies  
To test whether 7-DHC contributes to the result of the enzymatic cholesterol assay, we performed 
recovery experiments for cholesterol and 7-DHC in a human serum matrix and in human serum 
albumin solution (Sigma, no. A 16535; 50 g/L in 0.15 mol/L NaCl). The sterols, which had been 
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dissolved to 33 mmol/L solution in ethanol, were added to both matrices to yield final concentrations 
of 1, 2, and 3 mmol/L. Complete solubilization was obtained by adding Nonidet P-40 (no. N6507; 
Sigma) to a final concentration of 100 mL/L.  
 
 
RESULTS 
 
Enzymatic assay for plasma cholesterol  
Table 1 shows the plasma cholesterol concentrations obtained with the cholesterol oxidase method for 
our diseased control group and the SLO patients. For the group of SLO patients as a whole, the 
cholesterol concentrations generally were below the concentration range found in the control group.  
However, there was an overlap between values for the two groups. One SLO patient (case 8) had a 
plasma cholesterol concentration of 3.8 mmol/L with this test, which would be interpreted as a low but 
normal value for an adult. The values found for the SLO children (cases 1–3) were close to the range 
found in our diseased control group; their diagnosis could easily have been missed if no further data 
had been available. 
 
GC analysis of cholesterol, 7-DHC, and 8-DHC 
The gas chromatograms of the plasma samples from a patient in the diseased control group and from 
two patients with SLO all showed peaks for the internal standard, cholesterol, 8-DHC, and 7-DHC 
(Figure 1). Identification of the compounds was based on their retention times and on mass spectra 
(not shown). In agreement with the data from Axelson (Axelson et al. 1991), we observed that 7-DHC 
occurs in trace amounts in normal human plasma. Using calibration curves for cholesterol, 7-DHC, 
and the internal standard, we confirmed the linearity of the method for the concentration range used in 
this study (data not shown).  
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Figure 1. Capillary-column gas chromatograms of control plasma (top panel) and plasma from two SLO 
patients (the middle panel shows plasma from patient 1 and the bottom panel plasma from patient 5, Table 1 ). 
Peaks: IS, internal standard (5ß-cholestane-3-ol); A, cholesterol; B, 8-DHC; and C, 7-DHC. 
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Capillary-column gas chromatograms of control plasma (top panel) and plasma from two SLO patients 
(the middle panel shows plasma from patient 1 and the bottom panel plasma from patient 5, Table 1 ). 
Peaks: IS, internal standard (5ß-cholestane-3-ol); A, cholesterol; B, 8-DHC; and C, 7-DHC. 
Plasma concentrations of cholesterol measured with GC vary considerably among SLO patients (20–
2030 µmol/L) and also show an overlap in concentrations between the SLO group and the diseased 
control group, similar to the overlap observed in the enzymatic cholesterol assay. In all patients with 
SLO, the concentrations of 7-DHC and 8-DHC were clearly increased (GC results, Table 1 ). These 
data lead to a straightforward diagnosis for all SLO cases in this study. The ratio of (7-DHC + 8-
DHC)/cholesterol may correlate with the severity of the disease. Patients 1 and 2, who had a severe 
form of the disease (type 1), gave higher values for this ratio than did the rest of the SLO group.  
The correlation between the enzymatic assay and the GC assay results for plasma cholesterol was good 
in the diseased control group (Figure 2), the Passing and Bablok (Passing et al. 1983) regression line 
(and 95% confidence intervals) being y = 1.02 (0.95–1.08) x - 0.080 (-0.31 to 0.20). In the SLO group, 
the results of both methods for the plasma samples all deviated from that correlation line, to yield  
y = 0.68 (0.37–1.15) x - 0.211 (-0.84 to 0.44). Because the cholesterol concentrations found for the 
SLO group were systematically higher by the enzymatic test than by GC (Table 1 ), we hypothesized 
that 7-DHC and 8-DHC might contribute to the results of the enzymatic cholesterol assay; 
consequently, we performed recovery experiments with cholesterol and 7-DHC.  
 
Recovery experiments 
Cholesterol recovery in the enzymatic assay was complete, the mean recovery in the serum matrix 
being 108% (n = 9, range 100–120%) and the mean in the albumin matrix being 94% (n = 9, range 90–
100%). Most of the added 7-DHC was also measured: mean in serum matrix, 61% (n = 6, range 5–
70%); mean in albumin matrix, 71% (n = 6, range 70–75%). Possibly, the known instability of 7-DHC  
contributed to the partial recovery of this compound.  
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Figure 2. Correlation between enzymatic cholesterol oxidase results and GC results for plasma cholesterol in 
SLO patients (■) and diseased control patients (◇). 
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DISCUSSION  
 
Reliable quantitative results for cholesterol, 7-DHC, and 8-DHC are invaluable to confirm the 
diagnosis in patients clinically suspected to have SLO, and for follow-up of SLO patients being treated 
with high-cholesterol diets. Until now, studies on reference values for plasma cholesterol have focused 
on the upper limit of the reference range: Very few data are available for the lower limit of the 
cholesterol reference range in plasma from children of various age groups. Lane and McConathy have 
studied changes in serum cholesterol in the first month of life using GC (Lane et al. 1986). Lockitch 
(Lockitch et al. 1988) determined age-related reference values for serum cholesterol in 450 healthy 
children, ages 1 to 19 years. Plasma cholesterol data in our diseased control group are in line with the 
data of Lockitch et al. (Lockitch et al. 1988). The 0.025 fractile those authors found for the age groups 
older than 6 years is similar to the lowest value found in our diseased control group. For the age group 
between 1 and 5 years, Lockitch et al. found a 0.025 fractile value of 1.15 mmol/L, whereas the lowest 
value in our diseased control group was 1.67 mmol/L. Because patients with SLO are often severely 
affected at birth, reference values for plasma cholesterol in the first weeks of life are of special 
interest. Lane and McConathy (Lane et al. 1986) observed that cholesterol at day 28 postpartum 
ordinarily is in the lower 5th percentile of the adult population values; at day 3 postpartum, values 
were even lower (Lane et al. 1986). Age-related reference values are thus invaluable for the correct 
interpretation of plasma cholesterol concentrations in children.  
As Table 1 makes clear, SLO patients measured with the enzymatic assay may give 
plasma cholesterol values close to the lower limit of the range of the diseased control group or even 
within this range. In one of our adult patients (case 8), the plasma cholesterol concentration of 3.8 
mmol/L would be interpreted as normal. We were able to better discriminate between both groups by 
assessing the cholesterol values measured by GC. However, even with this assay, the result for 
cholesterol could easily be misinterpreted. We conclude that the diagnosis of SLO cannot be excluded 
definitely on the basis of the plasma cholesterol results. The control samples gave results by both the 
enzymatic and the GC method for cholesterol that correlated well (Table 1 and Figure 1 ). For SLO 
patients, however, obvious differences between the techniques were apparent, the cholesterol 
concentrations measured with the enzymatic assay being invariably higher than the GC results. As 
Table 1 shows, the summed GC data for cholesterol, 7-DHC, and 8-DHC correlated well with the 
enzymatically determined cholesterol concentration. This suggests that 7-DHC and 8-DHC may 
contribute to the plasma cholesterol results measured by the enzymatic cholesterol assay. We partly 
confirmed this by adding 7-DHC to solutions of albumin and to plasma samples. The majority (61–
71%) of 7-DHC added was measured as cholesterol by the enzymatic cholesterol test, in both the 
serum matrix and the human albumin matrix. The results for cholesterol measured by GC were not 
influenced by these additions (data not shown). Apparently the enzymatic cholesterol test cannot 
discriminate between the various steroids. This may be due to aspecific conversion of 7-DHC and 8-
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DHC by cholesterol oxidase. Using a sterol monolayer system, Slotte has described that cholesterol 
oxidase from Streptomyces cinnamomeus oxidizes 7-DHC at a rate 5.1-fold slower than it oxidizes 
cholesterol (Slotte et al. 1992). We expect that similar results will be found for other commercially 
available reagents for plasma cholesterol determinations that make use of cholesterol oxidase. Our 
results indicate that the enzymatic test for measuring plasma cholesterol gives falsely high results for 
SLO plasma samples. The plasma cholesterol concentration in our youngest patient with SLO was 20 
µmol/L, whereas the (7-DHC + 8-DHC)/cholesterol ratio for this patient was by far the greatest we 
saw. This is, to our knowledge, the lowest plasma cholesterol ever reported in humans. Clinically, the 
affected girl had a very severe form of the disease (type I), with major malformations; the patient died 
at age 5 weeks. As also described by Tint (Tint et al. 1995), we observed that the plasma cholesterol 
concentration in older SLO patients is generally higher than in young, more severely affected patients. 
In our study the lowest and the highest cholesterol values we saw differed by 20-fold. Those for 7-
DHC differ by only 6-fold, and the concentrations of 7-DHC and 8-DHC are not significantly different 
between younger and older patients in our study. The (7-DHC + 8-DHC)/cholesterol ratio, however, is 
clearly higher in the young patients (cases 1 and 2 in Table 1 ). The differences in plasma cholesterol 
concentrations of SLO patients at different ages might result from a higher dietary intake of 
cholesterol in older, clinically more mildly affected patients. Kelley (Kelley et al. 1994) suggested that 
higher cholesterol concentrations correlate more with the length of survival and the amount of dietary 
cholesterol than with clinical severity. Another explanation for higher cholesterol concentrations in 
older SLO patients could be the residual activity of the cholesterol biosynthesis pathway in older 
patients, as was suggested by Tint (Tint et al. 1995). This would also explain the milder course of the 
disease in this group. At present, it is unknown whether the shortage of cholesterol and the abundance 
of cholesterol precursors both contribute to the development of the clinical signs and symptoms of 
SLO. As with cholesterol oxidase, other enzymes involved in cholesterol-converting pathways may 
also accept a 7-dehydro or 8-dehydro variant of their normal substrates. This would give rise to 
unexpected intermediates with unpredictable functional characteristics. This concept may give further 
impetus to attempts to understand the importance of cholesterol precursors in the development of the 
clinical picture. 
Summarizing, we conclude that the enzymatic test for measuring plasma cholesterol 
gives unreliable results in SLO patients. For diagnosis of patients clinically suspected to have the 
disease, measurements of plasma cholesterol (by any method) should not be used. Obviously, 
quantification of plasma 7-DHC and 8-DHC is the method of choice here (Irons et al. 1993; Tint et al. 
1994; Tint et al. 1995). For follow-up studies of SLO patients receiving high-cholesterol dietary 
treatment, the enzymatic test for measuring plasma cholesterol is also not suitable. Instead, the method 
of choice for this purpose may be GC, which provides reliable quantitative data for plasma cholesterol, 
7-DHC, and 8-DHC.  
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The Smith-Lemli-Opitz syndrome is caused by deficient activity of Δ7-dehydrocholesterol reductase, 
the final enzyme of the cholesterol biosynthetic pathway, resulting in low cholesterol and high 
concentrations of its direct precursors, 7-dehydrocholesterol (7DHC) and 8DHC in blood and tissues 
(Irons et al. 1993; Tint et al. 1995). Cholesterol fulfils an essential role during embryogenesis where it 
functions as a transporter-molecule for hedgehog signalling proteins required for normal 
morphogenesis (Porter et al. 1996). Without cholesterol their transport is impaired (Porter et al. 1996).  
These findings may explain the phenotypic consequences of  Δ7-reductase deficiency as observed in 
Smith-lemli-Opitz syndrome: microcephaly, distinctive facies, organ malformations, syndactyly, and 
genital abnormalities. Once morphogenesis is complete, it is not known whether the low cholesterol or 
the increased concentration of precursors is more harmful. In abetalipoproteinaemia, cholesterol 
concentrations are similar to those in Smith-Lemli-Opitz syndrome without clinical side-effects; we 
thus postulated that 7DHC, 8DHC, or both may be the toxic substances. Therapeutical trials of dietary 
supplementation of cholesterol with or without bile acids have shown that plasma cholesterol 
concentrations can be increased in some patients. Concentrations of the precursors 7DHC and 8DHC, 
however, were only marginally altered and clinical results so far have been disappointing (Irons et al. 
1995; Ullrich et al. 1996).  
 
We performed repeated exchange transfusions in combination with inhibition of de-novo cholesterol 
synthesis with a HMG CoA reductase-inhibitor in a 3-month old girl with this disorder, after having 
obtained informed parental consent. This strategy aimed for simultaneously to remove precurors while 
supplying extra cholesterol from the donor blood and inhibit renewed de-novo production of 
precursors at a higher level in the cholesterol pathway. The girl underwent eight whole-blood 
exchange transfusions during a period of 5 months. Total exchanged volume accounted approximately 
for eight times her circulating blood volume. Oral simvastatin treatment was begun on day 20. No 
complications or drugrelated adverse effects were documented. Sterol plasma and erythrocyte-
membrane concentrations during the treatment period of 190 days showed a substantial decrease of 
7DHC (and 8DHC), as well as an increase in and finally a normal cholesterol (table).  
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Table. Gas chromatograph analysis of sterols in plasma (μmol/L) and erythrocyte membrane (μmol/60μL) 
isolated erythrocytes during therapy and percentage of initial concentration 
 
Plasma Erythrocyte membrane Day 
Cholesterol 7DHC 7DHC/CH 
Ratio 
Cholesterol 7DHC 7DHC/CH 
Ratio 
0* 1338 (100) 362 (100) 0.27 1273 (100) 1087 (100) 0.85 
38* 1196 (89) 272 (75) 0.23 1454 (114) 830 (76) 0.57 
93 1608 (120) 149 (41) 0.09 1762 (138) 388 (36) 0.22 
147* 2312 (173) 191 (53) 0.08 2621 (206) 470 (43) 0.18 
190 2594 (194) 160 (44) 0.06 2700 (212) 400 (37) 0.15 
 
Exchange transfusions were on day 1, 4, 11, 39, 40, 148, 150, and 152. Simvastatin was begun on day 
20, daily dose 0.2 mg/kg increasing to 0.4 mg/kg at day 30, and 0.6 mg/kg from day 40. * Immediately 
before exchange transfusions. CH=Cholesterol; percentages shown in parentheses. 
 
After the first three exchange transfusions, plasma 7DHC increased from 151 to 332 μmol/L over 5 
days. After exchange transfusions four and five (days 39 and 40) plasma 7DHC concentrations 
remained stable. Mental, motor, and social development improved. At age 8 months, the child’s 
neuromotor development corresponded to a child of 5 months on the Bayley scales of infant 
development. Measurements of head circumference, height, and weight followed the same percentage 
as before the start of treatment. 
Repeated exchange transfusions in combination with a HMG CoA-inhibitor reduced plasma and 
erythrocyte membrane precursor concentrations and improved the plasma 7DHC/cholesterol ratio 
greatly in this child. We are encouraged to explore the long-term effects of this treatment strategy as a 
potentially useful therapeutic option in the treatment of young patients with Smith-Lemli-Opitz 
syndrome. 
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ABSTRACT 
 
The Smith-Lemli-Opitz syndrome (SLOS) is caused by deficient 7-dehydrocholesterol reductase, 
which catalyzes the final step of the cholesterol biosynthetic pathway, resulting in low cholesterol and 
high concentrations of its direct precursors 7-dehydrocholesterol (7DHC) and 8DHC. We 
hypothesized that i) 7DHC and 8DHC accumulation contributes to the poor outcome of SLOS patients 
and ii) blood exchange transfusions with hydroxymethylglutaryl (HMG)-CoA reductase inhibition 
would improve the precursor-to-cholesterol ratio and may improve the clinical outcome of SLO 
patients. First, an in vitro study was performed to study sterol exchange between plasma and 
erythrocyte membranes. Second, several exchange transfusions were carried out in vivo in two SLOS  
patients. Third, simvastatin was given for 23 and 14 months to two patients. The in vitro results 
illustrated rapid sterol exchange between plasma and erythrocyte membranes. The effect of exchange 
transfusion was impressive and prompt but the effect on plasma sterol levels lasted only for 3 days. In  
contrast, simvastatin treatment for several months demonstrated a lasting improvement of the 
precursor-to-cholesterol ratio in plasma, erythrocyte membranes, and cerebrospinal fluid (CSF). 
Plasma precursor concentrations decreased to 28 and 33% of the initial level, respectively, whereas the  
cholesterol concentration normalized by a more than twofold increase. During the follow-up period all 
morphometric parameters improved. The therapy was well tolerated and no unwanted clinical side 
effects occurred.  
This is the first study in which the blood cholesterol level in SLOS patients is normalized with 
a simultaneous significant decrease in precursor levels. There was a lasting biochemical improvement 
with encouraging clinical improvement. Statin therapy is a promising novel approach in SLOS that 
deserves further studies in larger series of patients. 
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INTRODUCTION 
 
The Smith-Lemli-Opitz syndrome (SLOS) is caused by a deficient 7-dehydrocholesterol reductase 
activity, the final enzyme of the cholesterol biosynthetic pathway. Low cholesterol and high 
concentrations of its direct precursors 7-dehydrocholesterol (7DHC) and its isomer, 8-
dehydrocholesterol (8DHC), in blood and tissues are the biochemical hallmarks of the syndrome 
(Smith et al. 1964; Irons et al. 1993; Tint et al. 1995). Plasma sterol concentrations generally correlate 
with syndrome severity and outcome (Tint et al. 1995). 7-Sterol reductase activity in the liver of SLOS 
patients is markedly decreased (Shefer et al. 1995). The human 7-sterol reductase gene has been 
characterized and assigned to chromosome 11q12-13. Mutations in this gene cause SLOS (Fitzky et al. 
1998; Waterham et al. 1998; Wassif et al. 1998). Cholesterol fulfills an essential role in 
embryogenesis, during which it functions as a transporter molecule for sonic hedgehog signaling 
proteins required for correct morphogenesis. Without sufficient cholesterol their transport and function 
are impaired (Porter et al. 1996; Cooper et al. 1998). These findings may explain the phenotypic 
consequences of the 7-reductase deficiency as observed in SLOS: microcephaly, a distinctive facies, 
cleft palate, various organ malformations, syn/polydactyly, and genital abnormalities. 
It is still a matter of debate whether the low cholesterol or the increased concentration of 
precursors or both is the most harmful component in growth and development of these patients. On the 
basis of experience with familial hypobetalipoproteinemia (Linton et al. 1993), in which plasma 
cholesterol in heterozygotes is as low as in some SLOS cases, without any clinical effect, we 
hypothesized that the cholesterol precursors 7DHC and 8DHC may be toxic. Both precursors are 
structurally similar to cholesterol (differing only in having an extra double bond in the cholesterol B-
ring) and therefore may interfere with the important role of cholesterol. Cholesterol is the precursor of 
steroid hormones; therefore, a reduction of the availability of cholesterol or incorporation of 
precursors by adrenal and testicular cells may reduce or interfere with normal synthesis of 
corticosteroids and androgens. Steroid hormones also affect a wide variety of behavioral and 
psychological states. In SLOS abnormal bile acid profiles already have been documented (Natowicz et 
al. 1994). Furthermore, some enzyme systems accepting cholesterol as substrate have also been shown 
to accept 7DHC and 8DHC as a substrate (Jira et al. 1997).  
So far, therapeutic trials in SLOS patients used dietary supplementation of cholesterol with or 
without bile acids. The concentration of plasma cholesterol could be increased to subnormal levels in 
some patients. The concentrations of the precursors 7DHC and 8DHC, however, were only marginally 
influenced in patients and animal experiments, and clinical improvement until now was in general 
disappointing (Xu et al. 1995a; Irons et al. 1995; Ullrich et al. 1996; Elias et al. 1997; Irons et al. 
1997; Nwokoro et al. 1997; Xu et al. 1995b). We here report the results of a study performed to 
investigate i) the in vitro exchange kinetics of cholesterol and precursors between plasma and 
erythrocyte membranes, ii) the in vivo effect of exchange transfusions in SLOS patients, and iii) the 
  80
effect of simvastatin (hydroxymethylglutaryl [HMG]-CoA reductase inhibitor) on cholesterol and 
precursor levels in two young unrelated SLOS patients. The exchange transfusions aimed 
simultaneously to remove precursors while supplying additional cholesterol from the donor blood. 
Simvastatin inhibits de novo production of precursors at the level of HMG-CoA reductase in the 
cholesterol biosynthetic pathway (Figure 1). 
 
 
 
 
 
CLINICAL AND LABORATORY INVESTIGATIONS 
 
Subjects 
In the Pediatric Clinic (University Hospital Nijmegen, Nijmegen, The Netherlands) two patients with 
SLOS were treated with exchange transfusions and simvastatin. Parents were informed about the aim 
of the study, study protocol, and potential side effects. Informed parental consent was obtained on 
behalf of both patients for the application of repeated exchange transfusions and for the use of 
simvastatin as an investigational drug, based on previously published evidence of the safety and 
efficacy of statins in children. The consent to participate in the study was strictly voluntary and could 
be renounced at any time by the parents without disadvantage for further medical care of their  
child.  
Patient A  
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Patient A, a girl, first child of healthy unrelated parents, was born after an uneventful pregnancy. A 
cesarean section was performed at 38+4 weeks gestational age because of breech position. Apgar 
scores were 8 and 10 after 1 and 5 min, respectively. Birth weight was 3,520 g (97th percentile), 
length was 50 cm (75th percentile) and head circumference was 33 cm (50th percentile). The observed 
facial dysmorphias, ptosis, syndactyly of second and third toes, and failure to thrive gave rise to the 
suspicion of SLOS. At the age of 2 months she was admitted to our clinic, where the diagnosis was 
confirmed biochemically. Organ malformations were not present. Brain magnetic resonance imaging 
(MRI) was normal. Ophthalmological and neurophysiological (electroencephalogram [EEG], 
brainstem auditory evoked potential [BAEP]) examinations revealed no  
abnormalities.  
 
Patient B  
Patient B, a boy, was born after the second pregnancy of unrelated parents. At 37 weeks gestational 
age he underwent an external cephalic version due to a breech position and was born at 40 weeks. 
Apgar scores were 10 and 10 after 1 and 5 min, respectively. Birth weight was 2,570 g (5th 
percentile), length was 51 cm (90th percentile), and head circumference was 31.5 cm (25th percentile). 
He had mild facial dysmorphias, syndactyly of the second and third toe, and failure to thrive. 
Diagnosis of SLOS was confirmed biochemically in plasma at the age of 5 months. No organ 
malformations could be detected. MRI of the brain showed normal structures and myelinization and 
the EEG was normal. Ophthalmological examination showed no cataract or other abnormalities.  
 
Biochemical studies 
The initial diagnosis and the biochemical effect of our therapeutic approaches on cholesterol and 
precursors in plasma, erythrocyte membranes, and cerebrospinal fluid (CSF) were investigated by gas 
chromatography and gas chromatography/mass spectrometry as described previously (Jira et al. 
1997a; Van Rooij et al. 1997).  
 
In vitro sterol exchange study  
To study sterol exchange kinetics between plasma and erythrocyte membranes two in vitro 
experiments were designed: i) Erythrocytes from patient A were isolated, washed three times with 
saline, and incubated at 37°C in normal donor plasma. The patient's erythrocytes again were isolated 
after an incubation time of 0, 20, 40, 60, 120, and 240 min, washed  
three times with saline, and analyzed; ii) similarly, donor erythrocytes were incubated with plasma 
from patient A and studied after 0, 20, 60, 120, and 360 min of incubation. 
 
 
In vivo exchange transfusions 
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After surgical insertion of a subclavian venous catheter eight blood exchange transfusions with 800 
mL of donor blood were performed in patient A. The 2-h procedures took place on days 1, 4, 11, 39, 
40, 148, 150, and 152, in total accounting for eight times her circulating blood volume. In patient B 
three exchange transfusions were performed, on days 1, 4, and 7 with 800 mL each, accounting for 
five times his blood volume.  
 
HMG-CoA reductase inhibition by simvastatin therapy 
Simvastatin was started on day 20 and gradually increased from 0.2 to 1.0 mg/kg per day (two daily 
doses) during 23 months in patient A. In patient B the simvastatin dosage was not altered and was 
maintained at 0.6 mg/kg per day for 14 months. Study methods consisted of baseline hematological 
investigations and blood chemistry profiles. These were repeated at 2- to 6-week intervals from the 
start of therapy. Both children received standard pediatric formula without dietary supplementation of 
cholesterol or bile acids. Patient B was, in addition, treated during the last 3 months with oral 
cholesterol supplementation (100 mg/kg per day; cholesterol-module available from Nutricia (product 
code number 18,012; Special Product Service, Zoetermeer, The Netherlands) in combination with 
simvastatin therapy. Sterol analysis in plasma, erythrocytes and CSF was carried out before and during 
therapy. Clinical course, neuromotor development, neuroimaging by MRI, and growth were 
monitored, scored, and compared with normative data from the Dutch population (Gerver et al. 1996). 
Informed parental consent was obtained for the application of repeated exchange transfusions and for 
the use of simvastatin as investigational drugs based on previously published evidence of the safety 
and efficacy of statins in children (Stein 1989; Ducobu et al. 1992; Sinziger et al. 1992; Patterson et 
al. 1993; Knipscheer et al. 1996; Lambert et al. 1996; Coleman et al. 1996; Sanjad et al. 1997;).  
 
 
RESULTS 
 
Both patients had total cholesterol concentrations below the age-related reference values and 100-fold 
higher concentrations than the upper reference range limits for 7DHC and 8DHC in plasma, 
erythrocytes, and CSF before treatment, confirming the diagnosis of SLOS as shown in Table 1. 
Mutation analysis will be reported elsewhere.  
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Table 1. Sterol effect of simvastatin during a 23- and 14 month period in two young infants with SLO 
syndrome. 
 
 
Patient A 
 
 
Patient B 
 
Months of Therapy 
 
Months of Therapy 
 
0 
 
3 6 14 23 0 3 6 14 
 
 
 
 
Controls 
Age 
(Months) 
3 6 9 17 26 10 13 16 24  
Biochemistry 
Plasma 
Cholesterol 
(mmol/L) 
1.338 1.608 2.549 2.916 2.815 1.281 1.567 2.050 3.312 2.600-5.200 
7DHC+8DHC 
(mmol/L) 
0.625 0.289 0.289 0.212 0.172 0.407 0.147 0.178 0.136 < 0.01 
Ratioa 
 
0.47 0.18 0.11 0.07 0.06 0.32 0.09 0.09 0.04 < 0.01 
Erythrocytes 
Cholesterol 
(mmol/L) 
1.273 1.762 2.700 2.368 2.499 1.846 2.230 2.706 2.997 2.400-3.200 
7DHC+8DHC 
(mmol/L) 
1.547 0.583 0.577 0.372 0.299 1.137 0.388 0.451 0.212 < 0.01 
Ratioa 
 
1.22 0.33 0.21 0.16 0.12 0.62 0.17 0.17 0.07 < 0.01 
CSF 
Cholesterol 
(nmol/L) 
3.217 2.564 1.938 2.776 - 1.972 - 2.656 2.902 3.500-5.100d 
7DHC 
(mmol/L) 
610 340 168 160 - 404 - 276 280 < 20 
Ratiob 
 
0.19 0.13 0.09 0.06 - 0.20 - 0.10 0.10 < 0.01 
Morphometrics 
 
Length  
(cm) 
55 62 70 78 - 65 68 76 83 
SD -3.2 -1.8 -0.5 -1.2 - -6.6 -5.0 -1.9 -1.3 
Weight 
(kg) 
4.11 5.95 7.25 9.75 - 5.15 6.55 7.20 8.60 
SD -3.5 -1.9 -1.5 -0.7 - -5.6 -3.7 -2.7 -2.4 
Head 
Circumference 
(cm) 
34.0 38.0 40.5 43.2 - 40.4 42.3 43.2 44.0 
SDc -6.8 -4.7 -3.3 -2.6 - -5.2 -4.4 -3.5 -3.5 
 
a (7DHC+8DHC)/cholesterol 
b 7DHC/cholesterol ratio 
c Standard deviation below 50th percentile 
d Range of values from van Rooij et al. 1997 
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Sterol exchange study 
SLO erythrocytes were incubated in donor plasma with cholesterol, 7DHC, and 8DHC concentrations 
of 5,038, 6, and 16 µmol/L, respectively. A rapid increase in cholesterol in membranes of SLO 
erythrocytes in 240 min was observed, from 1,070 to 2,019 µmol/L. Simultaneously, the 7DHC + 
8DHC concentration in SLO erythrocytes decreased from 1,180 to 613 µmol/L, improving the (7DHC 
+ 8DHC)/cholesterol ratio from 1.10 to 0.30 (Figure 2, experiment 1).  
In the second incubation normal human donor erythrocytes were incubated in SLO plasma 
with concentrations of cholesterol, 7DHC, and 8DHC of 1,228, 326, and 274 µmol/L, respectively. A 
significant and rapid increase in the (7DHC + 8DHC)/cholesterol ratio from 0.01 to 0.32 occurred over 
6 h (Figure 2, experiment 2). These experiments show that cholesterol, 7DHC, and 8DHC exchange 
easily and rapidly between plasma and membrane compartments, which encouraged us to proceed in 
performing exchange transfusions in our two patients. Cholesterol exchange between red cell 
membrane and serum lipoproteins has been studied previously. In accordance with our observations, 
these investigators documented a rate constant for movement of cholesterol from erythrocytes to 
plasma and from plasma to erythrocytes with the half-time for efflux of 4 to 6 h (Gold et al. 1990; 
Gottlieb 1980). 
 
 
 
Figure 2. In vitro sterol exchange kinetics between erythrocyte membranes and plasma. Sterol composition of 
SLOS erythrocytes incubated in normal plasma (experiment 1) and sterol composition of normal erythrocytes 
incubated in plasma of an SLOS patient (experiment 2). 
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Exchange transfusions 
The effect of exchange transfusion on correcting plasma cholesterol, 7DHC, and 8DHC is prompt as 
illustrated by the plasma sterol concentrations in the period of three exchange transfusions on days 1, 
4, and 11 in patient A (Figure 3). A significant amount of cholesterol could be delivered to the patient. 
Also, a substantial quantity of precursors could be removed from the patient. The plasma precursor-to-
cholesterol ratio improved significantly. The beneficial effect on the plasma levels lasted for only 3 
days (Figure 3). 
 
 
 
Figure 3. Effect of the first three exchange transfusions (days 1, 4, and 11) on plasma cholesterol (solid 
squares) and precursor (solid triangles) concentration in time in patient A. 
 
 
The patient total body/tissue cholesterol uptake from donor blood, calculated from initial donor blood 
concentrations and the concentrations in the remaining exchanged blood in patient A during the 
exchange transfusions on days 148, 150, and 152, was 1.7 g (0.4 + 0.6 + 0.7 g, respectively). For 
patient B, cholesterol uptake was 1.9 g (0.6 + 0.6 + 0.7 g, respectively) during his three exchange 
transfusions. This body cholesterol delivery of 300–400 mg/kg, achieved by donor cholesterol uptake 
through three exchange transfusions in both patients, is substantial when seen from the perspective of 
a normal daily cholesterol synthesis of 8.3;–14.5 mg/kg documented in healthy children (Illingworth et 
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al. 1997; Illingworth et al. 1980). The mean amount of plasma precursors (7DHC + 8DHC) for both 
patients removed by one exchange transfusion is 53 mg (variation, 32–92 mg).  
Unfortunately, the effect of a single exchange transfusion on the plasma sterol levels was 
limited to 2–3 days. Also, repeated exchange transfusions did not result in a lasting change in either 
the plasma cholesterol or the plasma precursor concentrations (Figure 4). This limited effect motivated 
us to evaluate the effect of HMG-CoA reductase inhibition by simvastatin therapy for several months. 
 
Simvastatin effect 
Patients A and B were treated with simvastatin for 23 and 14 months, respectively. Precursor levels 
decreased significantly to 28 and 33% of the initial (pretreatment) level in plasma, in erythrocyte 
membranes, and CSF (Table 1 and Figure 4). Surprisingly, an increase and finally a normalization of 
the plasma cholesterol concentration (>2.6 mmol/L) was observed after several months. As mentioned 
earlier, patients did not receive cholesterol supplementation during the simvastatin treatment period 
(except for the last 3 months for patient B). The plasma (7DHC + 8DHC)/cholesterol ratio finally 
decreased from 0.47 to 0.06 in patient A and from 0.32 to 0.04 in patient B. Although promising, it is 
important to note that despite the significant reduction in precursor plasma level and the increase in 
cholesterol plasma level with this therapy, the (7DHC + 8DHC)/cholesterol ratio was still above 
normal. The 7DHC/8DHC ratio in the plasma of both patients remained unchanged during treatment 
(0.82–1.42), uninfluenced by the decrease in total precursor values. In erythrocyte membranes the 
7DHC/8DHC ratio was significantly higher (1.66–2.78) compared with plasma. These data suggest 
that erythrocyte membranes incorporate 7DHC more readily than 8DHC.  
During the months of treatment cholesterol precursor concentrations decreased in the CSF of 
both patients, improving the precursor-to-cholesterol ratio as illustrated in Table 1. During treatment, 
brain-specific proteins (neuron-specific enolase, S-100, and myelin basic protein) and neurotransmitter  
metabolites (homovanillic acid [HVA], 5-hydroxyindoleacetic acid [5-HIAA], and 3-methoxy-4-
hydroxy-phenylethyleneglycol [MHPG]) in the CSF of both patients remained in the normal range 
(results not shown). The blood–brain barrier (BBB) function was intact both before and during the  
therapy period. Simvastatin supplementation therapy was well tolerated. Neuromuscular complications 
were not observed. Plasma enzymatic activity of aminotransferases and creatine kinase remained in 
the normal range. No cataract developed.  
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Figure 4. Effect of exchange transfusions (solid triangles) and simvastatin on plasma cholesterol (solid squares) 
and precursor (solid diamonds) levels (mmol/L) in patient A (A) and patient B (B). Simvastatin dosage is 
illustrated by the black bars, which represent oral simvastatin dosage in mg per kilogram per day. 
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Patient outcome  
 
Mental, motor, and social development of both patients shows constant improvement. At the age of 17 
months (patient A) and 24 months (patient B), the neuromotor assessment of both patients, as 
determined by the Hoskins–Squires test (Hoskins et al. 1993), and cognitive skills corresponded to 11 
and 14 months, respectively. Weight, length, and head circumference during treatment are shown in 
Table 1. Eating behavior, however, was unchanged. Patient A received a percutaneous gastrostomy 
after prolonged nasogastric tube feeding while patient B is eating orally with substantial effort of his 
parents. By the age of 2 years both patients walked with help and started to communicate by word 
expression.  
Our results suggest that simvastatin therapy may represent a simple, effective, and safe way to 
reduce accumulated cholesterol precursors while improving cholesterol plasma levels in patients with 
SLOS.  
 
 
DISCUSSION 
 
Our therapeutic approach aimed at a fast supply of cholesterol and removal of a substantial amount of 
precursors by blood exchange therapy. Thereafter use of simvastatin was aimed at blocking the 
cholesterol biosynthesis pathway as a way to avoid the formation of large amounts of the cholesterol 
precursors 7DHC and 8DHC, which may be potentially harmful to patients. Both aims were met in our  
first patient, where we accomplished a significant reduction in the plasma levels of 7DHC and 8DHC 
as published earlier (Jira et al. 1997b). We were encouraged by this biochemical response and decided 
to continue therapy, using simvastatin as the only medication. Also, a second patient was included to 
confirm our findings. In this second patient three exchange transfusions were carried out for rapid 
supplementation of cholesterol and removal of part of the precursor load. The patient received 
simvastatin without dietary cholesterol for 11 months. As in our first patient the precursor levels in 
plasma, erythrocytes, and CSF declined significantly, fully confirming our findings in the first patient. 
 
This is the first time that a therapeutic approach has succeeded in normalizing plasma cholesterol 
levels with simultaneous significant reduction of cholesterol precursor levels in plasma. We believe 
that our therapeutic approach is superior to the approach of dietary cholesterol with or without bile 
acid supplementation (Irons et al. 1995; Ullrich et al. 1996; Elias et al. 1997; Irons et al. 1997; 
Nwokoro et al. 1997). In 11 SLOS patients, treated with cholesterol and bile acids, the mean 
cholesterol-to-total sterol ratio in plasma only increased from 55% to 72% (Irons et al. 1997). In 6 
other SLOS patients treated with cholesterol and bile acids this ratio did not exceed 60% (Nwokoro et 
al. 1997). These data are comparable to our own experience with 2 other SLOS-patients treated with 
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cholesterol and bile acid supplementation for more than 1 year. In these patients there was no 
significant decline in plasma precursor levels and only a temporary and limited increase in plasma 
cholesterol that never reached normal levels. The cholesterol-to-total sterol ratios were unchanged 
during therapy and remained below 79 and 68%. In contrast, the two patients in this study reached 
cholesterol-to-total sterol ratios of 94 and 96%.  
The gradual disappearance of cholesterol precursors 7DHC and 8DHC under statin therapy is 
relatively easy to understand. The statin blocks the de novo synthesis of the precursors at the level of 
HMG-CoA reductase. The simultaneous rise in plasma cholesterol is unexpected. It is difficult to 
understand because our patients did not receive extra cholesterol supplementation. Simvastatin may 
influence the expression level of the deficient 7-reductase. Such an effect was described for the 
combination of cholestyramine and lovastatin in rats (Bae et al. 1999). Moreover, Shefer (Shefer et al. 
1997) showed an upregulation of the 7-reductase in human fibroblasts in cholesterol-deficient medium 
supplemented with lovastatin.  
We observed in both patients an impressive improvement in all morphometric parameters 
(Table 1). In most of the described SLOS patients the head circumference, height, and weight stay 
below the third percentile, even during conventional therapy (Ullrich et al. 1996; Elias et al. 1997; 
Irons et al. 1997; Nwokoro et al. 1997). Whether growth and developmental progress are, in fact, the 
result of therapy and relate to the biochemical corrections, or might have occurred otherwise, is 
difficult to prove. Data derived from rats, however, support the view that oxidized 7DHC derivates 
play a role in embryo toxicity and growth retardation (Gaoua et al. 1999). Confirmation with a larger 
group of patients over a longer period of time is needed. Studies of cholesterol metabolism ultimately 
will result in more understanding of the origin and metabolism of cholesterol that is used in growth, 
development, and myelin in the CNS in children. 
A small number of studies demonstrated the efficacy and safety of statin therapy in childhood. 
Pediatric studies showed that statins were well tolerated by children with familial ypercholesterolemia 
(Knipscheer et al. 1996; Lambert et al. 1996; Ducobu et al. 1992; Sinziger et al. 1992; Stein 1989;), 
nephrotic syndrome (Sanjad et al. 1997; Coleman et al. 1996), and Niemann;–Pick disease type C 
(Patterson et al. 1993). One study, however, in which an attempt was made to reduce mevalonate 
accumulation by administering simvastatin to two children with mevalonate kinase deficiency 
(Hoffmann et al. 1993), documented impressive acute adverse effects. In adults the use of simvastatin 
did not show any significant adverse effects on brain activity measured by EEG, evoked potentials, 
mood, sleep, or cognitive performance (Harrison et al. 1994). The beneficial effects of simvastatin 
used in our study without any unwanted clinical side effects encouraged us to proceed to use this 
therapy in our patients. Of course, a careful clinical follow-up of the patients is required to prevent any 
complications in liver function or other unwanted side effects of the drug. It remains to be established 
whether simvastatin use will also work to the same extent in other, perhaps more severely affected 
SLOS patients. Further studies will also be required in new SLOS cases to find out whether the initial 
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exchange transfusions really are required. The transfusions have a relatively high clinical risk. When a 
similar effect of statin use on plasma cholesterol and precursor levels can be found without exchange 
transfusions this approach would of course be preferred. Also, it remains to be established in further 
studies whether dietary cholesterol supplementation therapy with simultaneous statin use can add to 
the success of statin use.  
Brain is the most cholesterol-rich organ in the body. Cholesterol in the human brain, 
developing sheep brain, and rat pup brain is made locally from glucose, acetate, or polyunsaturated 
fatty acids (Jurevics et al. 1995; Likhodii et al. 1995; Snipes et al. 1997). Sterols formed in the brain 
by the mevalonate pathway have an active and independently regulated biosynthesis. Cholesterol is 
not imported from peripheral blood across the BBB by lipoprotein uptake (Turley et al. 1996; Edmond 
et al. 1991). Even during fetal brain development, including the time before closure of the BBB, 
lipoproteins circulating through the central nervous system are not used as a source of cholesterol, but 
are synthesized locally (Edmond et al. 1991; Andersson et al. 1990; Bjorkheim et al. 1997; Serougne 
et al. 1976). In our two treated patients we demonstrated that precursor concentrations are highly 
increased and that cholesterol concentrations in CSF are decreased in comparison with controls. 
Dietary supplementation of cholesterol alone, in SLOS, will not influence an impaired (7DHC + 
8DHC)/cholesterol ratio in the central nervous system. In line with previously described evidence 
(Jurevics et al. 1995; Likhodii et al. 1995; Snipes et al. 1997; Turley et al. 1996; Edmond et al. 1991; 
Andersson et al. 1990; Bjorkheim et al. 1997; Serougne et al. 1976) the only way to reduce cerebral 
accumulation of cholesterol precursors in SLOS individuals is by means of local inhibition of brain 
cholesterol biosynthesis. Statins with lipophilic properties (simvastatin and lovastatin) cross the BBB 
(Saheki et al. 1994) and are potential inhibitors of cerebral cholesterol precursor accumulation in 
SLOS. The half-life for cholesterol calculated in rat brain studies was found to be about 5;–6 months 
(Snipes et al. 1997; Andersson et al. 1990; Bjorkheim et al. 1997). Elimination of brain cholesterol 
precursors is therefore not expected to be a rapid process. This could explain why in our patients the 
sterol improvement in plasma and erythrocyte membranes was faster and superior to the correction 
observed in CSF.  
In conclusion, simvastatin therapy reduced 7DHC and 8DHC and normalized cholesterol 
concentrations in two children with SLOS and was well tolerated without side effects. Blocking the de 
novo synthesis of cholesterol precursors reduced accumulation of these intermediates in plasma, 
membranes, and CSF. Biochemical and clinical follow-up was 23 and 14 months, respectively, and we 
are encouraged to explore the long-term beneficial effects of this new treatment strategy in these and 
other SLOS patients.  
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SUMMARY 
 
Background 
 Smith-Lemli-Opitz syndrome (SLOS) is a common autosomal recessive developmental disorder 
characterized by facial dysmorphisms, mental and developmental retardation, and multiple congenital 
anomalies. The disorder is caused by a reduced activity of the cholesterol biosynthetic enzyme 7-
dehydrocholesterol reductase (7DHCR), due to mutations in the encoding DHCR7 gene. As a 
consequence, patients have low cholesterol and elevated 7-dehydrocholesterol levels in plasma and 
tissues, correlating rather well with clinical severity.  
 
Methods  
We treated 3 relatively mild SLOS patients for 80, 49 and 31 months, respectively, with simvastatin, 
an oral HMG-CoA reductase inhibitor and determined the effect and efficacy of the treatment on 
development and general well being of the patients. In addition, we studied in vitro the effect of 
simvastatin on 7DHCR expression and activity in primary skin fibroblast cells of the patients. 
 
Findings  
All patients tolerated the simvastatin therapy well without apparent clinical side effects. During 
treatment, we observed a marked decrease of plasma 7-dehydrocholesterol levels in all three and a 
concomitant increase of the plasma cholesterol concentration in two patients. Moreover, two patients 
showed a good and one patient a moderate clinical improvement of growth and development.  
The in vitro studies with cultured primary skin fibroblast cells of the patients showed that simvastatin 
induces an increase in gene transcription of the DHCR7 gene, which results in an increase of 7DHCR 
protein and, consequently, an increase in (residual) 7DHCR activity. Since 7DHCR catalyses the rate-
limiting step in SLOS, this increase in residual 7DHCR activity leads to an increased flux through the 
cholesterol biosynthetic pathway resulting in lower 7-dehydrocholesterol and increased cholesterol 
levels, as observed in the treated patients.  
 
Interpretation  
Simvastatine treatment in SLOS patients with a mild phenotype and residual activity of 7DHCR in 
cells results in increased 7DHCR expression and activity levels leading to a lowering of 7-
dehydrocholesterol and an increase of cholesterol levels. 
 
Relevance  
The data provide an explanation for the unexpected rise of plasma cholesterol in SLOS patients upon 
simvastatin treatment. Simvastatin treatment may be a good long-term therapeutic option in SLOS 
patients with residual 7DHCR activity and a mild clinical presentation. 
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INTRODUCTION 
 
Smith-Lemli-Opitz syndrome (SLOS; MIM 270400) is an autosomal recessive inborn error of 
cholesterol biosynthesis with an incidence of 1:20,000-60,000 dependent on the geographic region. 
Patients with SLOS may display a variety of morphogenic and congenital anomalies, including 
dysmorphic craniofacial features, microcephaly, multiple internal organ, limb/skeletal, and urigenital 
malformations, (intrauterine) growth and mental retardation, and behavioural problems (Smith et al.  
1964; Cunniff et al. 1997; Kelley et al. 2000; Waterham et al. 2000) After the identification of the 
biochemical and molecular basis of SLOS (see below) it has become clear that patients with SLOS 
constitute a clinical and biochemical continuum ranging from hardly recognizably mild to a severe, 
lethal form. 
 SLOS is caused by a deficiency of the enzyme 3β-hydroxysterol Δ7-reductase (7DHCR; 
E.C.1.3.1.21 Tint et al. 1994; Irons et al. 1993) due to mutations in the encoding DHCR7 gene located 
at chromosome 11q13 (Fitzky et al. 1998; Waterham et al. 1998; Wassif et al. 1998). 7DHCR 
catalyses the predominant final step in cholesterol biosynthesis, which is the reduction of the C7-C8 
(Δ7) double bond of 7-dehydrocholesterol (7DHC; cholesta-5,7-dien-3β-ol) to produce cholesterol 
(cholest-5-en-3β-ol). As a consequence of the 7DHCR deficiency, patients with SLOS typically have 
reduced plasma and tissue cholesterol concentrations and elevated levels of 7DHC, constituting the 
major biochemical hallmark used to confirm the clinical diagnosis of the syndrome. In addition, 
elevated 8-dehydrocholesterol (8DHC; cholesta-5,8(9)-dien-3β-ol) levels are observed, presumably 
synthesized from the accumulating 7DHC by the enzyme sterol Δ8-Δ7 isomerase functioning in the 
reverse direction. 
Several studies have shown that overall clinical severity in SLOS correlates best either with 
the absolute cholesterol levels or with the sum of 7DHC plus 8DHC expressed as the fraction of total 
sterol (Tint et al. 1995; Cunniff et al.1997; Witsch-Baumgartner et al. 2000) Indeed, patients with 
only very minimal symptoms have been identified with (near) normal cholesterol levels and barely 
elevated levels of 7DHC and 8DHC reflecting partially reduced 7DHCR activities ranging from ~20 to 
50% of the activities in controls (Kelley et al. 2001; Langius et al. 2003). 
It is generally considered that the availability of cholesterol during development of the foetus 
is one of the major determinants of the phenotypic expression in SLOS. Since most anomalies 
occurring in SLOS are of early-embryonic origin, it will not be feasible to develop a postnatal therapy 
to entirely cure the patients. The therapy currently mostly employed aims to replenish the lowered 
cholesterol levels in the patients through dietary supplementation of cholesterol with or without bile 
acids. This treatment indeed leads to a substantial elevation of plasma cholesterol concentrations in 
patients, but plasma concentrations of 7DHC and 8DHC are only marginally altered. Moreover, this 
treatment does not significantly change the sterol levels in brain, which are dependent on de novo 
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cholesterol synthesis due to the limited ability of cholesterol to cross the blood-brain barrier (Jurevics 
& Morell 1995). Nevertheless, several reports have indicated that dietary cholesterol supplementation 
may improve behaviour, growth and general well being in children with SLOS (Nwokoro & Mulvihill 
1997; Elias et al. 1997; Irons et al. 1997). However, a recent standardized study with 14 patients 
indicated that cholesterol supplementation has hardly any effect on developmental progress Sikora et 
al. 2004). 
 
We recently reported promising results of an alternative therapeutic strategy aimed primarily at 
lowering of the elevated 7DHC and 8DHC levels through treatment with simvastatin, an oral HMG-
CoA reductase inhibitor. The observed biochemical effects in two treated SLOS patients were a 
marked decrease of 7DHC and 8DHC levels and, somewhat unexpectedly, a concomitant increase of 
cholesterol in both plasma and cerebrospinal fluid in conjunction with promising clinical improvement 
(Jira et al. 1997; Jira et al. 2000). We now report the results of a long-term biochemical and clinical 
follow-up of three SLOS patients treated with simvastatin. In addition, we studied the effect of 
simvastatin on the regulation of cholesterol biosynthesis in cultured primary skin fibroblast cells of 
these patients to provide an explanation for the effect on the patients’ sterol levels upon the 
simvastatin treatment. Our results show that the simvastatin treatment leads to an increased expression 
of the rate-limiting 7DHCR in SLOS patients, and thus results in an increased flux through the 
cholesterol biosynthesis pathway. The efficacy of the simvastatin treatment appears to correlate well 
with the residual activity of 7DHCR and clinical severity in patients.  
 
 
METHODS  
 
Patients 
Parents were informed about the aim of the study, study protocol, and potential side effects. Informed 
parental consent was obtained on behalf of the patients for the use of simvastatin as an investigational 
drug, based on previously published evidence of the safety and efficacy of statins in children (de 
Jongh et al. 2002). The consent to participate in the study was strictly voluntary and could be 
renounced at any time by the parents without disadvantage for further medical care of their child. 
Three young patients, diagnosed with SLOS based on clinical signs and confirmed at the biochemical 
and molecular level (Table 1), were treated for 80, 49 and 31 months, respectively with oral 
simvastatin (Zocor®; Merck Sharp & Dome) at a daily dose of 0.6 – 1.0 mg / kg body weight. During 
the first year of simvastatin therapy, all three patients received cholesterol supplementation at a dosage 
of 40 mg/kg/day. After one year the cholesterol supplementation was stopped without any noticeable 
effects.  
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Procedures 
To study the effect of simvastatin in vitro we used primary skin fibroblasts of 4 patients with SLOS, 
one carrier of SLOS and one control subject. These included fibroblasts of the three patients included 
in the simvastatin therapy and fibroblasts of a severe patient reported previously (Waterham et al. 
1998; Jira et al. 2000). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% Foetal Calf Serum (FCS) and 1% penicillin/streptomycin in a temperature and 
humidity controlled incubator (95% air, 5% CO2 as the gas phase) at 37°C. At day 1, the cells were 
trypsinized and seeded in duplo in T75 culture flasks (Costar) at 60% confluency in DMEM 
containing 10% FCS. At day 2, the medium was substituted for DMEM containing 10% lipoprotein 
(cholesterol)-depleted FCS to induce de novo cholesterol synthesis. At day 3, simvastatin (1 μM final 
concentration; for preparation of stock solution see (Houten et al. 2003) was added to one set of cells 
while a second set received the solvent without simvastatin. At day 8, all cells were harvested by 
trypsinization, washed twice with PBS, aliquoted, snap-frozen as pellets in liquid nitrogen and stored 
at –80oC until further use. 
For sterol analysis, fibroblasts were saponified for 2 h at 70°C in alkaline ethanol after which 
sterols were extracted with hexane, converted to trimethylsilyl derivatives using 
bis(trimethylsilyl)trifluoroacetamide-trimethylchlorosilane and analysed by gas chromatography/mass 
spectrometry as described previously (Waterham et al. 1998). Sterol analysis in plasma was performed 
as described previously (Jira et al. 2000). 
The enzyme activity of 7DHCR in homogenates of cultured fibroblasts was determined by 
measuring the time-dependent conversion of ergosterol into brassicasterol by sterol analysis using gas 
chromatography/mass spectrometry similar as described previously by (Langius et al. 2003; Honda 
et al. 1996). Protein concentrations of the lysates were determined with the bicinchoninic acid protein 
assay (Sigma).  
Mutations in the DHCR7 gene of the patients were identified after PCR amplification of 
coding exons 3-9 plus flanking intron sequences followed by sequencing of the DNA fragments on an 
ABI 377A automated DNA sequencer as described previously (Jira et al. 2001). 
Antibodies were produced in a rabbit against a fusion protein composed of amino acid 
residues D359 until K393 of 7DHCR (corresponding to a large cytosolic loop of the protein) fused to 
the C terminus of glutathione-S-transferase (GST) and expressed in Eschericha coli. The crude 
antiserum was affinity-purified on a column with an immobilized fusion protein composed of the same 
7DHCR peptide but then fused to the carboxyl terminus of maltose binding protein (MBP) expressed 
in E. coli and coupled to cyanogen bromide sepharose (Pharmacia) as described previously 
(Hogenboom et al. 2002). For the generation of the GST-7DHCR and MBP-7DHCR fusion proteins, a 
cDNA fragment comprising bp 1075 until 1179 of the DHCR7 coding region was amplified by PCR 
from human control cDNA using as forward primer  
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DHCR71075-1092  5’-TAATAGGATCCGACCTGTTCCGCCGCACG -‘3 (introduces a BamHI site) and 
as reverse primer DHCR71179-1160 5’-TATATGAATTCTCACTTGCTGTGGTGCCTCTGC-3’ 
(introduces an in-frame stop codon and an EcoRI site). After amplification, the DNA fragment was 
subcloned into the pGEM-T vector (Promega) followed by sequencing to verify the absence of PCR-
induced errors. Subsequently, the DHCR7 insert was released from pGEM-T as a BamHI-EcoRI 
fragment and ligated into the BamHI and EcoRI sites of pGEX-4T (Pharmacia; for GST-7DHCR 
expression) or as an BamHI-SalI fragment into the BamHI and SalI sites pMALC2 (New England 
Biolabs; for MBP-7DHCR expression).  
For immunoblot analysis, equal amounts of proteins were separated on a 10 % SDS-
polyacrylamide + 8M urea gel and transferred onto nitrocellulose by wet blotting. After blotting, the 
blots were stained reversibly with Ponceau-S to verify the equal transfer of proteins. Immunoblot 
analysis was performed using the western-light detection kit of Applied Biosystems. The affinity-
purified anti-7DHCR antibody was used in a 1:1000 dilution. 
The expression levels of DHCR7 mRNA in the various cell lines were determined and 
related to the expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mRNA using the LightCycler system (Roche). Total RNA, free from genomic DNA, was 
isolated with the SV RNA total isolation system (Promega) and used to prepare first strand 
cDNA as described previously (26). Quantitative real-time PCR analysis was performed with 
the LightCycler FastStart DNA Master SYBR green I kit (Roche) using the following 
primers: DHCR7-Fw 5’-TCGGGAAGTGGTTTGACTTC-‘3; DHCR7-Rev 5’-
TGTGGTTCATGTCTGGGACG-‘3; GAPDH-Fw 5’-ACCACCATGGAGAAGGCTGG-‘3; 
and GAPDH-Rev 5’-CTCAGTGTAGCCCAGGATGC-‘3. Expression levels in each sample 
were determined in triplicate. 
 
Role of the funding source 
No external funding was obtained for this study. 
 
 
 RESULTS 
 
We treated three SLOS patients with 0.6-1.0 mg simvastatin per kg body weight per day, following 
our previously described protocol (Jira et al. 2000). Patients SLOS-1, SLOS-2 and SLOS-3 were 
treated for 80, 49 and 31 months, respectively (Table 1). In this period, the combined plasma 7DHC  
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and 8DHC levels showed a marked decrease to 28, 32 and 22% of the levels at the start of the 
simvastatin therapy. Moreover, a concomitant increase of the plasma cholesterol concentration was 
observed in patients SLOS-1 and SLOS-3 eventually leading to normalization (i.e. >2.5 mmol/L). This 
effect on sterol levels was already apparent after two months on simvastatin and was independent of 
the supplementation of cholesterol. Although in all three patients a clear decrease in precursor to 
cholesterol ratio was observed, this ratio remained relatively high in patient SLOS-2, primarily due to 
the fact that his plasma cholesterol levels did not increase during the treatment. 
     All patients tolerated the simvastatin therapy well and no clinical side effects were evident. No 
neuromuscular complications or development of cataracts were observed and the enzyme activities of 
aminotransferases and creatine kinase in plasma remained within the normal range.  
During the course of the simvastatin treatment, all three patients showed clinical improvement 
of growth and development with the exception of length in patient SLOS-2 (Table 1). Accordingly, the 
improvement was judged as good in patients SLOS-1 and SLOS-3 and moderate in patient SLOS-2.  
Also the neuro-motor development improved during therapy in all three patients. Patient SLOS-1, who 
started simvastatin therapy at 3 months of age, was able to rotate at 11 months and could stand with 
some help at 22 months. At 36 months, she could speak a few words and understand simple 
instructions. She walked with help at 3.5 years and without help at 4 years. She currently enjoys horse-
riding and swimming.  
    Patient SLOS-2 was 5 years old at the start of the simvastatin therapy and at that time could 
only walk with extensive help. He currently walks independently with help of a rollator walker. 
Although his awareness and social behaviour improved during simvastatin therapy, his language 
perception and speech performance has only marginally improved. During therapy he learned to eat. 
His photosensitivity was not influenced by the statin treatment.  
    Patient SLOS-3, who started simvastatin therapy at 10 months, was able to crawl at 15 
months, to sit stable at 18 months, and to walk independently at 2 years and 1 month. He is currently 
able to climb stairs and to eat with a spoon.   
    To evaluate the effect of simvastatin on the cholesterol biosynthesis in SLOS, we incubated 
primary skin fibroblasts of four SLOS patients, one obligate heterozygote and one unaffected control 
subject with 1 μm simvastatin for six days in lipoprotein (cholesterol)-depleted medium. As a control, 
we treated in parallel cells in the same manner except for the addition of simvastatin. Sterol analysis 
after the six days incubation period showed that the cells of the SLOS patients treated with simvastatin 
did no longer contain detectable levels of 7DHC, except for the IVS8-1G>C homozygous cell line 
SLOS-4, which still contained a moderate 7DHC level. In contrast, all untreated SLOS cells contained 
significantly elevated 7DHC levels (Figure 1A; Table 2). 
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Figure 1. In vitro biochemical and molecular analysis of cells incubated with simvastatin. Primary skin 
fibroblasts of a control subject (CTR-1), an obligate heterozygote (CTR-2), the three SLOS patients treated with 
simvastatin (SLOS-1-3) and a severe SLOS patient (SLOS-4) were incubated for six days with (+) or without (-) 
1 μm simvastatin in lipoprotein (cholesterol)-depleted medium. After harvesting, the cells were analysed for 7-
dehydrocholesterol concentrations (A; expressed as μmol/mg protein), 7DHCR activity (B; expressed as 
pmol/min.mg protein) and DHCR7/GAPDH mRNA ratios (C). 
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Enzyme activity measurements in homogenates prepared from the cells after the six days incubation 
showed a 3-4-fold increase in 7DHCR activity in the simvastatin-treated control and heterozygote 
cells when compared to the same cells without treatment. An increase in 7DHCR activity was also 
observed in homogenates of the simvastatin-treated SLOS-1 and SLOS-3 cells, while the activity in 
the SLOS-2 and SLOS-4 cells remained below detection levels (Figure 1B; Table 2). 
  The increase in 7DHCR enzyme activity in the simvastatin-treated cells was paralleled by an 
increase of 7DHCR protein as demonstrated by immunoblot analysis of homogenates using affinity-
purified antibodies generated against a portion of 7DHCR (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Immunoblot analysis of 7DHCR in cells incubated with simvastatin. Primary skin fibroblasts of a 
control subject (CTR-1), an obligate heterozygote (CTR-2), the three SLOS patients treated with simvastatin 
(SLOS-1-3) and a severe SLOS patient (SLOS-4) were incubated for six days with (+) or without (-) 1 μm 
simvastatin in lipoprotein (cholesterol)-depleted medium. After harvesting, equal amounts of cell homogenates 
were analysed by immunoblot analysis for the presence of 7DHCR protein using affinity-purified antibodies 
raised against 7DHCR.  
 
 
We observed a significant increase in 7DHCR protein levels in the control cells and the SLOS1-3 
cells, but not in the SLOS-4 cells. It should be noted here, however, that our antiserum would not be 
able to detect any 7DHCR protein in the SLOS-4 cells, since it was raised against a portion of 7DHCR 
that is not synthesized due to the shift in reading frame resulting from the IVS8-1G>C mutation for 
which this cell line is homozygous. In accordance with this, the observed increase of 7DHCR protein 
observed in the SLOS1-3 cells and the CTR-2 cell line (which are all heterozygous for IVS8-1G>C) is 
solely due to the expression of the non-IVS8-1G>C allele, while in the control line both DHCR7 
alleles are responsible for the increase.  
  Quantitative real-time RT-PCR using primers that only identify and amplify the DHCR7 mRNA 
derived from the non-IVS8-1G>C allele (amplification of nt 686-979 of DHCR7 cDNA) revealed that 
the increase in 7DHCR protein upon simvastatin treatment can be explained by an increased 
transcription rate of the DHCR7 gene (Figure 1C; Table 2).  
 
 
Simvastatin     -    +    -    +     -    +    -    +     -    +    -    +    -     +
CTR-1 CTR-2 SLOS-1 SLOS-2 SLOS-3 SLOS-4 CTR-1
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 DISCUSSION 
 
SLOS is the most common defect among the various inborn errors of cholesterol biosynthesis known 
to date (Kelley & Hennekam 2000; Waterham & Wanders 2000; Kelley & Herman 2001; Waterham 
2002; Porter 2002). Cholesterol is one of the end products of the isoprenoid biosynthesis pathway, 
which, in addition to cholesterol, provides the cell with a variety of other important non-sterol 
isoprenoids involved in various cellular processes. The flux through the isoprenoid biosynthesis 
pathway is tightly regulated by the levels of its end products to prevent shortage of these or over-
accumulation of intermediates (Goldstein & Brown 1990). Under normal conditions, the rate-limiting 
step of the pathway is catalysed by the enzyme HMG-CoA reductase, which is subject to different 
regulatory mechanisms. For example, the translation efficiency of HMG-CoA reductase mRNA is 
dependent on the cell’s requirement of non-sterol isoprenoids, while the degradation rate of the protein 
is dependent on the cell’s requirement of both sterol and non-sterol isoprenoids (Goldstein & Brown 
1990). In addition to these post-transcriptional regulatory mechanisms involving primarily HMG-CoA 
reductase, all genes encoding the enzymes involved in cholesterol biosynthesis are subject to a 
coordinate transcriptional feedback regulation via the so-called sterol regulatory element binding 
protein type 2 (SREBP2; Brown & Goldstein 1997; Kim et al. 2001; Sakakura et al. 2001). SREBP2 is 
a conditional positive transcription factor that enhances transcription when sterols are absent, but is 
not required for basal transcription when sterols are present.  
     Statins, including simvastatin, are potent competitive inhibitors of HMG-CoA reductase 
and are widely used to treat atherosclerosis and familial hypercholesterolemia. These drugs reduce the 
synthesis of mevalonate by HMG-CoA reductase, which results in a decreased synthesis of isoprenoid 
end products, including sterols. This reduction in end products leads to activation of the SREBP 
regulatory pathway resulting in an increased transcription of the genes encoding the various enzymes 
involved in isoprenoid/cholesterol biosynthesis and, consequently, in elevated levels of proteins.  
      While under normal conditions the rate-limiting step in cholesterol biosynthesis is 
catalysed by HMG-CoA reductase, in SLOS patients the conversion of 7DHC into cholesterol has 
become rate-limiting due to the reduced activity of 7DHCR, the enzyme catalysing this conversion. 
Remarkably, however, despite the lower levels of the end product cholesterol in SLOS patients, there 
appeared no elevation of HMG-CoA reductase activity in SLOS cells and liver tissue, although two 
other enzymes of the pathway, HMG-CoA synthase and squalene synthase, were elevated (Honda et 
al. 1998; Honda et al. 2000). These findings point to a defective coordinate regulation between HMG-
CoA reductase and the other enzymes in the cholesterol biosynthetic pathway in SLOS patients. 
Indeed, it appeared that 7DHC is a much more potent feedback inhibitor of HMG-CoA reductase than 
cholesterol, suggesting that 7DHC is responsible for the uncoupled regulation in SLOS (Honda et al. 
1998; Honda et al. 2000). This was confirmed in more recent studies with a mouse model of SLOS in 
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which it was shown that 7DHC accelerates the proteolysis of HMG-CoA reductase protein (Fitzky et 
al. 2001), which results in a reduced flux through the cholesterol biosynthetic pathway independent of 
the feedback regulation by SREBP2 (Steiner et al. 2000). 
      Our results show that one direct effect of simvastatin treatment in SLOS is the lowering of 
the 7DHC levels, most probably due to a further inhibition of HMG-CoA reductase activity as can be 
deduced from the decreased 7DHC levels observed in the SLOS-4 cells, which completely lack 
7DHCR activity. In line with the feedback regulation mechanism discussed above, this induces an 
increase in gene transcription of the genes encoding cholesterol biosynthetic enzymes including 
DHCR7, which results in an increase of 7DHCR protein and, consequently, an increase in residual 
7DHCR activity. Since in SLOS, 7DHCR catalyses the rate-limiting step, this increase in residual 
7DHCR activity will lead to an increased flux through the cholesterol biosynthetic pathway causing a 
further lowering of 7DHC levels and an increase in cholesterol levels, as observed in the patients. The 
advantage of using simvastatin is that the drug passes the brain-blood barrier and thus also has this 
effect in the brain, as was confirmed by the previously reported decrease in 7DHC and increase in 
cholesterol levels in cerebrospinal fluids of patients SLOS-1 and SLOS-3 (Jira et al. 2000). This 
concept predicts that milder patients with relatively high residual 7DHCR activity should show the 
best response to simvastatin treatment. Indeed, in our study we found a good correlation between the 
clinical severity of the patient, the residual activity of 7DHCR in cells of the patient and the efficacy of 
the simvastatin treatment. Patients SLOS-1 and SLOS-3 displayed higher residual 7DHCR activities 
and showed a better response, biochemically as well as clinically, than patient SLOS-2. This is also 
supported by the reported outcome of simvastatin treatment in two more severely affected SLOS 
patients, who did not clinically benefit from the treatment and of whom the most severely affected 
patient showed hepatoxic side effects (Starck et al. 2002).   
 
 In conclusion, our combined results show that simvastatin treatment may provide a good long-term 
therapeutic option in SLOS patients with a mild presentation, but not in severe SLOS cases. Based on 
our promising results, the simvastatin treatment is currently tested in a larger cohort of SLOS patients 
in a multicenter European trial.  
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SUMMARY 
 
Smith-Lemli-Opitz syndrome (SLOS) is caused by mutations in the DHCR7 gene leading to a 
deficient activity of 7-dehydrocholesterol reductase (DHCR7; EC 1.3.1.21), the final enzyme of the 
cholesterol biosynthetic pathway resulting in low cholesterol and high concentrations of its direct 
precursor 7-dehydrocholesterol in plasma and tissues. We here report mutations identified in the 
DHCR7 gene of 13 children diagnosed with SLOS by clinical and biochemical criteria. We found a 
high frequency of the previously described IVS8-1G>C splice acceptor site mutation (two 
homozygotes, eight compound heterozygotes). In addition, thirteen missense mutations and one splice 
acceptor mutation were detected in eleven patients with a mild to moderate SLO-phenotype. The 
mutations include three novel missense mutations (W182L, C183Y, F255L) and one novel splice 
acceptor site mutation (IVSG-1G>T). 
Two patients, homozygous for the IVS8-1 G>C mutation, presented with a severe clinical phenotype 
and died shortly after birth. Seven patients with a mild to moderate SLO-phenotype disclosed 
compound heterozygosity of the IVS8-1 G>C mutation in combination with different novel and 
known missense mutations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY WORDS: Smith-Lemli-Opitz Syndrome, 7-DHCR, 7-dehydrocholesterol-7-reductase, 
mutations, cholesterol 
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INTRODUCTION 
 
 Smith-Lemli-Opitz syndrome (SLOS MIM 270400) is an inherited disorder of variable severity 
caused by a deficient activity of 7-dehydrocholesterol reductase (DHCR7; EC 1.3.1.21), the final 
enzyme of the cholesterol (Kandutsch-Russell) biosynthetic pathway. Low cholesterol and high 
concentrations of its direct precursor 7-dehydrocholesterol (7DHC) and its isomer 8-
dehydrocholesterol (8-DHC) in blood and tissues are the biochemical hallmarks of the syndrome 
(Smith et al. 1964; Irons et al. 1993; Tint et al. 1995). The plasma sterol concentration generally 
correlates with severity and outcome (Tint et al. 1995; Witsch-Baumgartner et al. 2000). Cholesterol 
has a pivotal role during embryogenesis where it functions as a transporter-molecule for the sonic 
hedgehog (Shh) signalling protein, which is essential for normal morphogenesis. Without cholesterol, 
Shh-transport and/or function is impaired (Porter et al. 1996; Lanoue et al. 1997; Cooper et al. 1998). 
The sterol derangement in SLOS (accumulation of 7DHC/8DHC) may influence the activation of the 
Shh-receptor. These findings may explain the phenotypic consequences of the DHCR7 deficiency as 
observed in this syndrome: microcephaly, a distinctive facies, cataract, syn-/polydac-tyly, and a 
variety of organ malformations including genital abnormalities ranging from intersex to complete sex 
reversal in boys. 
   The human 7-dehydrocholesterol reductase gene (DHCR7) was identified recently and 
assigned to chromosome region 11q13 (Fitzky et al. 1998; Wassif et al. 1998; Waterham et al. 1998). 
Over 60 different mutations in the DHCR7 gene of patients with Smith-Lemli-Opitz syndrome have 
been described (Fitzky et al. 1998; Wassif et al. 1998; Waterham et al. 1998; Yu et al. 2000; De Brasi 
et al. 1999; Witsch-Baumgartner et al. 2000; Patrone et al. 2000; Krakowiak et al. 2000). Molecular 
cloning of the cDNA showed that the human enzyme is a microsomal membrane-bound protein with a 
calculated molecular weight of 54.5 kDa and nine putative transmembrane segments (Moebius et al. 
1998). The cDNA has an open reading frame of 1,425 bp coding for a polypeptide of 475 amino acids. 
Structurally,  the protein is strongly related to plant and yeast sterol reductases (Rahier et al. 1996; 
Waterham et al. 1998). In humans the mRNA is expressed ubiquitously with the highest expression in 
adrenal gland, liver, testis, and brain (Moebius et al. 1998). 
   We performed sequence analysis of the DHCR7 gene of 13 children diagnosed with 
SLOS. Clinical, biochemical and molecular data are presented. This paper is a further delineation of 
DHCR7-mutations in man. 
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MATERIALS AND METHODS 
 
Patients 
 The clinical diagnosis of SLOS in patients included in this study was based on clinical manifestations 
as previously described (Smith et al. 1964; Irons et al. 1993. Tint et al. 1995). Patients were 
characterized by a revised scoring system wherein malformations in each of ten embryologically 
distinct areas were scored to weigh embryologically separate organ systems equally (Kelley et al. 
2000). The clinical diagnosis was biochemically confirmed by analysis of sterols in plasma and/or 
tissue by gas chromatography as described earlier (Jira et al. 1997). Patient 2, 4 and 13 are Dutch 
SLOS-patients reported previously (Waterham et al. 1998).  
 
Mutation analysis of DHCR7 gene 
Genomic DNA was extracted from skin fibroblasts or lymphocytes from patients using the Wizard 
Genomic DNA Purification Kit according to the instructions of the supplier (Promega). Four sets of 
DHCR7-specific primers with either -21M13 (5'-TGTAAAACGACGGCCAGT-3') or M13-Rev (5'-
CAGGAAACAGCTATGACC-3') extensions were used to amplify by PCR the coding exons 3-9 of 
the DHCR7 gene. Sequences of these primers are as follows: primer set A for amplification of exons 
3+4: DHCR7-IVS2-fw (5'-[-21M13]-GGTGGATGCAACAGGGAAAG-3') and DHCR7-IVS4-rev 
(5'-[M13-Rev]-GCTCCCCACCTGCTGTGTC-3'); primer set B for amplification of exons 5+6: 
DHCR7-IVS4-fw (5'-[-21M13]-GTGATCAGGCTGCTTGTGTG-3') and DHCR7-IVS6-rev (5'-[M13-
Rev]-TTCTACATCAGGCTGGACCC-3'); primer set C for amplification of exons 7+8: DHCR7-
IVS6-fw (5'-[-21M13]-TGGGCTCTCGCTAAGTAAGG-3') and DHCR7-IVS8-rev (5'-[M13-Rev]-
TAGCATGTGTCTGCCAAATGC-3'); primer set D for amplification of coding part of exon 9: 
DHCR7-IVS8-fw (5'-[-21M13]-CGTGTGTCAGAGGCAGAGC-3') and DHCR71510-1490 (5'-[M13-
Rev]-AGTTGGAGCTGGGATGCCAG-3'). PCR reactions contained 0.4 m of each primer, 10 mM 
Tris/HCl pH8.4, 50 mM KCl, 1.5 mM (primer set A) or 2 mM MgCl2 (primer sets C-D), 0.01% w/v 
BSA, 0.2 mM dNTPs and 1.5 U Taq DNA polymerase (Promega). PCR amplification involved 2 min 
of denaturation at 96C followed by 17 cycles during which the annealing temperature was lowered 
with 1C per cycle from 72C to 55C. Every cycle started with 30 s of denaturation at 94C followed by 
30 s of annealing and 1.5 min of extension at 72C. These 'touchdown' cycles were followed by 12 
cycles composed of 30 s of denaturation at 94C and 1.5 min of annealing/extension at 72C followed 
by a final extension step of 15 min at 72C. PCR fragments were sequenced by means of -21M13 or 
M13-Rev fluorescent primers on an Applied Biosystems 377A automated DNA sequencer according 
to the manufacturer's protocol (Perkin-Elmer). 
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RESULTS 
 
 Thirteen patients (8 Dutch, 4 German and 1 Scottish) with biochemically confirmed SLOS were 
studied. All had mental retardation, facial anomalies, bilateral second-third toe syndactyly, and failure 
to thrive. Three patients had a cleft palate and two Hirschsprungs’ disease. 
   Table 1 summarises the patients: karyotyping, plasma (or tissue) sterol concentrations, 
7DHC/cholesterol ratio, ancestry, clinical presentation, clinical severity score and age at biochemical 
diagnosis (age of death in patients 1, 2 and 5). Plasma sterol concentrations are initial values on 
standard diet without supplemental cholesterol. The patients in both tables are ordered based on the 
mutational findings shown in Table 2. Clinical severity and outcome in our cohort was strongly 
correlated with the plasma sterol abnormality. The most predictive biochemical value is the 
7DHC/cholesterol ratio in plasma. In general patients with plasma 7DHC/Cholesterol ratio between 
0.5 - 1.0 had moderate SLOS. Patients with a plasma ratio <0.5 had a mild presentation and course 
while plasma 7DHC/Cholesterol ratio >1.0 was associated with severe SLOS. This chemical ratio is a 
usefull tool considering prognosis and treatment in SLOS but cannot predict severity accurately. 
   Table 2 shows the results of mutation analysis in the 13 patients by: affected exon and 
transmembrane domain, nucleotide position of the mutation, amino acid substitution and their effect 
on the coding sequence (for numbering of nucleotides and amino acids see: Waterham et al. 1998) and 
clinical phenotype. DNA sequencing of 26 SLO-alleles identified 13 different mutations. Among these 
mutations we detected 4 novel mutations; 3 missense (W182L, C183Y and F255L) and one IVS8-1 
G>T splice acceptor site mutation. 
   Patients 1-11 were either homozygotes or compound heterozygotes for a IVS8-1 splice 
acceptor mutation. This mutation causes aberrant mRNA splicing which leads to the introduction of 
134 basepairs and a frameshift resulting in a truncated protein lacking 154 amino acids of its original 
C-terminal sequence (Waterham et al. 1998). Patient 6 contained a new variant of the IVS8-1 G>C, 
namely an IVS8-1 G>T resulting in the same truncated protein. In this patient, with a mild SLOS-
phenotype, the mutation was combined with a missense 765 C>A (Phe255Leu) mutation at the other 
allele. 
   Eleven of the 13 patients (patients 3 - 13) were compound heterozygous for two different 
mutations altering the sequence of the 7-sterol reductase. The mutational site and effect on the coding 
sequence seemed to be only partially predictive for clinical and biochemical severity. Although 
unrelated, patients 7 and 8 had the same genotype with, a mild phenotype, however, the girl was 
diagnosed earlier in life and had a significantly different plasma sterol level and clinical course. Two 
sibs (patients 9 and 10) with the same DHCR7-mutations but differing in age, had different plasma 
sterol values with a similar clinical presentation.  
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DISCUSSION 
 
 SLOS is an autosomal recessive disorder. The DHCR7 gene mutations identified in our SLOS-cohort 
and by others (Fitzky et al. 1998; Wassif et al. 1998) are likely to have deleterious effects on the 
function of the DHCR7 protein. Cholesterol is an important constituent of the cell membrane of most 
eukaryotic cells and has important interaction with proteins, which control embryonic development. In 
addition, cholesterol acts as the precursor for steroid hormones, bile acids and myelin formation in the 
brain, spinal cord and peripheral nervous system. 
   The IVS8-1 G>C mutation causes aberrant splicing producing an mRNA with 134 base-
pairs of retained intron 8 sequence at nucleotide position 963 which leads to a frame shift and a 
stopcodon at nucleotide 1235 (TGA). This premature termination of translation results in a truncated 
and inactive DHCR7 protein as was confirmed by enzyme activity measurements in the patients 
homozygous for this mutation (Waterham et al. unpublished). Fitzky predicted that homozygotes for 
this mutation would be lethal if affected, which is confirmed by patients 1 and 2 from our study. These 
two SLOS individuals manifest a severe and lethal phenotype with microcephaly, cataract, 
polydactyly, multiple organ (cardiac, renal and intestinal) malformations leading to early death. In 
patient 2, with a 46 XY karyotype, this mutation led to apparent sex reversal (Waterham et al.1998). 
Remarkably, in a recent paper it has been reported that not all SLOS-individuals with two null 
mutations, although severely affected, are lethal (Witsch-Baumgartner et al. 2000). 
   Patients 3 - 11, who overall presented with a moderate to mild SLOS phenotype all were 
compound heterozygotes for a IVS8-1 splice acceptor site mutation on one allele in combination with 
a missense mutation on the other allele. Patient 5, with a severe clinical phenotype, is the only 
exception. The Leu109Pro mutation may affect the enzymatic activity more severly than the other 
missense mutations in this group. The clinical severity and biochemical features of our patient 5 are 
similar to patient D73 with the same combination of mutations described by Witsch-Baumgartner et 
al. 2000. 
   The five most frequent mutations described by Witsch-Baumgartner et al. 2000 in 168 
SLOS-alleles are: IVS8-1 G>C, R404C, T93M, W151X, V326L with a frequency of: 29, 11, 8, 8 and 
7 percent, respectively. Apart from the IVS8 G>C mutation, most of the mutations detected in SLOS 
are single amino acid substitutions. Mutations occur further throughout the whole gene without 
evident hotspots. In the region between codon 242 to 248, however, 5 different mutations have been 
detected until now (R242C, A247V: Witsch-Baumgartner et al. 2000; G244R, W248C: Waterham et 
al. 1999; R242H: Patient 12 from this paper). In two of these SLOS patients codon 247 and 248 are 
affected by a point mutation, changing an alanine into a valine and a tryptophan into a cystein, 
respectively. These two missense mutations are found within ten basepairs downstream of a  "TGGA" 
motif at nucleotide 742 (according to the nucleotide sequence of Waterham et al. 1998). This motif is 
hypothesised to be, in general, a hotspot for point mutations or deletions (Cooper et al. 1995). 
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   Most of the missense mutations found in patients 3, 4, 6, 9-13 are within the so called 
"sterol-sensing domain" containing five transmembrane segments as proposed by Fitzky et al. 1999 
and Bae et al. 1999 (Figure 1).  
 
 
 
Figure 1. Predicted membrane topology of the 7-dehydrocholesterol reductase. The topology model for 
DHCR7 is based on the data of Fitzky et al., 1998. Transmembrane segments 4 to 8 (dark grey) represent the 
putative, highly conserved, sterol-sensing domain (Bae et al. 1999). Arrows (↓) mark the position of the various 
mutations found in patients 1 to 13. 
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Sequence comparisons of these specific DHCR7 membrane-spanning segments show strong homology 
to segments found in four other human proteins. These proteins in nature all have crucial interaction 
with sterols: 1] HMG-CoA reductase (Olender et al. 1992), 2] Niemann-Pick C1 gene product (Loftus 
et al. 1997), 3] Sterol regulatory element-binding protein-SCAP (Nohturfft et al. 1998), and 4] the 
morphogene receptor PATCHED (Loftus et al. 1997). In HMG-CoA reductase the orientation of the 
sterol-sensing domain (membrane-spanning segments 2 to 6) has a similar configuration as segments 4 
to 8 of DHCR7. According to the hydrophobicity in the DHCR7 protein, membrane-spanning 
segments 4 to 8 are closely spaced and joint by relatively short hydrophilic amino acid loops. In 
contrast to DHCR7, SCAP and HMG-CoA reductase have a long COOH-terminal domain that 
projects into the cytosol (Nohturfft et al. 1998). Mutations that alter, interfere with or truncate the 
sterol-sensing domain of the DHCR7 protein are likely to cause a more severe biochemical and 
clinical SLOS-phenotype however making predictions of the SLOS phenotype from genotype, 
continues to be difficult since there is significant clinical and biochemical variability among 
genetically identical or comparable infants (see patients 7, 8 and 10, 11). 
   In our study, six of the eight Dutch SLOS patients were carriers for the IVS8-1 G>C 
mutation on one or both alleles. The high proportion of this severe frameshift mutation could explain 
the lower incidence of SLOS occurring in the Dutch population. One could hypothesise that in 
homozygous individuals this particular genetic defect may lead to intra-uterine or early neonatal death 
before the diagnosis SLOS is made. On the other hand, in healthy carriers, mutations in cholesterol 
biosynthesis could result in an evolutionary advantage either reducing the risk of cardiovascular 
morbidity by decreasing individual plasma cholesterol levels or by increased Vitamin D levels, 
preventing the occurrence of rickets (a common pediatric disease in the past) as suggested by Kelley 
and Hennekam (2000). We analysed plasma of some parents of our SLOS-patients (data not shown) 
and found plasma cholesterol levels below the 50th centile with a mean of 4.4 mmol/l. We found the 
IVS8-1 G>C in SLOS-patients not only from different sites in the Netherlands but also in patients 
from Germany. The same IVS8-1 G>C mutation was detected in one of 90 normal adult Caucasian 
Americans; but not among 121 Africans from Sierra Leone, 120 Caucasians from Finland, 95 Chinese 
or 103 Japanese adults by Yu et al. 2000. From the number of cases diagnosed in our laboratories we 
estimate a SLOS frequency of ~ 1/100,000 in the Netherlands. This frequency is lower than the 
incidence of 1 / 40,000 - 50,000 for the SLOS described by Opitz et al. 1994 and Cunniff et al. 1997. 
Currently, we are working on a more accurate estimation of the carrier frequency of the mutation in 
the Dutch population. The high incidence found in our European SLOS-study (50%) confirms and 
exceeds the findings of Yu et al. 2000 and Bataille et al. 2000 who identified the IVS8-1G>C 
mutation in 21 of 66 (32%) and 18 of 52 (35%) SLOS-alleles, respectively. The development of a 
simple PCR-RFLP can be used as a screening-method for detecting this frequent SLO-mutation (Yu et 
al. 2000). The mutation seems to be an ancient variant frequently occurring in SLOS. In order to 
determine whether this and other mutations have been introduced into the European, and later 
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American, population by a single founder, it is necessary to study the chromosome 11 haplotype of the 
patients carrying mutations. 
 
In conclusion, our study showed that of the known SLOS mutations (including missense, nonsense, 
frameshift and deletions) the IVS8-1 G>C is the most frequent one occurring in our cohort of SLOS 
patients from Western-Europe and found in 13 of 26 studied alleles. This occurrence of 50% is the 
highest of all published studies, leading to lethal phenotypes in two homozygotes, and mild to 
moderate SLOS-phenotype when combined with missense mutations. We identified four novel 
mutations in the DHCR7 gene. Further molecular genetic studies will enable insight in genotype-
phenotype correlations in SLOS and determine carrier frequency of specific DHCR7 mutations in 
various populations. Additional search for environmental, other genetic and compensatory 
determinants that can modify the phenotypical consequences of the functional DHCR7 deficiency in 
SLOS is needed. 
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ABSTRACT 
 
We report on a newborn boy with clinical manifestations of the Smith-Lemli-Opitz syndrome (SLOS, 
also known as RSH syndrome) including prenatal growth retardation, microcephaly, hyperplasia of the 
upper alveolar ridges, micropenis with glandular hypospadias and bilateral 2-3-toe syndactyly, he also 
had unilateral choanal atresia and severe an/microphthalmia. Gas chromatographic analysis of plasma 
sterols showed normal concentrations of the cholesterol precursor 7-dehydrocholesterol, thereby 
excluding a Δ7-dehydrocholesterol reductase deficiency, the primary cause of SLOS. Chromosome 
analysis demonstrated a distal 7q36.1 deletion. Extensive fluorescence in situ hybridization analysis 
showed that the holoprosencephaly (HPE3) critical gene region on chromosome band 7q36, inclusive 
the Sonic Hedgehog (SHH) gene, was deleted. A mutation in the SHH gene of the non-deleted allele 
could be excluded. This case suggests that in addition to patients with a defect in cholesterol biosyn-
thesis, patients with a distal 7q deletion may present with a SLOS-like phenotype. Some, if not all, of 
the clinical findings of SLOS may be due to a defective SHH signalling pathway caused by sterol 
disturbances, which is consistent with results obtained in experimental animals.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY WORDS:   Smith-Lemli-Opitz syndrome (SLOS), Sonic Hedgehog (SHH) gene,  
   terminal 7q deletion, holoprosencephaly (HPE3). 
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INTRODUCTION 
 
Smith-Lemli-Opitz (SLOS or RSH syndrome), is a multiple congenital anomalies/mental retardation 
syndrome caused by a deficient Δ7-dehydrocholesterol-reductase activity, the final enzyme of the 
cholesterol biosynthesis pathway (Smith et al. 1964; Tint et al. 1994; Tint et al. 1995; Kelley & 
Hennekam, 2000). The clinical diagnosis of SLOS requires experience in clinical morphology. The 
holoprosencephaly (HPE) sequence is a genetically heterogeneous malformation complex that affects 
midline development of forebrain and midface. The strongly variable clinical presentation within types 
of HPE ranges from severe brain malformations (lethal expression) to minimal facial anomalies 
(single central maxillary incisor). Distal deletions of the long arm of chromosome 7 are associated 
with HPE (Young et al. 1984; Lurie et al. 1990; Bogart et al. 1990; Frints et al. 1998a). 
  Sonic Hedgehog (SHH) is one of the human segmentation genes. Mutations in this gene have 
been shown to cause familial holoprosencephaly in the subset linked to chromosome band 7q36 
(Roessler et al. 1996; Belloni et al. 1996). Cytogenetic deletions and/or rearrangements of this region 
on the distal long arm of chromosome 7 containing SHH, and translocations that may suppress gene 
expression through a position effect are common mechanisms leading to HPE (Gurrieri et al. 1993; 
Benzacken et al. 1997; Roessler et al. 1997; Frints et al. 1998b; Vance et al. 1998). Evidence was 
obtained from animal experiments that cholesterol biosynthesis is essential for normal SHH protein 
function and suggested that the phenotypic characteristics of SLO syndrome may be mediated by 
SHH.  Here we describe a patient with apparent SLOS and HPE with a terminal deletion of the long 
arm of chromosome 7. This observation reinforces the notion that the pathogenesis of SLOS involves 
dysfunction of the SHH signalling pathway and that impairment of sterol disturbances causes a wide 
range of genetic defects. 
 
 
CLINICAL REPORT 
 
The index patient, a boy, the first child of nonconsanguineous caucasian parents, was born at term, 
after an uneventful pregnancy. His birthweight was 2,590 g (15th centile), length was 43 cm (3rd 
centile), and occipitofrontal circumference (OFC) was 29 cm (<< 3rd centile, -3 SD). Clinical 
examination showed microcephaly, inner canthal distance/outer canthal distance = 1.8 cm / 6.5 cm 
(10th centile / 60th centile), deeply set invisible eyes, bilateral epicanthus, narrow upslanting palpebral 
fissures, midface hypoplasia, depressed nasal bridge, small nose, microphthalmia, retro/micrognathia 
with upper alveolar ridge hyperplasia. His ears were small, malformed, and apparently low-set with a 
prominent antihelix, and large earlobes (Figure 1A and 1B). There was complete bilateral syndactyly 
of toe 2 and 3 (Figure 1C). External genitalia were abnormal with a chordee and micropenis of 1.5 cm 
(-2SD) (Figure 1D).  
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Figure 1. Patient’s appearance at birth.  
 
Unilateral choanal atresia was suspected and confirmed on CT-scanning. Deep tendon reflexes were 
diminished. MRI-scanning, ophthalmic examination and orbital ultrasonography showed bilateral 
anophthalmia with a dysgenetic cyst on the right with normal corpus callosum and (midline) brain 
structures (Figure 2).  
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Radiological examination of the spine and hips showed a normal vertebral spine and sacrum but left 
hip dysplasia with an acetabular angle of 36 degrees. Echocardiography excluded cardiac 
malformations. No renal abnormalities were detected by ultrasound. The electro-encephalography was 
normal. Since early detection of deafness in this blind patient is important, a brain stem auditory 
evoked potential investigation was performed. No respons could be obtained with this test, suggesting 
the patient might be deaf. Endocrine status was normal; gonadotrophins, LH: 2.0 U/l, FSH: <0.6 U/l, 
testosterone: 6.0 nmol/l, ACTH: 4.1 pmol/l, cortisol: 0.20 mmol/l, TSH: 2.47 mU/l, tyroxine; 191 
nmol/l, free T4: 16.6 pmol/l. TORCHES screening negative. 
 Feeding problems were treated by initial nasogastric tube feeding. At the age of 4 months he 
developed severe vomiting, pyloric stenosis was surgically corrected and during this operation a 
percutaneous gastric tube was implanted. At this age his weight was 5220 g (3rd  centile) and the OFC 
36.2 cm (still below 3rd centile). The inner canthal distance measured 22 mm (50th centile). He was 
delayed in psychomotor development, however, due to his severe sensory impairment a judgement 
about the severity of the development retardation could not be made at that age. At the age of 14 
months a central maxillary incisor became visible. At the age of 16 months he started to roll over and 
at 24 months he was able to sit without support.  
 At the age of 5 years and 9 months the boy still has a percutaneous gastric tube and is not 
interested in oral feeding. His height is 104 cm (-3.3 SD), weight is 16.5 kg (-2.5 SD) and OFC 45.5 
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cm (-4.9). Although he can stand and walk independently from the age of four his gait is limited. 
Hearing has improved gradually and a slight hearing impairment of 25 dB is detectable after one 
adenoidectomy and three times placement of bilateral myringotomy tubes between the age of 2 ½  and 
5 ½ years. Nevertheless there is no passive or active language development.  At the age of 5 9/12 years 
his developmental status was examined in the context of degree of visual the Reynell-Zinkin scales 
(Reynell 1978). His scores on the five developmental areas of social adaptation, sensori-motor 
understanding, exploration of environment, verbal comprehension and  expressive language were 9-11 
months, 1.1-1.4 years, 9-11 months, 1.2-1.7 years and 5-7 months, respectively.   
 
 
MATERIALS AND METHODS 
 
Defects of cholesterol biosynthesis investigated at birth by gas chromatographic analysis of plasma 
sterols and chromosome analysis of two peripheral blood lymphocyte cultures were performed. 
Parents had normal chromosomes, establising a de novo origin of the 7q deletion. In order to define 
more precisely the deletion-breakpoint and the presence/absence of genes located at this chromosomal 
region, which are important for normal extremity, facial and brain development, we performed 
fluorescence in situ hybridization (FISH) analysis on metaphase chromosomes.  A panel of 
informative C.E.P.H. yeast artificial chromosomes (YACs) was selected all containing well-defined 
marker loci and one cosmid clone; 738D7, 761H5, 744A8, 850G5, Y965C12, COS2000 (Morton et al. 
1987). The deletion-breakpoint was concluded to reside between YACS 761H5 and 744A8, as 
illustrated in Fig. 3.  
 
To exclude the possibility of a coincidental mutation on the other allele we performed mutational 
analysis of the complete coding region and intron-exon junctions of the non-deleted SHH gene by 
direct sequencing using primers as described before (Roessler et al. 1996, 1997a; Nanni et al. 1999). 
No mutation in the other SHH allele could be detected. 
 
 
RESULTS AND DISCUSSION 
 
Sterol analysis revealed normal concentrations of cholesterol (2235 μmol/l), 7-dehydrocholesterol 
(<15 μmol/l) and 8-dehydrocholesterol (<15 μmol/l) (Jira et al. 1997). Chromosome analysis of two 
peripheral blood lymphocyte cultures demonstrated a terminal 7q deletion: 46,XY,del(7)(q36.1→qter). 
The patient reported here illustrates the clinical presentation of SLOS and minimal expression of HPE. 
After ruling out a Δ7-sterol reductase deficiency, the hallmark of SLOS, chromosomal investigation 
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Figure 3.  A. Chromosomes 7 of the patient. De left chromosome has a terminal deletion. The size of the 
deletion is indicated by a bar along the normal chromosome 7. B. Ideogram of the entire (left) and terminal part 
of the long arm (right) of chromosome 7. The deletion extends from band q35 to qter. C. Location of the yacs 
(CEPH-probes) and cosmid used for in-situ-hybridisation. The probes located in band q36are deleted on the 
derivative chromosome 7. The SHH-gene is located between CEPH850G5 and cos2000 and thus deleted in the 
patient. D. FISH results with the subterminal probe cos2000. A fluorescence signal is visible on the normal, but 
not on the derivative chromosome 7. 
 
 
applying FISH showed a deletion of the terminal long arm of chromosome 7. The deletion-breakpoint 
resides between YAC clone markers 761H5 and 744A8, preserving the Eng2 (Hox1) gene but 
eliminating the SHH gene. The deleted distal arm contains about 12 cM and at least 30 known human 
genes. 
 SLOS is an autosomal recessive disorder showing considerable phenotypic variability 
including craniofacial abnormalities (microcephaly, ptosis, cataract, cleft palate, upper alveolar ridge 
hyperplasia), limb anomalies (postaxial syndactyly and/or polydactyly), incomplete development of 
male genitalia, failure to thrive, gastrointestinal abnormalities such as pyloric stenosis and 
Hirschprung disease, mental retardation and various internal anomalies including holoprosencephaly 
in some cases (Smith et al. 1964; Tint et al. 1994; Tint et al. 1995; Nowaczyk et al. 2001). Defective 
conversion of 7-dehydrocholesterol (7-DHC) to cholesterol in SLOS patients is due to mutations in the 
7
7
+ CEPH 738D7
+ CEPH 761H5
- CEPH 744A8
- CEPH 850G5
- cos2000
A B C
D
SHH gene
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Δ7-sterol-reductase gene that was mapped to chromosome band 11q13 (Fitzky et al. 1998; Waterham 
et al. 1998; Wassif et al. 1998). Less severe symptoms of HPE can occur in SLOS (Kelley et al. 
1996). However, not all patients clinically suspected of SLOS can be confirmed biochemically 
(Guzetta et al. 1996; Krajewska-Walasek et al. 1999). 
 Some of the malformations seen in SLOS can be mimicked in experimental animal models 
utilizing specific cholesterol lowering drugs: BM 15.766, AY-9944 and YM 9429 inhibiting the Δ7-
reductase enzyme in cholesterol biosynthesis (Honda et al. 1996; Kolf-Clauw et al. 1996; Dehart et al. 
1997; Roux et al. 2000). The most characteristic malformations of this rat/mouse "holoprosencephalic 
syndrome" include cyclocephaly, cyclopia, monorhinia, palatoschisis and agenesis of the pituitary 
gland in up to 80 % of subjects (Honda et al. 1996; Kolf-Clauw et al. 1996). 
 Although some of these defects, especially holoprosencephaly, were described previously in 
cholesterol-deficient rats (Dehart et al. 1997), limb and external genital defects as seen in SLOS have 
not been seen in animal experiments. Some similarities between the SLO syndrome in humans and the 
AY-9944/BM 15.766 animal experimental teratogenic effects suggest, but do not explain, that the Δ7-
reductase enzyme deficiency is directly responsible for the malformations. 
 SHH (MIM 600725) is one of the genes identified to cause HPE in humans. It maps to 7q36 
that is near the HPE3 locus (MIM 142945) (Gurrieri et al. 1993; Belloni et al. 1993; Muenke et al. 
1994; Roessler et al. 1997). SHH mutations have been identified in HPE patients and include 
missense, nonsense, deletion, insertion, and frameshift mutations located throughout the gene 
(Roessler et al. 1996; Roessler et al. 1997; Nanni et al. 1999; Odent et al. 1999; Wallis et al. 2000). 
Proper function of SHH depends on cholesterol modification. Specifically, cholesterol is important for 
the way Hedgehog proteins spread through tissues where they split in two. The hydrophobic 
modification is apparently necessary to restrict hedgehog signaling to the proper spatial pattern in the 
developing embryo (Porter et al. 1996a; Porter et al. 1996b; Cooper et al. 1998). The cholesterol-
Hedgehog complex attaches to its 12-span transmembrane receptor proteins Patched-1 and Patched-2 
in target cells (Villavicencio et al. 2000; Ingham and McMahon, 2001). Although the mechanism of 
Shh-induced signaling pathway in vertebrates is not completely defined, it is known to regulate dorso-
ventral patterning within the neural tube, limb, lung, genital, ocular, and retinal development as well as 
craniofacial morphogenesis (Marigo et al. 1995; Hall et al. 1995; Kumar et al. 1996; Krishnan et al. 
1997; Imokawa et al. 1997; Levine et al. 1997, Helms et al. 1997; Hayes et al. 1998; Ingham and 
McMahon 2001). Dysregulation of the sonic Hedgehog-Pathed-Gli pathway leads to several human 
diseases, including birth defects and cancers (Villavicencio et al. 2000). 
 Through recent animal studies there is growing evidence linking cholesterol deficiency-based 
birth defect and the SHH gene. In SLOS the effects of perturbed cholesterol biosynthesis are shown 
confirming the important role of cholesterol in transport, activation and receptor-binding of embryonic 
signaling SHH proteins (Porter et al. 1996a; Porter et al. 1996b; Cooper et al. 1998; Ingham and 
McMahon 2001). SHH gene studies in the mouse showed that this gene plays a critical role in 
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patterning of vertebrate embryonic tissues, including brain, spinal cord, axial skeleton and limbs. Shh 
mutated mice show a SLOS-like phenotype with craniofacial and limb abnormalities (Chiang et al. 
1996). 
 
Cholesterol deficiency in utero, whether genetic, environmental or multifactorial, can result in 
malformations representing a wide spectrum of severity. In patients presenting with malformation of 
brain, face, eye, limbs, or genitalia defects in cholesterol biosynthesis and SHH-functioning should be 
considered and ruled out (Lanoue et al. 1997; Kelley et al. 1996). 
 Our patient presented with a SLOS more than an HPE phenotype. MRI scanning of the brain 
revealed no gross abnormalities. Initially there were no signs of holoprosencephaly at all. Later 
development of a single central maxillary incisor disclosed a minor HPE-variant. Microphthalmia has 
been reported once previously in a fetus with holoprosencephaly and sacral agenesis due to a deletion 
7q36→qter (Morichon-Delvallez et al. 1993). Thus, we would like to reinforce two other observations 
made by Berry (et al. 1998) and Warburg (et al. 1995). The first described a family of apparent SLOS 
and Miller-Dieker syndrome (MDS) with segregating translocation t(7;17)(q34;p13.1) presenting with 
a phenotype similar to that of our patient. The patient with MDS had inherited the derivative 
chromosome 17, thus lacking 17p13.1, resulting in MDS. The patient with SLOS phenotype had 
inherited the abnormal chromosome 7 with a deletion of 7q34→qter. The latter authors documented 
the clinical findings of a boy with blepharophimosis, epicanthus inversus, right atresia and left choanal 
stenosis and developmental delay with genital malformations. This patient had a single mesial 
maxillary incisor suggesting the HPE anomaly but a normal CT scan of the brain. Chromosome 
analysis showed a de novo terminal deletion of the long arm with a breakpoint at band 7q36.  
 In the perspective of the facial anomalies (a long philtrum, upper alveolar ridge hyperplasia, 
and microcephaly) documented above we conclude that the patient had the SLOS. A single central 
maxillary incisor, as apparent in our patient, can also occur in biochemically and genetically proven 
SLO patients (own observation). In SLOS genital anomalies (65%) 2-3 toe syndactyly (97%) and 
pyloric stenosis (14%) as disclosed by our patient are common (Kelley, Hennekam, 2000). These 
phenomena have to be mediated by impaired SHH function rather than a primary disruption of 
cholesterol biosynthesis. Mental retardation and failure to thrive are non-specific manifestations in 
many syndromes. 
 The existence of phenocopies of SLOS after exclusion of a Δ7-reductase deficiency may point 
to a defect in important morphogenetic signaling pathways, such as the Sonic Hedgehog-Patched-Gli 
pathway, causing similar malformations. High-resolution cytogenetic studies and mutation analyses 
focusing on chromosome band 7q36, and other pathway genes in these patients therefore should 
always be considered. 
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SUMMARY AND GENERAL DISCUSSION 
 
The Smith-Lemli-Opitz syndrome (SLOS) is a developmental disorder associated with a broad 
spectrum of congenital anomalies and is one of the recently discovered defects of cholesterol 
biosynthesis in humans (Smith et al. 1964; Irons et al. 1993; Tint et al. 1995; Fitzky et al. 1999; 
Battaile & Steiner 2000). In chapter 1 the Smith-Lemli-Opitz syndrome and its enzymatic defect, the 
7-dehydrocholesterol reductase (DHCR7) deficiency, is introduced. The aim of our study is described 
in chapter 2 and current knowledge about diagnosis, clinical presentation, therapy, molecular genetics 
and pathophysiology in SLOS are reviewed in chapter 3 (Jira et al. 2003). 
 
Biochemical Diagnosis 
The biochemical hallmark of SLOS was disclosed in 1993 (Irons et al. 1993). In chapter 4 we studied 
cholesterol levels in plasma of 8 SLOS patients with gas-chromatography (GC) and with the common 
oxidase method used routinely in clinical chemistry laboratories to measure cholesterol in body fluids. 
We described pitfalls in measuring plasma cholesterol in SLOS with this common cholesterol-oxidase 
method. 
 First of all, healthy newborns normally may have low plasma cholesterol levels around or even 
below 2000 μmol/L. All SLOS patients studied had increased 7DHC (143 - 848 μmol/L) and 8DHC 
(107 - 555 μmol/L) plasma levels, diagnostic for SLOS. In healthy control groups, cholesterol-
precursor concentrations are below 10 μmol/L. Secondly, we could demonstrate that the oxidase 
method for measuring cholesterol in plasma cannot discriminate between cholesterol, 7DHC or 8DHC. 
When measured with GC, all patients had a plasma cholesterol concentration (20 - 2030 μmol/L) 
below the reference range for age. In contrast, only 6 of 8 patients had decreased cholesterol plasma 
levels when measured with the cholesterol-oxidase method. Since this method in fact measures the 
sum of cholesterol and its precursors 7DHC and 8DHC, it gives falsely high cholesterol levels. This 
could potentially lead to erroneous conclusions. The GC technique detects separate precursor and 
cholesterol peaks. This enables a proper biochemical diagnosis and can be of use in scoring severity 
and in monitoring therapy in SLOS (Jira et al. 1997a). 
 
Therapy 
Chapter 5 and 6 describe new treatment strategies in SLOS. Conventionally, patients were treated 
with cholesterol and/or bile acid suppletion without impressive biochemical or clinical response.  
 In chapter 5 erythrocytes of SLOS patients were incubated in normal donor plasma and we 
observed a rapid exchange between precursors (7DHC and 8DHC) from the erythrocyte membrane 
and cholesterol from the plasma. When normal erythrocytes were incubated in SLOS plasma, a similar 
uptake velocity of precursors into normal erythrocyte-membranes could be detected. This motivated 
our group to evaluate the effect of blood exchange transfusions in two young SLOS patients. Repeated 
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blood exchange transfusions showed a significant reduction in circulating cholesterol-precursor levels 
and increases of cholesterol to normal levels in plasma. The procedure, however, is invasive for the 
patient, time-consuming and the biochemical effect of blood exchange transfusions in plasma was 
limited to three days (Jira et al. 1997b). Therefore, this cannot be considered as a long-term 
therapeutical approach.  
 We incubated cultured SLOS fibroblasts with a HMG-CoA reductase inhibitor, simvastatin, to 
study its effect on sterol synthesis. As expected, we observed a marked reduction of accumulated 
7DHC and 8DHC precursors. However, the unexpected observation that cholesterol concentration 
increased was surprising. This improvement in precursor/cholesterol ratio in cultured SLOS 
fibroblasts motivated us in treating SLOS patients with simvastatin. Chapter 6 describes the long-
term effect (23 and 14 months) of oral HMG-CoA reductase inhibition with simvastatin in two SLOS 
patients. A significant reduction of total precursors (7DHC+8DHC), to 28% and 33% of the initial 
plasma values, could be documented. Cholesterol concentration normalised unexpectedly by a more 
than two-fold increase in that period for both patients. The 7DHC+8DHC/Cholesterol ratio improved 
from 0.47 to 0.06 and 0.32 to 0.04 in plasma and from 1.22 to 0.12 and from 0.62 to 0.07 in 
erythrocyte membranes, respectively. During the follow-up period, morphometric parameters (length, 
weight, head circumference) and neuromotor development improved in both patients. The therapy was 
well tolerated and no unwanted clinical or biochemical side effects occurred. This is the first study in 
which the blood cholesterol level in SLOS patients normalised with a simultaneous significant 
decrease in precursor levels. There was a lasting biochemical improvement with an encouraging 
clinical effect (Jira et al. 2000).  
 The decreased accumulation of 7DHC and 8DHC in SLOS patients treated with an oral HMG-
CoA reductase inhibitor could be expected. The beneficial effect in increasing cholesterol 
concentration in SLOS patients treated with statin, however, was unexpected. Further studies were 
designated to explain this observation in both fibroblasts and patients' plasma. Chapter 7 describes 
three relatively mild SLOS patients treated with simvastatin for 80, 49 and 31 months, respectively. 
We determined the efficacy of the treatment on development and general well being of the patients. In 
addition, we studied in vitro the effect of simvastatin on DHCR7 expression and activity in primary 
skin fibroblast cells of the patients. All patients tolerated the simvastatin therapy well without apparent 
clinical or biochemical side effects. During treatment, a marked decrease of plasma 7DHC levels in all 
three and a concomitant increase of the plasma cholesterol concentration was observed in two patients. 
Moreover, two patients showed good and one patient moderate clinical improvement of growth and 
development. The in vitro studies with cultured primary skin fibroblast cells of the patients showed 
that simvastatin induces an increase in gene transcription of the DHCR7 gene, which results in an 
increase of DHCR7 protein and enzyme activity. An increase in (residual) DHCR7 activity by a factor 
6.1, 3.6 and 4.2, respectively could be documented in the three SLOS cell lines. DHCR7 catalyses the 
rate-limiting step in SLOS, and an increase in residual DHCR7 activity leads to an increased flux 
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through the cholesterol biosynthetic pathway and explains lower 7DHC and (almost normalizing) 
cholesterol levels, as observed.  
 Biochemical and clinical improvement was strongly correlated with the residual DHCR7 
activity. Up-regulation of DHCR7 activity in cultured fibroblasts by simvastatin was also correlated 
with the patients' clinical severity and genotype. Our study is the first to demonstrate that simvastatin 
therapy in SLOS patients with a relatively mild phenotype and residual activity of 7DHCR in cells 
results in increased DHCR7 expression. This increased DHCR7 activity level leads directly to a 
lowering of 7DHC and an increase of cholesterol levels. Since the efficacy and outcome of the 
simvastatin treatment appears to correlate well with the residual 7DHCR activity and clinical severity 
in patients, the treatment may provide a good therapeutic option in SLOS patients with a mild to 
moderate presentation (Jira et al. 2005a, submitted). Statin therapy is a promising, novel approach in 
SLOS that deserves further studies in larger series of patients. Currently, the European NISLOS 
(Nijmegen International Simvastatin SLOS) Study is being performed on the long-term biochemical 
and clinical effects of simvastatin with and without cholesterol suppletion. Estimation of residual 
DHCR7 enzyme activity, without any doubt, will be useful in predicting statin effect in SLOS patients 
before therapy is initiated (Ginat et al. 2004). From the initial precursor/cholesterol ratio or genotype, 
an attempt will be made to predict the SLOS patients that will benefit most from long term treatment 
with simvastatin. 
 
Molecular Genetics 
In 1998, the human DHCR7 gene was identified and assigned to chromosome region 11q12-q13. 
More than one hundred different mutations in the DHCR7 gene have been described to date. In 
chapter 8 we describe new and known mutations found in the DHCR7 gene in 13 European patients 
with SLOS. We, and other groups, observed that most (∼80%) of the patients are compound 
heterozygous for a severe and a mild mutation in the DHCR7 gene. The most frequent mutation in 
Western Europe is the severe IVS8-1G>C mutation, causing aberrant splicing. This mutation results in 
a mRNA with 134 base-pairs of retained intron 8 sequence at nucleotide position 963. Upon 
translation, this leads to a frame shift and a stop codon at nucleotide 1235 (TGA), producing an 
inactive, truncated protein lacking 154 amino acids of its original C-terminal sequence. The patient in 
our study, who was homozygous for the IVS8-1G>C null mutation, indeed showed a very severe 
lethal phenotype with the lowest plasma cholesterol concentration (20 μmol/L) ever reported (Jira et 
al. 2001).  
 A severe clinical phenotype in SLOS patients is due to null allele and fourth loop mutations, 
whereas C-terminal and transmembrane mutations cause a mild to moderate clinical phenotype. 
Further molecular genetic studies will enable insight in carrier frequency of specific DHCR7 
mutations in various populations. Making predictions of the SLOS phenotype from genotype, 
however, continues to be difficult since there is significant clinical and biochemical variability among 
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genetically identical SLOS patients (such as siblings). Additional clues for prenatal, maternal, 
environmental, other genetic and compensatory biochemical determinants that can modify the 
phenotypical consequences of the functional DHCR7 deficiency in SLOS is needed. 
 
Pathogenesis 
Chapter 9 describes a patient with a “Smith-Lemli-Opitz-like” phenotype caused by distal 
chromosome 7q36 deletion disrupting the human Sonic Hedgehog (SHH) gene. This remarkable 
finding is in line with SLOS pathogenesis and the role of cholesterol in the important, recently 
revealed morphogenetic Cholesterol-SHH-Patched-Smoothened-Gli cascade. The newborn boy 
presented clinical manifestations of SLOS, including prenatal growth retardation, microcephaly, 
hyperplasia of the upper alveolar ridges, micropenis with glandular hypospadias and bilateral 2-3-toe 
syndactyly. He also revealed an unilateral choanal atresia and severe an/microphthalmia. Gas 
chromatographic analysis of plasma sterols showed normal concentrations of the cholesterol 
precursors 7DHC, 8DHC and also of cholesterol, thereby excluding a DHCR7 deficiency, the primary 
cause of SLOS. Chromosome analysis demonstrated a distal 7q36.1 deletion. Extensive fluorescence 
in situ hybridization analysis showed that the holoprosencephaly (HPE3) critical gene region on 
chromosome band 7q36, including the SHH gene, was deleted. Mutations in or microdeletion of the 
SHH gene of the non-deleted allele could be excluded. This case suggests that, in addition to patients 
with a defect in cholesterol biosynthesis, patients with a distal 7q deletion may present a SLOS-like 
phenotype (Jira et al. 2005b, submitted). 
 
Morphogenesis 
SHH genes are highly conserved and have been identified within a variety of species, including 
humans, mice, frogs and chickens. Mouse and human Shh protein are 92% identical at the amino acid 
level. In the human embryo, Shh is expressed in the notochord, the floor plate of the neural tube, the 
gut, and in the developing limbs. The Shh protein is a secreted intercellular signaling molecule , which 
is synthesized as a precursor, that undergoes autocatalytic cleavage into a highly conserved N-terminal 
domain (Shh-N) and a more divergent C-terminal domain (Shh-C), as shown in the Figure. During the 
auto-processing reaction, a cholesterol moiety is covalently attached to the C-terminus of Shh-N 
(Porter et al. 1996). Shh-N contains all the known signaling activities. In contrast, Shh-C mediates 
both the enzymatic cleavage and cholesterol modification of the protein. This modification is crucial 
for proper patterning activity. The covalently attached moiety tethers the N-terminal signaling 
fragment to the cell membrane proteins Patched and Smoothened. Cholesterol-modified Shh-N binds 
to Patched. Binding results in the dissociation and activation of Smoothened. Active Smoothened 
triggers the activation of transcription factor Gli-1 and subsequent factors involved in a variety of 
developmental processes, including neurogenesis, myogenesis, skeletal patterning, and left-right axis 
establishment (Lum & Beachy 2004; Ogden et al. 2004). Some, if not all, of the clinical findings of 
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SLOS may be due to a defective SHH signaling pathway caused by sterol disturbances, which is 
consistent with results obtained in experimental animals. Much has been learned about the 
mevalonate-cholesterol biosynthetic pathway in the last decade. Eight clinical entities are caused by 
defects in the cholesterol biosynthesis (Table in Chapter 1).  
 In addition, several malformation syndromes, diseases and malignancies are associated with 
genes involved down-stream in the Cholesterol-SHH-Patched-Smoothened-Gli signaling pathway, as 
illustrated below; 
 
Sonic Hedgehog   Holoprosencephaly (MIM 236100) 
Patched 1 and 2   Gorlin syndrome (MIM 109400) 
    basal cell carcinoma, medulloblastoma, trichoepithelioma 
    oesophageal squamous cell carcinoma ,  
    bladder transitional carcinoma 
Smoothened   basal cell carcinoma,  medulloblastoma 
Gli-1    basal cell carcinoma, glioblastoma, rhabdomyosarcoma,  
    osteosarcoma, predicts sarcoma grade 
Gli-3    Greig syndrome (MIM 175700) 
    Pallister-Hall (MIM 146510) 
    Postaxial polydactyly A/IV and pre-axial polydactyly A/B 
CBP    Rubinstein-Taybi (MIM 180849)  
Twist    Saethre-Chotzen (MIM 1014000)  
 
 Recently, disruption of the SHH pathway genes has been associated with small-cell lung cancer 
(Watkins et al. 2003) and colon cancer (Oniscu et al. 2004). Finally, the Hedgehog-Gli1 signaling 
pathway is a new candidate, therapeutic target for breast cancer (Kubo et al. 2004) and prostate cancer 
(Sanchez et al. 2004). 
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Figure. Removal of the N-terminal signal peptide from the initial Shh-translation product yields the 20-kDa 
precursor, which is covalently attached to cholesterol. This “Cholesterol-Shh-N” molecule attaches to Patched 
(Ptch) and this activates the protein Smoothened (Smo) by uncoupling. This in turn activates nuclear Gli and 
subsequently Gli-target genes. SSD marks the homologous “Sterol Sensing Domain” present in two key 
pathway-enzymes (HMG-CoA reductase and DHCR7) and the membrane-bound receptor Patched. 
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Precursor toxicity 
The main question in the pathogenesis of SLOS remains: Is it the lack of cholesterol in plasma and 
tissue or the accumulation of harmful sterol precursors that cause disease? There are firm clues that the 
primary precursor accumulation in SLOS may lead to secondary negative effects on cholesterol 
metabolism and disturb intracellular trafficking. 
 7DHC binds to the "sterol sensing domain" site of the DHCR7 enzyme that encompasses five 
central transmembrane segments 4 – 8 (Fitzky et al. 1999; Bae et al. 1999). This specific DHCR7 
membrane-spanning segment shows strong homology to the SSD found in five other human proteins. 
These proteins in nature all have crucial interaction with sterol-synthesis, metabolism, trafficking or 
signaling: 1] HMG-CoA reductase (Olender et al. 1992); 2] Niemann-Pick C1 gene product (Loftus et 
al. 1997); 3] Sterol regulatory element-binding protein-SCAP (Nohturfft et al. 1998); 4] the 
morphogene receptor PATCHED (Loftus et al. 1997); 5] the DISPATCHED protein (Burke et al. 
1999). 7DHC may interfere with proper function of the five proteins that contain a similar SSD. When 
the SDD of DHCR7 normally recognises 7DHC, other homologous enzymes should in theory be 
influenced when 7DHC accumulates in hundred-to-thousand-fold increased concentrations, as in 
SLOS.  
There are three possible sites where accumulation of 7DHC precursors can interfere with 
cholesterol synthesis and signaling: HMG-CoA reductase, DHCR7, and Patched (Figure). Low plasma 
and tissue cholesterol do not lead to poor growth, organ malformations or individual lethality, per se, 
as illustrated by familial abetalipoproteinaemia and many living species such as rodents. Increased 
7DHC concentration in cultured skin fibroblasts from SLOS patients has been shown to lead directly 
to a reduced HMG-CoA reductase activity, suppressing cholesterol synthesis in the cell. HMG-CoA 
synthase and LDL binding were inhibited equally by 7DHC and cholesterol. Not only cholesterol but 
also 7DHC is a very effective feedback inhibitor of HMG-CoA reductase (Honda et al. 1998).  
 Using filipin staining, it has been shown that SLOS fibroblasts accumulate unesterified sterols 
(Wassif et al. 2002). Further studies showed that this increased filipin staining was due to an abnormal 
accumulation of LDL-derived cholesterol rather than to storage of endogenously synthesized 7DHC. 
SLOS fibroblasts failed to degrade LDL at a normal rate. Examination of SLOS fibroblasts by 
electron microscopy demonstrated the formation of lysosomal inclusions similar to those seen in 
Niemann-Pick type C (NPC) cells. 7DHC may directly or indirectly inhibit the function of the NPC 
protein through its sterol-sensing domain (SSD). 7DHC accumulation may have a negative effect on 
the function of other SSD containing proteins (Wassif et al. 2002). These observations and insights 
stress that in the future not only the important role of cholesterol but the possible negative toxic role of 
cholesterol precursors, intermediates and sterol-like compounds such as dietary plant sterols 
(phytosterols) should be intensively studied in humans and other species. 
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Medical management 
SLOS demonstrates the fundamental importance of understanding the pathogenesis of dysmorphology 
in multiple malformation syndromes. The key role of sufficient and structurally normal (chole)sterol 
in humans, animals and plants is illustrated by several organ malformations and developmental delay 
in SLOS.  
 Important clinical progress however, has to be made in the near future on syndrome-specific 
behaviour in SLOS. Patients have severe sleep disorders, feeding problems and auto-mutilating 
behaviour. Autism or autistic symptoms have been observed in most SLOS patients and have great 
impact on patients and their families. Other medical complications may include cholestatic liver 
disease, subclinical or apparent adrenal insufficiency, recurrent infections and a multifactorial, severe 
feeding intolerance. Anaesthetic management, when needed, should use propofol and fentanyl, to 
prevent malignant hyperthermia, as reported after using of halothane or suxamethonium (Petersen & 
Crouch 1995). Further intubations could be difficult because of micrognatia, cleft palate or tongue 
abnormalities. The variability and complexity of features and symptoms in SLOS requires a 
multidisciplinary approach providing optimal care for children and their families. 
 
Future Perspectives 
In the future, against the background of the broad spectrum of the SLOS, phenotypes with only 
mild/moderate retardation and/or minor dysmorphias should be screened biochemically and 
genetically. These individuals may have two mild missense mutations in the DHCR7 gene, since the 
carrier frequency for some DHCR7 mutations is quite high, with 1 in 30 to 1 in 100 individuals, 
suggesting an incidence of 1 in 1,700 to 1 in 13,400. This high number is supported by observation of 
newborn and prenatal incidence of 1 in 22,000 in the Caucasian population (Witsch-Baumgartner et 
al. 2000; Waterham et al. 2000). In the future, patients with pylorus stenosis, intersex, hypospadias, 
polydactyly, single central incisors, Hirschprungs’ disease, bilateral cataract, II-III toe syndactyly, 
microcephaly or unexplained mental retardation without other signs of SLOS may be screened 
biochemically for sterol abnormalities and at the molecular genetic level for mutations in the DHCR7 
gene or in other genes involved in the post-squalene biosynthesis. Sterols prove to be crucial and 
essential for cell survival in micro-organisms, yeast, plants, animals and humans.  
 Millions of people being treated for hypercholesterolemia with statins showed not only a 
decrease in circulating lipids but statins also revealed cardio protection, even within weeks after 
initiation. One should explore the anti-bacterial potency of statins in inhibiting the essential 
cholesterol biosynthesis in the bacteria. Cholesterol biosynthesis is not only extensively studied in 
designing lipid-lowering agents but is also a target for antifungals. Sterol 14α-demethylase is inhibited 
by azole antifungals as fluconazole and ketoconazole, which are widely used for the treatment of 
fungal infections (Nakayama et al. 2001). The wide range of species that need (chole)sterol synthesis 
for survival and the multiple enzymes involved in this process affords researchers many opportunities. 
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Study designs can focus on growth and signaling cascades, hormone-production, myelin formation 
and cell survival. Future studies should investigate the potential benefit of statins and lipid-lowering 
agents in cancer research by inhibiting malignant cell division through its vital cholesterol 
biosynthesis. 
At the end of the past millennium new insights were gained on the impressive role of 
cholesterol on prenatal and postnatal growth, neuromotor development, behaviour, morphogenic and 
signaling pathways. The Smith-Lemli-Opitz malformation syndrome is the most frequent and most 
widely studied inborn error of cholesterol biosynthesis. It confronted us with lack of basic knowledge 
about cholesterol biosynthesis. It motivated scientists, biologists, molecular engineers and physicians 
to enlarge their knowledge about healthy humans, patients and design new treatment strategies. These 
insights have opened new opportunities in understanding and improving growth, cell signaling, 
development, cancer treatment, and their possible use in autoimmune and infectious diseases in the 
twenty-first century. 
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SAMENVATTING  
 
Het Smith-Lemli-Opitz Syndroom (SLOS) is een zeldzame, autosomaal recessief erfelijke 
stofwisselingsziekte. De belangrijkste symptomen bij patienten zijn een ontwikkelingsachterstand en 
overeenkomstige kenmerken zoals een karakteristiek gelaat, kleine schedelomtrek, syndactylie 
(versmelting) van de tweede en derde teen en een onduidelijk geslacht bij jongens. Afwijkingen 
kunnen verder voorkomen in alle inwendige organen inclusief cataract (staar) en hersenafwijkingen. 
De eerste klinische beschrijving van drie jongens die op elkaar leken dateert van 1964 en verbond het 
syndroom aan de namen van de drie artsen; William Smith, John Opitz en Luc Lemli. 
 De ontdekking in 1993 dat een stoornis in de aanmaak van cholesterol leidt tot het SLOS was een 
doorbraak. Er is een deficiëntie (onvoldoende werkzaamheid) van het enzym 7-dehydrocholesterol 
reductase (DHCR7), onmisbaar voor de cholesterol biosynthese. Dit defect geeft aanleiding tot lage 
concentraties van cholesterol en een ophoping van twee voorlopers van cholesterol; 7-dehydro-
cholesterol (7DHC) en 8-dehydrocholesterol (8DHC) in plasma en weefsels. Deze observatie heeft 
talloze opwindende vragen opgeworpen zoals beschreven in hoofdstuk twee. De kennis en inzichten 
betreffende SLOS worden uiteengezet in hoofdstuk drie. 
 Dit proefschrift beschrijft de resultaten van klinisch-, biochemisch-, moleculair genetisch-,  
therapeutisch- en pathofysiologisch onderzoek. Hoewel het bij SLOS gaat om een zeldzaam 
ziektebeeld waarvan in Nederland slechts enkele patienten per jaar geboren worden is dankzij de 
bereidheid en enthousiasme van enkele ouders en hun kinderen dit onderzoek mogelijk gemaakt.    
 
Biochemische diagnostiek 
In hoofdstuk vier wordt middels gas-chromatografie (GC) de analyse van cholesterol waarden in 
plasma van acht SLOS patienten vergeleken met de gangbare oxidase-methode die routinematig in 
klinisch chemische laboratoria gebruikt wordt om cholesterol in lichaamsvloeistoffen te meten. Wij 
beschrijven valkuilen in de bepaling van plasma cholesterol indien de gangbare cholesterol-oxidase 
methode in SLOS wordt toegepast.  
 Allereerst hebben gezonde pasgeborenen uitgesproken lage plasma cholesterol concentraties 
rond of zelfs onder de 2.0 mmol/l. Alle SLOS patienten die wij bestudeerden hadden verhoogde 
7DHC (143-848 μmol/l) en 8DHC (107-555 μmol/l) plasma concentraties, diagnostisch voor SLOS. In 
een gezonde controle-groep, zijn cholesterol-precursor concentraties onder de 10 μmol/l. Als tweede, 
konden wij aantonen dat de oxidase methode om cholesterol in plasma te meten geen onderscheid kan 
maken tussen respectivelijk cholesterol, 7DHC of 8DHC. Indien de analyse middels GC wordt 
toegepast, bleken alle SLOS patienten een plasma cholesterol concentratie (20 - 2030 μmol/l) te tonen 
onder de referentie waarden voor de leeftijd. Na toepassing van de cholesterol-oxidase methode, 
hadden daarentegen slechts 6 van de 8 patienten, verlaagde plasma cholesterol waarden. Doordat deze 
methode in feite de som van cholesterol en haar precursors 7DHC en 8DHC samen meet, komt het tot 
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vals hoge cholesterol-waarden. Dit kan in potentie tot foutieve conclusies leiden. De GC methode 
detecteert separate precursor- en cholesterol-pieken. Deze methode maakt het derhalve mogelijk bij 
SLOS de juiste diagnose te stellen en is bruikbaar om de biochemische ernst en de effectiviteit van 
behandeling te evalueren. 
 
Behandeling 
 Hoofdstukken vijf en zes beschrijven nieuwe behandelstrategieën in SLOS. Conventioneel werden 
patienten behandeld met cholesterol en/of galzuur suppletie zonder indrukwekkende biochemische 
dan wel klinische verbetering. In hoofdstuk vijf worden allereerst erythrocyten van SLOS patienten 
geincubeerd in normaal donor plasma en konden wij een snelle uitwisseling tussen precursors (7DHC 
and 8DHC) van het eryhrocyten membraan en cholesterol uit het plasma observeren. Indien normale 
erythrocyten werden geincubeerd in SLOS plasma, konden wij een vergelijkbare opname-snelheid van 
precursors in de normale erythrocyten membranen vaststellen. Dit motiveerde onze onderzoeksgroep 
om het effect van bloed-wisseltransfusie bij twee jonge SLOS patienten te evalueren. Herhaalde 
bloed-wisseltransfusies toonden een significante daling van circulerende cholesterol-precursor 
spiegels en verhoogden het cholesterol in plasma tot normale concentraties. Deze procedure is echter 
invasief voor patienten, tijdrovend en het biochemische effect van bloed-wisseltransfusie was slechts 
beperkt tot drie dagen. In dit kader kan deze behandelstrategie niet beschouwd worden als een 
blijvende curatieve lange termijn optie. Vervolgens incubeerden wij gekweekte SLOS 
huidfibroblasten met een HMG-CoA reductase remmer (simvastatine) om het effect op de sterol 
synthese te bestuderen. Zoals verwacht, konden wij een significante daling in accumulatie van 7DHC 
en 8DHC aantonen. De observatie dat de cholesterol concentratie steeg kwam echter als een positieve 
verrassing. De indrukwekkende verbetering van de precursor/cholesterol ratio in gekweekte SLOS 
huidfibroblasten motiveerde ons uiteindelijk om SLOS patienten met simvastatine te gaan behandelen. 
    In hoofdstuk zes worden de lange termijn effecten (23 en 14 maanden) van de orale HMG-
CoA reductase remming door simvastatine bij twee SLOS patienten beschreven. Wij konden een 
significante reductie van totale precursors (7DHC+8DHC) tot respectivelijk 28% en 33% van de 
initiële plasma waarden waarnemen. De cholesterol concentratie normaliseerde onverwacht door een 
meer dan verdubbeling in de behandelperiode bij beide patienten. De 7DHC+8DHC/Cholesterol ratio 
verbeterde in plasma van 0.47 naar 0.06 en 0.32 naar 0.04, respectievelijk, en van 1.22 naar 0.12 en 
van 0.62 naar 0.07 in erythrocyten membranen. Gedurende de follow-up periode verbeterden zowel de 
morphometrische parameters (lengte, gewicht, schedelomtrek), als de neuromotore ontwikkeling bij 
beide patienten. De therapie werd goed verdragen zonder dat er klinische- dan wel biochemische 
bijwerkingen optraden. Dit was de eerste studie waarin een simultane stijging en normalisering in 
bloed cholesterol naast een significante daling van precursor spiegels in SLOS patienten kon worden 
aangetoond. De simvastatine behandeling resulteert in een langdurige en bijvend biochemisch effect 
met een hoopgevende klinsche verbetering. De daling in accumulatie van 7DHC en 8DHC in SLOS 
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patienten behandeld met een orale HMG-CoA reductase-remmer kon worden verwacht. Het gunstige 
effect met stijging van de plasma cholesterol concentratie in SLOS patienten behandeld met een 
statine was echter onverwacht. Volgende studies werden ontwikkeld om deze observatie in gekweekte 
huidcellen en in plasma van patienten te verklaren.  
   Hoofdstuk zeven beschrijft drie klinisch relatief milde SLOS patienten die gedurende 
respectievelijk 80, 49 en 31 maanden, met simvastatine werden behandeld. Wij vervolgden de 
effectiviteit van de behandeling op hun ontwikkeling en algemeen welbevinden. In aanvulling 
bestudeerden wij in vitro het effect van simvastatine op de DHCR7-expressie en DHCR7-activiteit in 
primaire gekweekte huidfbroblasten van deze patienten. De simvastatine therapie werd door de 
patienten goed verdragen zonder evidente klinische en biochemische bijwerkingen. Gedurende de 
behandeling kon een duidelijke daling van de plasma 7DHC concentratie bij allen en een simultane 
stijging van de  cholesterol concentratie in plasma bij twee van de drie patienten worden 
waargenomen. Belangrijker nog, twee patienten toonden een goede en één patient een matige 
klinische respons in groei en ontwikkeling.  
 De in vitro studies in gekweekte huidfibroblasten van de patienten toonden  aan dat simvastatine 
een toegenomen gen transcriptie van het DHCR7-gen induceert,  hetgeen resulteert in een toegenomen 
DHCR7 eiwit- en enzym-activiteit. In de drie SLOS cellijnen kon een toename in residuele activiteit 
worden aangetoond met respectivelijk een factor 6.1, 3.6 en 4.2. DHCR7 katalyseert de 
snelheidsbepalende stap in SLOS, en een toename in residuele DHCR7 activiteit leidt tot een 
toegenomen flux in de cholesterol biosynthese en verklaart de verlaging van 7DHC en (vrijwel 
normalisering) van cholesterol concentraties zoals aangetoond. De biochemische en klinische 
verbetering was bovendien sterk gecorreleerd met de residuele DHCR7 activiteit. De opregulatie van 
de DHCR7 activiteit in gekweekte huidfibroblasten door simvastatine in onze studie was eveneens 
sterk gerelateerd aan de klinische score en het genotype (mutaties) van de betreffende SLOS patient.  
 Onze studie is het eerste onderzoek dat aantoont dat simvastatine behandeling van SLOS 
patienten met een relatief mild phenotype en residuele DHCR7-activiteit in gekweekte huidcellen 
resulteert in een toegenomen DHCR7-expressie. Deze toegenomen DHCR7-activiteit leidt 
rechtstreeks tot een verlaging van 7DHC en een toename in cholesterol concentratie. Doordat de 
effectiviteit en verbetering van de simvastatine therapie goed correleert met de residuale 7DHCR- 
activiteit en de klinische ernst van de patienten, kan deze behandel-strategie beschouwd worden als 
een goede behandel optie bij SLOS patienten met een licht tot matig ernstige klinische presentatie. 
Statine therapie is een veelbelovende, nieuwe benadering in SLOS dat verder onderzoek rechtvaardigt 
in een grotere serie patienten. Thans vindt een Europese NISLOS studie (Nijmegen International 
Simvastatin SLOS Study) plaats naar de lange termijn biochemische- en klinische effecten van 
simvastatine in combinatie met of zonder cholesterol suppletie. Bepaling van de residuele DHCR7 
enzym activiteit kan inzicht geven of statine-behandeling effectief zal zijn in SLOS patienten voor 
start van de behandeling. Gepoogd zal worden met behulp van de initiele precursor/cholesterol ratio of 
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van het genotype, te voorspellen welke SLOS patienten het meest kunnen/zullen profiteren van de 
lange termijn behandeling met simvastatine. 
 
Moleculaire Genetica 
In 1998, kon het humane DHCR7 gen worden geidentificeerd en gelocaliseerd op chromossom 11q12-
13. Inmiddels zijn er ruim honderd verschillende mutaties in het DHCR7 gen beschreven. In 
hoofdstuk acht beschrijven wij nieuwe en reeds bekende mutaties in het DHCR7 gen bij 13 Europese 
SLOS patienten. Zoals andere onderzoeksgroepen konden ook wij aantonen dat de meeste (∼80%) 
patienten compound heterozygoot zijn voor combinaties van zowel een ernstige als een milde mutatie 
in het DHCR7-gen. De meest frequente mutatie in West-Europa is de ernstige IVS8-1G>C mutatie, 
die aanleiding geeft tot abberante splicing. Deze mutatie resulteert in een mRNA  met een insertie van 
134 baseparen vanaf intron 8 op nucleotide-postie 963. Na translatie leidt dit tot een frame shift en een 
stop codon ter hoogte van nucleotide 1253 (TGA), waardoor een getrunceerd eiwit wordt 
geproduceerd dat 154 van zijn oorspronkelijke C-terminale aminozuren mist. Bij de patient in onze 
studie die homozygoot was voor de IVS8-1G>C nul mutatie was inderdaad sprake van een ernstig en 
lethaal phenotype. De patient presenteerde zich met de laagste plasma cholesterol concentratie (20 
μmol/l) ooit beschreven.  
 Het ernstige phenotype bij SLOS is vaak het gevolg van nul mutaties en mutaties in de vierde 
eiwit-loop, terwijl C-terminale- en mutaties in het transmembraan gedeelte aanleiding geven tot milde- 
en matig ernstige klinische phenotypes. In de toekomst zal verder moleculair genetisch onderzoek de 
dragerschap-frequentie van specifieke DHCR7 mutaties mogelijk maken. Het voorspellen van 
klinische ernst van het SLOS op basis van het genotype zal moeilijk blijven daar er een aanzienlijke 
klinische en biochemische variabliteit aanwezig is tussen genetisch identieke SLOS patienten (zoals 
bij verwanten). Gezocht zal moeten worden naar additionele mechanismen als verklaring voor het 
uiteindelijke phenotype bij de functionele DHCR7 deficiëntie in deze cholesterol aanmaakstoornis.   
 
Pathogenese 
Hoofdstuk negen beschrijft een patient met een op “Smith-Lemli-Opitz-gelijkend” phenotype dat 
wordt veroorzaakt door een terminale 7q36 deletie leidend tot afwezigheid van het Sonic Hedgehog 
(SHH) gen. Deze opmerkelijke bevinding bekrachtigt de pathogenese van het SLOS en de rol van 
cholesterol in de belangrijke, recent ontdekte, cholesterol-SHH-Patched-Smoothened-Gli cascade. 
Deze morphogenetische pathway is belangrijk bij de aanleg van vele organen en weefsels. 
 De pasgeboren jongen, toonde een aantal kenmerken zoals gezien worden bij het SLOS: een 
prenatale groeiachterstand, microcephalie, hyperplasie van de bovenkaak, een micropenis met een 
glandulaire hypospadie, en een bilaterale syndactylie van de tweede en derde teen. Verder was er 
sprake van een unilaterale choane (neusholte) atresie en een ernstige an/microphtalmie. Gas 
chromatografische analyse van de plasma sterolen toonde normale concentraties van cholesterol 
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precursors 7DHC, 8DHC en tevens van cholesterol waardoor een DHCR7 deficiëntie (zoals bij SLOS) 
kon worden  uitgesloten. Chromosoom analyse toonde een distale 7q36.1 deletie aan. Uitgebreide 
fluorescentie in situ hybridisatie analyse bevestigde de afwezigheid van de holoprosencephaly (HPE3) 
critical gene region waaronder het SHH gen. Mutaties in of microdeletie van het nog aanwezig SHH 
gen op het nog aanwezige allel konden worden uitgesloten. Deze casus suggereert dat naast patienten 
met een stoornis in de cholesterol biosynthese tevens patienten met een distale 7q deletie zich kunnen 
presenteren met een op SLOS-gelijkend phenotype. 
 
In hoofdstuk tien worden onze onderzoeksbevindingen samengevat en bediscussieerd. Het Smith-
Lemli-Opitz syndroom is één van de acht recent ontdekte defecten in de cholesterol biosynthese. Dat 
verschillende specifieke defecten allen aanleiding geven tot ernstige ziektebeelden en syndromen, 
vaak met malformaties, geeft aan hoe belangrijke cholesterol is voor iedere cel. Tot slot belichten wij 
de rol van cholesterol en SHH voor toekomstig wetenschappelijk onderzoek naar celgroei, kanker- en 
infectiebehandeling. 
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DANKWOORD 
 
Lieve patienten en ouders, zonder jullie bereidheid, enthousiasme en nieuwsgierigheid was ons 
onderzoek de laatste jaren onmogelijk geweest. Jullie hebben de wetenschap en medische kennis een 
stapje verder gebracht. Ik bewonder en respecteer jullie om het vertrouwen en de durf nieuwe 
behandelingen aan te gaan. Door nieuwe paden te bewandelen helpen jullie kinderen met een 
zeldzame stoornis in de cholesterol-aanmaak in de toekomst beter te kunnen behandelen.  
Ik dank jullie zeer.  
 
Prof. R. Wevers, beste Ron. Vanaf het begin van het onderzoek was jij als klinisch chemicus de 
animator en stuwende kracht. Je hebt mij als kinderarts veel geleerd over biochemische processen en 
met je kennis en inzicht ben je steeds een belangrijke basis geweest voor ons team. In je werkkamer 
met honderden mapjes wist je mijn mapjes er altijd uit te vissen. Je kennis en stimulans hebben mij de 
kracht en motivatie gegeven om door te gaan. Jij bent met recht een startmotor en promotor. Ik hoop 
dat onze samenwerking en contactpunten nooit zullen afslaan. 
 
Prof. J. Smeitink, beste Jan. Je creatieve en soms wilde ideëen als metabool kinderarts stuwden het 
onderzoek steeds naar een nieuwe, soms onverwachte, richting. Jij, Ron en ik deelden de verbazing 
over SLOS als nieuwe stofwisselingsstoornis. Je deur stond altijd open voor overleg, ondanks je 
overvolle agenda en spervuur van e-mails van anderen. Jij bent met recht een promotor en katalysator.  
 
Prof. R. Sengers, beste Rob. Je was mijn opleider en coach van twee deel-specialisaties en hebt mij 
bijgestaan met adviezen en raad tijdens ons SLOS-onderzoek. Toen Jan en Ron nog geen hoogleraar 
waren heb jij mij gerustgesteld met je rol als pater familias. Nadat Ron en Jan beiden hun leerstoel 
beklommen heb je (always a gentleman) deze rol overgelaten aan dit chemisch-metabole duo. Je hebt 
dan ook balans en evenwichtigheid gebracht in het onderzoek en mijn loopbaan. Ik ging met 
knikkende knieën naar je kamer om te vertellen dat ik naar Den Bosch vertrok. Gelukkig had je altijd 
respect voor goed overwogen beslissingen. Ik hoop dat je nu geniet van je rust en levensfase met 
Marguérite en je (klein)kinderen. 
 
Prof. U. Wendel, beste Udo. Ik ben blij dat jij als “Europees” kinderarts nuances kon brengen in de 
benadering en behandeling van metabole patienten. Je kunstzinnige en relativerende filosofie leerde 
mij dat een arts meer is dan een lopend leerboek. Ik lach nog vaak over je “freud-hapje” dat ouders zo 
graag al bij drie maanden aan hun zuigeling willen geven. De totempaal in je tuin en rondslingerende 
saxefoon in het gastvrije Hilden vormen waardevolle herinneringen. Je exposties kom ik graag een 
keer bezoeken omdat jouw wetenschap en kunst minimaal één ding gemeen hebben: intuïtie.    
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Fokje Zijlstra, lieve Fokje. Zonder jouw inzet en kennis op het gebied van sterol analyse was 
diagnostiek, behandeling en het onderzoek van de afgelopen jaren onmogelijk geweest. Alleen al de 
combinatie van je goede humeur en zeer accurate werk zijn uniek te noemen. Nooit nam je genoegen 
met een uitslag of bepaling als je hem niet drie keer had gecontroleerd en naberekend. Alle publicaties 
zijn mede het resultaat van jouw inspanningen.  
 
Dr. J. de Jong,  beste Jan. Onze ontdekkingsreizen naar cholesterol-experts in Utrecht en hormoon-
experts in Rotterdam maakten het onderzoek voor mij tot een avontuur. We wisten nooit in welk 
laboratorium we nieuwe sterol-inzichten zouden aantreffen. Jouw eerste ervaringen met gekweekte 
huidcellen van SLOS-patienten waren erg verrassend. Je kennis omtrent GC-MS en rustige maar 
volhardende benadering van problemen maakten ons SLOS-team compleet. 
 
Het AMC-team, beste Hans, Ronald en Raoul. Jullie hebben mij geleerd wat samenwerking kan 
opleveren. Jullie moleculair- en klinisch genetische kennis was onmisbaar. De samenwerking tussen 
Amsterdam en Nijmegen is zeer vruchtbaar geweest en zal in de toekomst ongetwijfeld nog vele 
vruchten afwerpen. In dat kader blijft Amsterdam “ the Big Apple ” . 
 
Sandra Hoenderop, lieve Sandra. Je advies over Powerpoint, Word en het submitten van manuscripten 
hebben mijn de afgelopen jaren enorm geholpen. Nooit was iets lastig, te veel of kwam ongelegen. Je 
leermomenten neem ik zeker mee. 
 
Lovice Sutherland, lieve Lovice. Samen trekken wij de Europese NISLOS behandel Trial waarmee 
onze samenwerking (gelukkig) nog niet over is. Als je niet “down under” bent help je mij bij het 
afkicken van de frequente bezoeken aan het UMCN. Bedankt voor de plezierig samenwerking die 
zeker nog zal doorgaan. 
 
Beste Estela, Arno en Willem. Jullie hebben met raad en daad het begin van het onderzoek 
ondersteund. Deze boeiende eerste jaren waren niet alleen nieuw en druk, maar ook inspirerend en mij 
zeer dierbaar. 
 
Beste Aad, jouw onderzoek naar CTX had vele paralellen met SLOS. Ik heb dan ook zeer goede 
herinneringen aan de fietstochten met een ondergaand zomerzonnetje op weg naar huis. We deelden 
als onderdeel van “ onze Trias Lipidica “ samen met Michèl de verwondering over vers verworven 
inzichten. Als voortrekkers van de Jonge Garde in het UMCN hebben we de strijd om de 
arbeidvoorwaarden van jonge specialisten in de academie te verbeteren op moeten geven.  
We zijn beiden zonder rancune of spijt naar de periferie gegaan onder het motto: “a man’s gotto do 
what a man’s gotto do“ (Clint Eastwood). 
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Beste Michèl. Als collega, Trias Lipidica lid, “ mijn geweten “ en beste vriend ben je uitgegroeid tot 
een rode draad in mijn leven. Jij en Anneloes hebben mij zelfs onderdak geboden in moelijke tijden. 
We hebben wat afgewandeld en gepraat de afgelopen jaren, met Schotland als hoogtepunt. Ook al 
spreken we elkaar door onze drukke carrieres en gezinsleven soms te lange tijd niet, weet ik altijd wat 
ik aan je heb. Je bent voor mij onmisbaar geworden. 
 
Beste Bibi, Rens, Milou en Puck. Jullie hebben mij vaak ontzien en de gelegenheid geboden aan mijn 
onderzoek te werken. Ik ga de komende jaren met jullie nog meer zwemmen, schaatsen, 
trampospringen, tafeltennissen, speurtochten uitzetten en basketballen dus “ maak jullie borst maar 
nat!”           
 
Vele mensen hebben zich samen met ons de afgelopen jaren ingezet om nieuwe inzichten te vergaren 
op het gebied van de cholesterol stofwisseling. Met name alle medeauteurs die bijgedragen hebben bij 
de tot standkoming van de hoofdstukken zijn de basis geweest voor dit boekje. Ik kan niet iedereen 
persoonlijk noemen maar wil iedereen bedanken die zich voor zowel de patienten als het SLOS-
onderzoek heeft ingezet.   
 
Last but not least, lieve Lia. Je gaf mij alle kans, liefde en kracht om “het af te maken”. Nooit twijfelde 
jij aan een goede afloop en riep “straks is de donderdag lekker van ons” als ik weer van Berlicum naar 
Nijmegen reed. Je bent een steun en toeverlaat geweest en zonder jou had ik het onmogelijk gered. 
Dank je lief en haal de skeelers maar uit de kast. 
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CURRICULUM VITAE 
 
Petr Edvard Jira, werd op 17 maart 1963 geboren achter het “ ijzeren gordijn” te Hradec Králové in 
Tsjecho-slowakije. In 1969 emigreerde hij met zijn ouders naar het beloofde land, Nederland. Hij 
groeide op in Nijmegen alwaar hij in 1982 het diploma Atheneum B aan het St. Dominicus college 
behaalde. Zijn studie geneeskunde aan de Katholieke Universiteit Nijmegen resulteerde in het 
artsexamen, dat hij in 1991 cum laude in ontvangst mocht nemen. 
De specialisatie kindergeneeskunde vond plaats tussen 1992 en 1997 in het St. Radboud ziekenhuis 
(Opleider: Prof. Rob Sengers) en zijn B-opleiding in het Canisius Wilhelmina Ziekenhuis te Nijmegen 
(Opleider: Dr. Paul van Wieringen). Na de registratie tot kinderarts volgden twee deel-specialisties 
Neonatologie (Opleider: Prof. Margot van de Bor) en Kinder-nefrologie (Opleider: Prof. Leo 
Monnens). 
Sederts 1 mei 2001 is hij full-time werkzaam als kinderarts in het Jeroen Bosch Ziekenhuis te ’s-
Hertogenbosch, alwaar hij deel uitmaakt van de maatschap kindergeneeskunde.  
De auteur leeft gelukkig met zijn Lia, Bibi, Rens, Milou en Puck.   
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